<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Baclofen for alcohol use disorder - Agabio, R - 2023 | Cochrane Library</title> <meta content="Baclofen for alcohol use disorder - Agabio, R - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012557.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Baclofen for alcohol use disorder - Agabio, R - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012557.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012557.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Baclofen for alcohol use disorder" name="citation_title"/> <meta content="Roberta Agabio" name="citation_author"/> <meta content="University of Cagliari" name="citation_author_institution"/> <meta content="agabio@unica.it" name="citation_author_email"/> <meta content="Rosella Saulle" name="citation_author"/> <meta content="Lazio Regional Health Service" name="citation_author_institution"/> <meta content="Susanne RÃ¶sner" name="citation_author"/> <meta content="Forel Klinik" name="citation_author_institution"/> <meta content="Silvia Minozzi" name="citation_author"/> <meta content="Lazio Regional Health Service" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD012557.pub3" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/01/13" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012557.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012557.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012557.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acamprosate [adverse effects, therapeutic use]; Alcohol Drinking [drug therapy]; *Alcoholism [drug therapy]; *Baclofen [adverse effects, therapeutic use]; Chronic Disease; Naltrexone [adverse effects, therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012557.pub3&amp;doi=10.1002/14651858.CD012557.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012557.pub3&amp;doi=10.1002/14651858.CD012557.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012557.pub3&amp;doi=10.1002/14651858.CD012557.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012557.pub3&amp;doi=10.1002/14651858.CD012557.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012557.pub3&amp;doi=10.1002/14651858.CD012557.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012557.pub3&amp;doi=10.1002/14651858.CD012557.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012557.pub3&amp;doi=10.1002/14651858.CD012557.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012557.pub3&amp;doi=10.1002/14651858.CD012557.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012557.pub3&amp;doi=10.1002/14651858.CD012557.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012557.pub3&amp;doi=10.1002/14651858.CD012557.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012557.pub3&amp;doi=10.1002/14651858.CD012557.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012557.pub3&amp;doi=10.1002/14651858.CD012557.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012557.pub3&amp;doi=10.1002/14651858.CD012557.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012557.pub3&amp;doi=10.1002/14651858.CD012557.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012557.pub3&amp;doi=10.1002/14651858.CD012557.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012557.pub3&amp;doi=10.1002/14651858.CD012557.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012557.pub3&amp;doi=10.1002/14651858.CD012557.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012557.pub3&amp;doi=10.1002/14651858.CD012557.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012557.pub3&amp;doi=10.1002/14651858.CD012557.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012557.pub3&amp;doi=10.1002/14651858.CD012557.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012557.pub3&amp;doi=10.1002/14651858.CD012557.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012557.pub3&amp;doi=10.1002/14651858.CD012557.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012557.pub3&amp;doi=10.1002/14651858.CD012557.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="mvgXlmVk";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012557\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012557\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012557\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012557\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","th","ms","ja","hr","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012557.pub3",title:"Baclofen for alcohol use disorder",firstPublishedDate:"Jan 13, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Drugs and Alcohol Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mvgXlmVk&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012557.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012557.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> EspaÃ±ol </option> <option class="content-language-option" data-languagecode="fa" value="fa"> ÙØ§Ø±Ø³Û </option> <option class="content-language-option" data-languagecode="fr" value="fr"> FranÃ§ais </option> <option class="content-language-option" data-languagecode="hi" value="hi"> à¤¹à¤¿à¤¨à¥à¤¦à¥ </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> æ¥æ¬èª </option> <option class="content-language-option" data-languagecode="ko" value="ko"> íêµ­ì´ </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> PortuguÃªs </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Ð ÑÑÑÐºÐ¸Ð¹ </option> <option class="content-language-option" data-languagecode="ro" value="ro"> RomÃ¢nÄ </option> <option class="content-language-option" data-languagecode="ta" value="ta"> à®¤à®®à®¿à®´à¯ </option> <option class="content-language-option" data-languagecode="th" value="th"> à¸ à¸²à¸©à¸²à¹à¸à¸¢ </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> ç¹é«ä¸­æ </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> ç®ä½ä¸­æ </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012557.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012557.pub3/full/es"> EspaÃ±ol </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012557.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012557.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;ÚÚ©ÛØ¯Ù&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;RÃ©sumÃ© scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;à¸à¸à¸à¸±à¸à¸¢à¹à¸­&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en tÃ©rminos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;Ø®ÙØ§ØµÙ Ø¨Ù Ø²Ø¨Ø§Ù Ø³Ø§Ø¯Ù&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;RÃ©sumÃ© simplifiÃ©&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;LaiÄki saÅ¾etak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;ä¸è¬èªè¨³&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym jÄzykiem&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;à¸à¹à¹à¸­à¸ªà¸£à¸¸à¸à¸ à¸²à¸©à¸²à¸à¸£à¸£à¸¡à¸à¸²&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;æ·ºé¡¯ææçå£èªçµè«&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012557.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012557.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012557.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012557.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views:Â </span> <span>6925 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012557.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012557.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012557.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012557.pub3/full#CD012557-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012557.pub3/full#CD012557-sec-0162"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012557.pub3/full#CD012557-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012557.pub3/full#CD012557-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012557.pub3/full#CD012557-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012557.pub3/full#CD012557-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012557.pub3/full#CD012557-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012557.pub3/full#CD012557-sec-0151"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012557.pub3/appendices#CD012557-sec-0167"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/supinfo/CD012557StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/supinfo/CD012557StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012557.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012557.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012557.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012557.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012557.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012557.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright Â© 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Baclofen for alcohol use disorder</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012557.pub3/information#CD012557-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Roberta Agabio</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012557.pub3/information#CD012557-cr-0005">Rosella Saulle</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012557.pub3/information#CD012557-cr-0006">Susanne RÃ¶sner</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012557.pub3/information#CD012557-cr-0007">Silvia Minozzi</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/information/en#CD012557-sec-0182">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 13 January 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012557.pub3">https://doi.org/10.1002/14651858.CD012557.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012557-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012557-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012557-abs-0015">EspaÃ±ol</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012557-abs-0010">ÙØ§Ø±Ø³Û</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012557-abs-0012">FranÃ§ais</a> </li> <li class="section-language"> <a class="" href="full/th#CD012557-abs-0005">à¸ à¸²à¸©à¸²à¹à¸à¸¢</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012557-abs-0001" lang="en"> <section id="CD012557-sec-0001"> <h3 class="title" id="CD012557-sec-0001">Background</h3> <p>Alcohol use disorder (AUD) is one of the most widespread psychiatric disorders leading to detrimental consequences to people with this disorder and others. Worldwide, the prevalence of heavy episodic drinking (30âday prevalence of at least one occasion of 60 g of pure alcohol intake among current drinkers) is estimated at 20% and the prevalence of AUD at 5% of the adult general population, with highest prevalence in Europe and North America. Therapeutic approaches, including pharmacotherapy, play an important role in treating people with AUD. </p> <p>This is an update of a Cochrane Review first published in 2018.</p> </section> <section id="CD012557-sec-0002"> <h3 class="title" id="CD012557-sec-0002">Objectives</h3> <p>To evaluate the benefits and harms of baclofen on achieving and maintaining abstinence or reducing alcohol consumption in people with AUD compared to placebo, no treatment or any other pharmacological relapse prevention treatment. </p> </section> <section id="CD012557-sec-0003"> <h3 class="title" id="CD012557-sec-0003">Search methods</h3> <p>We used standard, extensive Cochrane search methods. The latest search was 22 November 2021. </p> </section> <section id="CD012557-sec-0004"> <h3 class="title" id="CD012557-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) of at least four weeks' treatment duration and 12 weeks' overall study duration comparing baclofen for AUD treatment with placebo, no treatment or other treatments. </p> </section> <section id="CD012557-sec-0005"> <h3 class="title" id="CD012557-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods. Our primary outcomes were 1. relapse, 2. frequency of use, 3. amount of use, 4. adverse events, 5. dropouts from treatment and 6. dropouts from treatment due to adverse events. Our secondary outcomes were 7. craving, 8. anxiety, 9. depression and 10. frequency of most relevant adverse events. </p> </section> <section id="CD012557-sec-0006"> <h3 class="title" id="CD012557-sec-0006">Main results</h3> <p>We included 17 RCTs (1818 participants) with a diagnosis of alcohol dependence according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition or International Classification of Diseases 10th edition criteria. Mean age was 46.5 years and 70% were men. Ten studies compared baclofen to placebo or another medication; seven compared two baclofen doses to placebo or another medication. Globally, 15 studies compared baclofen to placebo, two baclofen to acamprosate and two baclofen to naltrexone. In 16 studies, participants received psychosocial treatments. </p> <p>We judged most studies at low risk of selection, performance, detection (subjective outcome), attrition and reporting bias. </p> <p>Ten studies detoxified participants before treatment; in seven studies, participants were still drinking at the beginning of treatment. Treatment duration was 12 weeks for 15 RCTs and longer in two studies. Baclofen daily dose was 30 mg to 300 mg: 10 RCTs used low doses (30 mg or less); eight RCTs medium doses (above 30 and 100 mg or less) and four RCTs high doses (above 100 mg). </p> <p>Compared to placebo, moderateâcertainty evidence found that baclofen probably decreases the risk to relapse (risk ratio (RR) 0.87, 95% confidence interval (CI) 0.77 to 0.99; 12 studies, 1057 participants). This result was confirmed among detoxified participants but not among other subgroups of participants. </p> <p>Highâcertainty evidence found that baclofen increases the percentage of days abstinent (mean difference (MD) 9.07, 95% CI 3.30 to 14.85; 16 studies, 1273 participants). This result was confirmed among all subgroups of participants except nonâdetoxified or those who received medium doses. </p> <p>There was no difference between baclofen and placebo in the other primary outcomes: heavy drinking days (standardised mean difference (SMD) â0.18, 95% CI â0.48 to 0.11; 13 studies, 840 participants; moderateâcertainty evidence); number of drinks per drinking days (MD â0.45, 95% CI â1.20 to 0.30; 9 studies, 392 participants; moderateâcertainty evidence); number of participants with at least one adverse event (RR 1.05, 95% CI 0.99 to 1.11; 10 studies, 738 participants; highâcertainty evidence); dropouts (RR 0.88, 95% CI 0.74 to 1.03; 17 studies, 1563 participants; highâcertainty evidence); dropouts due to adverse events (RR 1.39, 95% CI 0.89 to 2.18; 16 studies, 1499 participants; highâcertainty evidence). These results were confirmed by subgroup analyses except than for the dropouts that resulted lower among participants who received high doses of baclofen and studies longer than 12 weeks. </p> <p>Compared to placebo, there was no difference in craving (SMD â0.16, 95% CI â0.37 to 0.04; 17 studies, 1275 participants), anxiety (MD â0.01, 95% CI â0.14 to 0.11; 15 studies, 1123 participants) and depression (SMD 0.07, 95% CI â0.12 to 0.27; 11 studies, 1029 participants). </p> <p>Concerning the specific adverse events, baclofen increases fatigue, dizziness, somnolence/sedation, dry mouth, paraesthesia and muscle spasms/rigidity. There was no difference in the other adverse events. </p> <p>Compared to acamprosate, one study (60 participants) found no differences in any outcomes but the evidence was very uncertain: relapse (RR 1.25, 95% CI 0.71 to 2.20; very lowâcertainty evidence); number of participants with at least one adverse event (RR 0.63, 95% CI 0.23 to 1.69; very lowâcertainty evidence); dropouts (RR 0.56, 95% CI 0.21 to 1.46; very lowâcertainty evidence); dropouts due to adverse events (RR 0.33, 95% CI 0.01 to 7.87; very lowâcertainty evidence) and craving (MD 5.80, 95% CI â11.84 to 23.44); and all the adverse events evaluated. </p> <p>Compared to naltrexone, baclofen may increase the risk of relapse (RR 2.50, 95% CI 1.12 to 5.56; 1 study, 60 participants; very lowâcertainty evidence) and decrease the number of participants with at least one adverse event (RR 0.35, 95% CI 0.15 to 0.80; 2 studies, 80 participants; very lowâcertainty evidence) but the evidence is very uncertain. One study (60 participants) found no difference between baclofen and naltrexone in the dropouts at the end of treatment (RR 1.00, 95% CI 0.32 to 3.10; very lowâcertainty evidence), craving (MD 2.08, 95% CI â3.71 to 7.87), and all the adverse events evaluated. </p> </section> <section id="CD012557-sec-0007"> <h3 class="title" id="CD012557-sec-0007">Authors' conclusions</h3> <p>Baclofen likely reduces the risk of relapse to any drinking and increases the percentage of abstinent days, mainly among detoxified participants. It does not increase the number of participants with at least one adverse event, those who dropout for any reason or due to adverse events. It probably does not reduce number of heavy drinking days and the number of drinks per drinking days. Current evidence suggests that baclofen may help people with AUD in maintaining abstinence. The results of comparisons of baclofen with acamprosate and naltrexone were mainly based on only one study. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012557-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012557-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012557-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012557-abs-0016">EspaÃ±ol</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012557-abs-0011">ÙØ§Ø±Ø³Û</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012557-abs-0013">FranÃ§ais</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012557-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012557-abs-0008">æ¥æ¬èª</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012557-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012557-abs-0014">Polski</a> </li> <li class="section-language"> <a class="" href="full/th#CD012557-abs-0006">à¸ à¸²à¸©à¸²à¹à¸à¸¢</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012557-abs-0004">ç¹é«ä¸­æ</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012557-abs-0002" lang="en"> <h3>Baclofen for alcohol use disorder</h3> <p><b>Key messages of the review</b> </p> <p>We reviewed the evidence about the effectiveness and safety of baclofen for treating people with alcohol use disorder (AUD) in order to achieve and maintain abstinence (stopping drinking) or reduce alcohol consumption. </p> <p>Current evidence suggests that it may help people with AUD in maintaining abstinence, particularly in people who are already detoxified. The results of comparisons with other medications were mainly based on a single study and do not allow us to draw conclusions. </p> <p><b>Review topics and aims</b> </p> <p>AUD is one of the most widespread psychiatric disorders, leading to specific physical, mood, learning and memory problems, and consequences for overall wellâbeing and health. The misuse of alcohol is one of the biggest risks to health worldwide, causing 20% to 30% of oesophageal (food pipe) cancer, liver disease, epilepsy (fits), motor vehicle accidents, murders and other intentional injuries. </p> <p>For many years, the main treatments for AUD have been psychosocial strategies (helping people to recognise that they need help), but using only psychosocial treatments has limited success. A high proportion of people with AUD do not respond to treatment at all, and those who do respond do not stay alcoholâfree in the longâterm. Medications such as baclofen could play an important role in treating people with AUD. </p> <p><b>Review methods</b> </p> <p>We searched for randomised controlled trials (studies where people were allocated at random to one of two or more treatments or control groups) evaluating the effect of baclofen in reducing alcohol consumption or in achieving and maintaining abstinence (or both) when compared to placebo (inactive medication) or other medications. We pooled similar studies and evaluated the effects dividing the studies according to the doses of baclofen, duration of treatment, and alcohol consumption and the beginning of treatment (i.e. into detoxified or nonâdetoxified participants on the basis if they were abstinent or were still drinking at the beginning of treatment). </p> <p><b>Summary of results</b> </p> <p>We found 17 studies with 1818 participants with AUD. The duration of the interventions ranged from three months to one year. Five studies were in the USA; two each in Australia, France, India and Italy; and one each in Germany, Israel and the Netherlands. </p> <p>Doses of baclofen were 30 mg a day to 300 mg a day, and, in some cases, the doses were increased during the treatment. Seventeen studies compared baclofen to placebo (dummy medication), two compared baclofen to acamprosate (medication used to treat AUD), and two compared baclofen to naltrexone (medication used to treat AUD). </p> <p>Compared with placebo, baclofen probably helps people with AUD at reducing the risk of relapse and increasing the rate of abstinent days. These effects may be more evident among detoxified than nonâdetoxified people with AUD. Baclofen probably makes no difference in the rate of heavy drinking days; drinks per drinking days; craving, anxiety and depression severity; number of participants who dropout from treatment for any reason; those who dropped out due to adverse events (side effects); or the number of participants with at least one adverse event. Baclofen may increase adverse events such as fatigue, vertigo (a feeling that everything is spinning), sleepiness, dry mouth, numbness and muscle spasm but we found no differences between baclofen and placebo for other adverse events. </p> <p><b>Certainty of evidence</b><br/>The certainty of evidence (how much we can be confident that the evidence is reliable) was high for results about the percentage of days of abstinence, the number of participants with at least one adverse event, people dropping out of the studies for any reason, and people dropping out due to adverse events. The certainty of the evidence was moderate for results about returning to any drinking, heavy drinking days and number of drinks per drinking days. </p> <p><b>Search date</b><br/>The evidence is current to November 2021. This is an update of a Cochrane Review first published in 2018. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012557-sec-0162" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012557-sec-0162"></div> <h3 class="title" id="CD012557-sec-0163">Implications for practice</h3> <section id="CD012557-sec-0163"> <p>Based on evidence from 17 randomised controlled trials with 1818 participants with alcohol use disorder (AUD), the review demonstrates the effectiveness of baclofen for treatment of AUD in reducing the risk of relapse and increasing the percentage of abstinent days. Compared to placebo, baclofen reduces the risk to return to any drinking at the end of treatment by approximately 13%. That is, 13 additional participants out of 100 avoid any drinking, for the entire duration of treatment when they receive baclofen compared to participants who receive placebo. This finding is particularly relevant considering that the duration of treatment of studies selected by this review ranged from three months to one year. Among detoxified participants, this effect was higher with an additional 27 participants out of 100 maintaining abstinence when treated with baclofen compared to placebo. </p> <p>Regarding the percentage of abstinent days, baclofen increases this percentage by 9% compared to placebo. This finding means that participants treated with baclofen spend almost three additional abstinent days, per month, compared to participants who receive placebo. This effect is equal to almost four additional abstinent days, per month, among the subgroup of detoxified participants, compared to participants who receive placebo. </p> <p>This review also demonstrates that baclofen does not increase the number of participants with at least one adverse event at the end of treatment, compared to placebo. That means that participants who receive baclofen do not experience a higher number of adverse events compared to those who receive placebo. In addition, participants who receive baclofen do not differ from those who receive placebo in the numbers who prematurely interrupt the trial because of any reason or adverse events. Similarly, baclofen does seem to reduce HDDs, the number of drinks per drinking days, or the severity of craving, anxiety, and depression. These findings mean that baclofen does not have an effect in other important measures of alcohol consumption compared to placebo. </p> <p>Finally, this review demonstrates that, compared to placebo, baclofen increases specific adverse events such as fatigue, dizziness and somnolence/sedation but not others. </p> <p>Conversely, this review provides no evidence on possible differences between baclofen and acamprosate or naltrexone because of the limited number of the available studies for these comparisons. </p> <p>Regarding its safety, our findings do not allow conclusions on the possible risk related to the combination of baclofen with sedative drugs (e.g. alcohol or benzodiazepines, or both) or in specific patient subgroups, such as people with suicidal ideation. </p> <p>Globally, current evidence suggests that baclofen may help people with AUD aimed at maintaining abstinence. </p> </section> <h3 class="title" id="CD012557-sec-0164">Implications for research</h3> <section id="CD012557-sec-0164"> <p>Further studies should investigate baclofen's profile of efficacy and safety among certain categories of people with AUD such as people with other mental disorders (bipolar disorder, anxiety disorders) or physical disorders (e.g. severe liver disease) and data should always be reported separately for men and women to investigate possible gender differences. </p> <p>One potential threat to bias that needs to be further addressed by research is the unmasking of blinding in the course of treatment. Even though quality of blinding is ensured by various measures of bias control, such as allocation concealment and blinding of participants and personnel, adverse events can potentially reveal a participant's affiliation to treatment conditions in the course of treatment. The use of active placebo mimicking adverse events of baclofen could prevent an overestimation of effects through response bias, placebo effects or differential attrition (<a href="./references#CD012557-bbs2-0085" title="HrÃ³bjartssonA , EmanuelssonF , Skou ThomsenAS , HildenJ , BrorsonS . Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies. International Journal of Epidemiology2014;43(4):1272-83.">HrÃ³bjartsson 2014</a>). If inert placebo is used, testing of blinding integrity by querying participants about their assumed group allocation would be a simple method that allows at least a retrospective assessment of blinding integrity (<a href="./references#CD012557-bbs2-0155" title="WilseyB , DeutschR , MarcotteTD . Maintenance of blinding in clinical trials and the implications for studying analgesia using cannabinoids. Cannabis and Cannabinoid Research2016;1(1):139-48.">Wilsey 2016</a>). </p> <p>The exploration of baclofen's profile of efficacy and safety and the identification of moderators and mediators of baclofen's effects remains a challenge mainly due to the risk of specific adverse events such as sedation. Preclinical data suggest that Î³âaminobutyric acid type B (GABA<sub>B</sub>)âpositive allosteric modulators may constitute the possible solution to overcome these risks (<a href="./references#CD012557-bbs2-0103" title="MaccioniP , ColomboG . Potential of GABAB receptor positive allosteric modulators in the treatment of alcohol use disorder. CNS Drugs2019;33(2):107-23. [PMID: 30604283]">Maccioni 2019</a>). GABA<sub>B</sub>âpositive allosteric modulators indeed reproduce baclofenâinduced effects on alcoholârelated behaviours displaying a more favourable safety profile. At present, the first clinical trial to evaluate the efficacy and safety of a GABA<sub>B</sub>âpositive allosteric modulator for the treatment of AUD is ongoing (<a href="https://clinicaltrials.gov/show/NCT05096117" target="_blank">NCT05096117</a>). </p> <p>As most people with AUD still receive no treatment (<a href="./references#CD012557-bbs2-0080" title="HanB , JonesCM , EinsteinEB , PowellPA , ComptonWM . Use of medications for alcohol use disorder in the US: results from the 2019 national survey on drug use and health. JAMA Psychiatry2021;78(8):922-4. [PMID: 34132744]">Han 2021</a>), the development of new, effective, safe and manageable medications is expected to considerably increase the number of people who seek and receive medical treatment. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012557-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012557-sec-0008"></div> <div class="table" id="CD012557-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span>Â <span class="table-title">Summary of findings table â Baclofen compared to placebo for alcohol use disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Baclofen compared to placebo for alcohol use disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> alcohol use disorder<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> baclofen<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>â of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with baclofen</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse: return to any drinking at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>816 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>710 per 1000</b><br/>(628 to 808) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.87</b><br/>(0.77 to 0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1057<br/>(12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compared to placebo, baclofen probably decreases the risk to relapse to any drinking.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Frequency of use: % days abstinence at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean frequency of use: % days abstinence at end of treatment was <b>53.58</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>9.07 higher</b><br/>(3.3 higher to 14.85 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1273<br/>(16 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compared to placebo, baclofen increases the % of days abstinent.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Frequency of use: heavy drinking days at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD <b>0.18 lower</b><br/>(0.48 lower to 0.11 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>840<br/>(13 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compared to placebo, baclofen may not reduce heavy drinking days.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amount of use: drink per drinking days at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean amount of use: drink per drinking days at end of treatment was <b>4.28</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.45 lower</b><br/>(1.2 lower to 0.3 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>392<br/>(9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compared to placebo, baclofen probably does not reduce the number of drinks per drinking days. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: number of participants with â¥ 1 adverse event at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>636 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>668 per 1000</b><br/>(629 to 706) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b><br/>(0.99 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>738<br/>(10 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compared to placebo, baclofen does not increase the number of participants with â¥ 1 adverse event at the end of treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dropouts at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>420 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>369 per 1000</b><br/>(311 to 432) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b><br/>(0.74 to 1.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1563<br/>(17 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compared to placebo, baclofen does not increase the number of participants who dropout at the end of treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dropouts due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61 per 1000</b><br/>(39 to 95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.39</b><br/>(0.89 to 2.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1499<br/>(16 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compared to placebo, baclofen does not increase the number of dropouts due to adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_432179672169955326" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_432179672169955326</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for inconsistency IÂ² = 73%.<br/><sup>b</sup> Downgraded one level for inconsistency IÂ² = 71%.<br/><sup>c</sup> Downgraded one level for risk of bias: one study at high risk for attrition and reporting bias. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012557-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span>Â <span class="table-title">Summary of findings table â Baclofen compared to acamprosate for alcohol use disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Baclofen compared to acamprosate for alcohol use disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> alcohol use disorder<br/><b>Setting:</b> <br/><b>Intervention:</b> baclofen<br/><b>Comparison:</b> acamprosate </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>â of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with acamprosate</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with baclofen</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse: return to any drinking at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b><br/>(284 to 880) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.25</b><br/>(0.71 to 2.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is uncertain whether baclofen and acamprosate differ in the return to any drinking.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: number of participants with at least one adverse event at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>267 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>168 per 1000</b><br/>(61 to 451) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.63</b><br/>(0.23 to 1.69) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is uncertain whether baclofen and acamprosate differ in the number of participants with â¥ 1 adverse event at the end of treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dropouts at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>168 per 1000</b><br/>(63 to 438) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.56</b><br/>(0.21 to 1.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is uncertain whether baclofen and acamprosate differ in dropouts at the end of treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dropouts due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b><br/>(0 to 262) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b><br/>(0.01 to 7.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is uncertain whether baclofen and acamprosate differ in dropouts due to adverse events at the end of treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_432318545502233572" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_432318545502233572</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level: one study at high risk of performance, detection, and attrition bias and at unclear risk of selection bias.<br/><sup>b</sup> Downgraded two levels for imprecision: fewer than 100 events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012557-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span>Â <span class="table-title">Summary of findings table â Baclofen compared to naltrexone for alcohol use disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Baclofen compared to naltrexone for alcohol use disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> alcohol use disorder<br/><b>Setting:</b> <br/><b>Intervention:</b> baclofen<br/><b>Comparison:</b> naltrexone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>â of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with naltrexone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with baclofen</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse: return to any drinking at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b><br/>(224 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.50</b><br/>(1.12 to 5.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is uncertain whether baclofen and naltrexone differ in the risk to return to any drinking. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: number of participants with â¥ 1 adverse event at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>450 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>158 per 1000</b><br/>(68 to 360) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.35</b><br/>(0.15 to 0.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is uncertain whether baclofen and naltrexone differ in the number of participants with â¥ 1 adverse event at the end of treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dropouts at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b><br/>(53 to 517) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/>(0.32 to 3.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is uncertain whether baclofen and naltrexone differ in dropouts at the end of treatment.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_432318841614592889" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_432318841614592889</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level: one study at high risk of performance, detection and attrition bias.<br/><sup>b</sup> Downgraded two levels due to imprecision: fewer than 100 events. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012557-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012557-sec-0009"></div> <section id="CD012557-sec-0010"> <h3 class="title" id="CD012557-sec-0010">Description of the condition</h3> <p>Alcohol use disorder (AUD) is a severe mental disorder characterised by the inability to control alcohol consumption and frequent episodes of heavy drinking leading to detrimental consequences for both people with this disorder and others (<a href="./references#CD012557-bbs2-0054" title="CarvalhoAF , HeiligM , PerezA , ProbstC , RehmJ . Alcohol use disorders. Lancet2019;394(10200):781-92. [PMID: 31478502]">Carvalho 2019</a>; <a href="./references#CD012557-bbs2-0104" title="MacKillopJ , AgabioR , Feldstein EwingS , HeiligM , KellyJ , LeggioL , et al. Hazardous drinking and alcohol use disorders. Nature Reviews Disease Primers2022;8:80. [DOI: Hazardous drinking and alcohol use disorders]">MacKillop 2022</a>). AUD as a disease category has been introduced in the latest version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSMâ5) (<a href="./references#CD012557-bbs2-0049" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Washington (DC): American Psychiatric Association, 2013.">APA 2013</a>). While the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSMâIV) (<a href="./references#CD012557-bbs2-0048" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington (DC): American Psychiatric Association, 2000.">APA 2000</a>) and International Classification of Diseases 11th edition (ICD)â11 (<a href="./references#CD012557-bbs2-0154" title="World Health Organization. International Classification of Diseases 11th revision (ICD-11). World Health Organization2019.">WHO 2019</a>) subdivided substance use disorders into dependence and a secondary category, called 'abuse' in DSMâIV and 'harmful use' in ICDâ11 (<a href="./references#CD012557-bbs2-0104" title="MacKillopJ , AgabioR , Feldstein EwingS , HeiligM , KellyJ , LeggioL , et al. Hazardous drinking and alcohol use disorders. Nature Reviews Disease Primers2022;8:80. [DOI: Hazardous drinking and alcohol use disorders]">MacKillop 2022</a>), the DSMâ5 integrates both categories into a single substance use disorder concept that ranges along a continuum from mild to severe (<a href="./references#CD012557-bbs2-0049" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Washington (DC): American Psychiatric Association, 2013.">APA 2013</a>). </p> <p>AUD and alcoholârelated impairments belong to the most widespread psychiatric disorders (<a href="./references#CD012557-bbs2-0054" title="CarvalhoAF , HeiligM , PerezA , ProbstC , RehmJ . Alcohol use disorders. Lancet2019;394(10200):781-92. [PMID: 31478502]">Carvalho 2019</a>; <a href="./references#CD012557-bbs2-0074" title="GrantBF , GoldsteinRB , SahaTD , ChouSP , JungJ , ZhangH , et al. Epidemiology of DSM-5 alcohol use disorder: results From the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry2015;72(8):757-66.">Grant 2015</a>). Worldwide, according to the World Health Organization (WHO), oneâyear AUD prevalence was estimated at approximately 5% of the general population in 2016, equivalent to 1 in 20 adults (<a href="./references#CD012557-bbs2-0153" title="World Health Organization. Global status report on alcohol and health 2018. www.who.int/publications/i/item/9789241565639 (accessed 8 December 2022).">WHO 2018</a>). Statistics vary between regions, with a higher prevalence of AUD in highâincome countries compared to lowâ and middleâincome countries (<a href="./references#CD012557-bbs2-0071" title="GlantzMD , BharatC , DegenhardtL , SampsonNA , ScottKM , LimCC , et al, WHO World Mental Health Survey Collaborators. The epidemiology of alcohol use disorders cross-nationally: findings from the World Mental Health Surveys. Addictive Behaviors2020;102:106128. [DOI: 10.1016/j.addbeh.2019.106128]">Glantz 2020</a>), with the highest oneâyear prevalence of AUD in European countries and North America (<a href="./references#CD012557-bbs2-0153" title="World Health Organization. Global status report on alcohol and health 2018. www.who.int/publications/i/item/9789241565639 (accessed 8 December 2022).">WHO 2018</a>). The latest WHO status report on alcohol and health selected the heavy episodic drinking (HED, defined as 60 g or more of pure alcohol on at least one single occasion at least once per month) as an indicator of the pattern of excessive alcohol consumption (<a href="./references#CD012557-bbs2-0153" title="World Health Organization. Global status report on alcohol and health 2018. www.who.int/publications/i/item/9789241565639 (accessed 8 December 2022).">WHO 2018</a>). Worldwide, using survey data from 118 countries, the prevalence of HED was estimated at 20% of the adult general population (aged 15 years and older) (<a href="./references#CD012557-bbs2-0105" title="MantheyJ , ShieldKD , RylettM , HasanOS , ProbstC , RehmJ . Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study. Lancet2019;393(10190):2493-502. [PMID: 31076174]">Manthey 2019</a>), with the highest values in European countries (26% of the general population) and America (21% of the general population) (<a href="./references#CD012557-bbs2-0153" title="World Health Organization. Global status report on alcohol and health 2018. www.who.int/publications/i/item/9789241565639 (accessed 8 December 2022).">WHO 2018</a>). There is evidence indicating an enormous increase in alcohol use, highârisk drinking and DSMâIV AUD in the US population between 2001/2002 and 2012/2013 (<a href="./references#CD012557-bbs2-0075" title="GrantBF , ChouSP , SahaTD , PickeringRP , KerridgeBT , RuanWJ , et al. Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001â2002 to 2012â2013: results from the National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiatry2017;74(9):911-23.">Grant 2017</a>). Nevertheless, with the improved industrialisation and centralisation of alcohol production, alcohol consumption is increasingly becoming a problem in many lowâ and middleâincome countries (<a href="./references#CD012557-bbs2-0153" title="World Health Organization. Global status report on alcohol and health 2018. www.who.int/publications/i/item/9789241565639 (accessed 8 December 2022).">WHO 2018</a>). </p> <p>Irrespective of region, AUD is prevalent in more men than women (<a href="./references#CD012557-bbs2-0071" title="GlantzMD , BharatC , DegenhardtL , SampsonNA , ScottKM , LimCC , et al, WHO World Mental Health Survey Collaborators. The epidemiology of alcohol use disorders cross-nationally: findings from the World Mental Health Surveys. Addictive Behaviors2020;102:106128. [DOI: 10.1016/j.addbeh.2019.106128]">Glantz 2020</a>), with lifetime prevalence estimated at 14.8% among men and 3.5% among women in the Europe and 11.5% among men and 5.1% among women in the Americas (<a href="./references#CD012557-bbs2-0153" title="World Health Organization. Global status report on alcohol and health 2018. www.who.int/publications/i/item/9789241565639 (accessed 8 December 2022).">WHO 2018</a>). However, there is evidence on converging drinking patterns between genders (<a href="./references#CD012557-bbs2-0142" title="SladeT , ChapmanC , SwiftW , KeyesK , TonksZ , TeessonM . Birth cohort trends in the global epidemiology of alcohol use and alcohol-related harms in men and women: systematic review and metaregression. BMJ Open2016;6(10):e011827. [PMID: 27797998]">Slade 2016</a>; <a href="./references#CD012557-bbs2-0150" title="WhiteA , CastleIJ , ChenCM , ShirleyM , RoachD , HingsonR . Converging patterns of alcohol use and related outcomes among females and males in the United States, 2002 to 2012. Alcoholism, Clinical and Experimental Research2015;39(9):1712-26.">White 2015</a>). </p> <p>The misuse of alcohol is one of the leading global health risk factors causing cancer, liver disease, heart disease, neurological disorders, fetal alcohol spectrum disorder, motor vehicle accidents, murder and other intentional injuries (<a href="./references#CD012557-bbs2-0068" title="GBD 2019 Cancer Risk Factors Collaborators. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019. Lancet2022;400(10352):563-91.">GBD 2019 Cancer Risk Factors Collaborators 2022</a>; <a href="./references#CD012557-bbs2-0069" title="GBD 2020 Alcohol Collaborators. Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020. Lancet2022;400(10347):185-235. [DOI: 10.1016/S0140-6736(22)00847-9]">GBD 2020 Alcohol Collaborators 2022</a>). Worldwide, in 2016, alcohol use was the seventh leading risk factor for deaths accounting for 2.2% of female and 6.8% of male deaths (<a href="./references#CD012557-bbs2-0067" title="GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990â2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet2018;392(10152):1015-35. [PMID: 30146330]">GBD 2018</a>). It has been estimated that alcohol use will remain one of the leading risk factors for the burden of disease for the foreseeable future (<a href="./references#CD012557-bbs2-0105" title="MantheyJ , ShieldKD , RylettM , HasanOS , ProbstC , RehmJ . Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study. Lancet2019;393(10190):2493-502. [PMID: 31076174]">Manthey 2019</a>). The risk of allâcause mortality is dose related and the level of consumption that minimises health loss is zero (<a href="./references#CD012557-bbs2-0067" title="GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990â2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet2018;392(10152):1015-35. [PMID: 30146330]">GBD 2018</a>). Men with AUD have a threeâfold higher mortality risk compared to men without AUD; in women, the risk is even higher (<a href="./references#CD012557-bbs2-0129" title="RoereckeM , RehmJ . Alcohol use disorders and mortality: a systematic review and meta-analysis. Addiction2013;108(9):1562-78.">Roerecke 2013</a>). In 2016, 5.3% of all global deaths and 5.0% of global disabilityâadjusted lifeâyears were attributable to alcohol (<a href="./references#CD012557-bbs2-0139" title="ShieldK , MantheyJ , RylettM , ProbstC , WettlauferA , ParryCD , et al. National, regional, and global burdens of disease from 2000 to 2016 attributable to alcohol use: a comparative risk assessment study. Lancet Public Health2020;5(1):e51-61. [DOI: 10.1016/S2468-2667(19)30231-2]">Shield 2020</a>). Studies also suggest that AUD increases the risk of COVIDâ19 infections and mortality (<a href="./references#CD012557-bbs2-0065" title="FondG , NemaniK , Etchecopar-EtchartD , LoundouA , GoffDC , LeeSW , et al. Association between mental health disorders and mortality among patients with COVID-19 in 7 countries: a systematic review and meta-analysis. JAMA Psychiatry2021;78(11):1208-17. [PMID: 34313711]">Fond 2021</a>; <a href="./references#CD012557-bbs2-0143" title="SpagnoloPA , MontemitroC , LeggioL . New challenges in addiction medicine: COVID-19 infection in patients with alcohol and substance use disorders â the perfect storm. American Journal of Psychiatry2020;177(9):805-7. [PMID: 32660296]">Spagnolo 2020</a>). The costs attributable to alcohol consumption are estimated to be on average 2.6% of gross domestic product, the majority of costs due to loss in productivity (<a href="./references#CD012557-bbs2-0106" title="MantheyJ , HassanSA , CarrS , KilianC , Kuitunen-PaulS , RehmJ . What are the economic costs to society attributable to alcohol use? A systematic review and modelling study. Pharmacoeconomics2021;39(7):809-22. [DOI: 10.1007/s40273-021-01031-8]">Manthey 2021</a>). At the same time, alcohol consumption is one of the major, potentially avoidable risk factors, underscoring the need for effective strategies to reduce excessive drinking and maintain abstinence in people with AUD (<a href="./references#CD012557-bbs2-0079" title="HaberPS , RiordanBC , WinterDT , BarrettL , SaundersJ , HidesL , et al. New Australian guidelines for the treatment of alcohol problems: an overview of recommendations. Medical Journal of Australia2021;215(Suppl 7):S3-32. [PMID: 34601742]">Haber 2021</a>). </p> <p>The treatment of AUD was exclusively dominated by psychosocial strategies for many decades. Even though techniques from different theoretical and therapeutic backgrounds have been developed, treatment effects obtained by an exclusive application of psychosocial treatment are limited. A high proportion of patients do not respond to the interventions and, of those who respond, few succeed in maintaining abstinence in the long term (<a href="./references#CD012557-bbs2-0113" title="MoosRH , MoosBS . Rates and predictors of relapse after natural and treated remission from alcohol use disorders. Addiction2006;101(2):212-22.">Moos 2006</a>). With the investigation of the neurobiological mechanism of AUD, several pharmacological agents have been examined for their potential to support people with AUD in achieving abstinence or in cutting down their alcohol consumption (<a href="./references#CD012557-bbs2-0157" title="WitkiewitzK , LittenRZ , LeggioL . Advances in the science and treatment of alcohol use disorder. Science Advances2019;5(9):eaax4043. [PMID: 31579824]">Witkiewitz 2019</a>). Four agents are approved for the pharmacological treatment of AUD: the opioid antagonists naltrexone and nalmefene; the glutamate antagonist acamprosate; and the aversive agent disulfiram (<a href="./references#CD012557-bbs2-0117" title="MutschlerJ , GrosshansM , SoykaM , RÃ¶snerS . Current findings and mechanisms of action of disulfiram in the treatment of alcohol dependence. Pharmacopsychiatry2016;49(4):137-41.">Mutschler 2016</a>; <a href="./references#CD012557-bbs2-0127" title="ReusVI , FochtmannLJ , BuksteinO , EylerAE , HiltyDM , Horvitz-LennonM , et al. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. American Journal of Psychiatry2018;175(1):86-90. [PMID: 29301420]">Reus 2018</a>). While the primary mechanism of action of the two opioid antagonists is to block alcoholâinduced reward effects, acamprosate is assumed to work by restoring the balance between inhibitory and excitatory neurotransmitters (<a href="./references#CD012557-bbs2-0133" title="RÃ¶snerS , Hackl-HerrwerthA , LeuchtS , LehertP , VecchiS , SoykaM . Acamprosate for alcohol dependence. Cochrane Database of Systematic Reviews2010, Issue 9. Art. No: CD004332. [DOI: 10.1002/14651858.CD004332.pub2]">RÃ¶sner 2010a</a>; <a href="./references#CD012557-bbs2-0134" title="RÃ¶snerS , Hackl-HerrwerthA , LeuchtS , VecchiS , SrisurapanontM , SoykaM . Opioid antagonists for alcohol dependence. Cochrane Database of Systematic Reviews2010, Issue 12. Art. No: CD001867. [DOI: 10.1002/14651858.CD001867.pub3]">RÃ¶sner 2010b</a>). In contrast to naltrexone, nalmefene and acamprosate, which are assumed to modulate neurobiological mechanisms of addiction, disulfiram works by producing an aversive reaction when combined with alcohol (<a href="./references#CD012557-bbs2-0117" title="MutschlerJ , GrosshansM , SoykaM , RÃ¶snerS . Current findings and mechanisms of action of disulfiram in the treatment of alcohol dependence. Pharmacopsychiatry2016;49(4):137-41.">Mutschler 2016</a>; <a href="./references#CD012557-bbs2-0141" title="SkinnerMD , LahmekP , PhamH , AubinHJ . Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLOS One2014;9(2):e87366. [PMID: 24520330]">Skinner 2014</a>). Various Cochrane Reviews have investigated the effects of pharmacological interventions for the treatment of alcohol withdrawal (<a href="./references#CD012557-bbs2-0042" title="AmatoL , MinozziS , VecchiS , DavoliM . Benzodiazepines for alcohol withdrawal. Cochrane Database of Systematic Reviews2010, Issue 3. Art. No: CD005063. [DOI: 10.1002/14651858.CD005063.pub3]">Amato 2010</a>; <a href="./references#CD012557-bbs2-0043" title="AmatoL , MinozziS , DavoliM . Efficacy and safety of pharmacological interventions for the treatment of the alcohol withdrawal syndrome. Cochrane Database of Systematic Reviews2011, Issue 6. Art. No: CD008537. [DOI: 10.1002/14651858.CD008537.pub2]">Amato 2011</a>; <a href="./references#CD012557-bbs2-0070" title="GillmanMA , LichtigfeldF , YoungT . Psychotropic analgesic nitrous oxide for alcoholic withdrawal states. Cochrane Database of Systematic Reviews2007, Issue 2. Art. No: CD005190. [DOI: 10.1002/14651858.CD005190.pub2]">Gillman 2007</a>; <a href="./references#CD012557-bbs2-0096" title="LeoneMA , Vigna-TagliantiF , AvanziG , BrambillaR , FaggianoF . Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database of Systematic Reviews2010, Issue 2. Art. No: CD006266. [DOI: 10.1002/14651858.CD006266.pub2]">Leone 2010</a>; <a href="./references#CD012557-bbs2-0098" title="LiuJ , WangLN . Baclofen for alcohol withdrawal. Cochrane Database of Systematic Reviews2015, Issue 4. Art. No: CD008502. [DOI: 10.1002/14651858.CD008502.pub4]">Liu 2015</a>; <a href="./references#CD012557-bbs2-0111" title="MinozziS , AmatoL , VecchiS , DavoliM . Anticonvulsants for alcohol withdrawal. Cochrane Database of Systematic Reviews2010, Issue 3. Art. No: CD006754. [DOI: 10.1002/14651858.CD006754.pub4]">Minozzi 2010</a>; <a href="./references#CD012557-bbs2-0135" title="SaraiM , TejaniAM , ChanAH , KuoIF , LiJ . Magnesium for alcohol withdrawal. Cochrane Database of Systematic Reviews2013, Issue 6. Art. No: CD008358. [DOI: 10.1002/14651858.CD008358.pub2]">Sarai 2013</a>), and for relapse prevention in AUD (<a href="./references#CD012557-bbs2-0120" title="PaniPP , TroguE , PaciniM , MaremmaniI . Anticonvulsants for alcohol dependence. Cochrane Database of Systematic Reviews2014, Issue 2. Art. No: CD008544. [DOI: 10.1002/14651858.CD008544.pub2]">Pani 2014</a>; <a href="./references#CD012557-bbs2-0122" title="PedersenB , AskgaardG , OppedalK . Disulfiram for alcohol use disorder. Cochrane Database of Systematic Reviews2013, Issue 4. Art. No: CD010487. [DOI: 10.1002/14651858.CD010487]">Pedersen 2013</a>; <a href="./references#CD012557-bbs2-0133" title="RÃ¶snerS , Hackl-HerrwerthA , LeuchtS , LehertP , VecchiS , SoykaM . Acamprosate for alcohol dependence. Cochrane Database of Systematic Reviews2010, Issue 9. Art. No: CD004332. [DOI: 10.1002/14651858.CD004332.pub2]">RÃ¶sner 2010a</a>; <a href="./references#CD012557-bbs2-0134" title="RÃ¶snerS , Hackl-HerrwerthA , LeuchtS , VecchiS , SrisurapanontM , SoykaM . Opioid antagonists for alcohol dependence. Cochrane Database of Systematic Reviews2010, Issue 12. Art. No: CD001867. [DOI: 10.1002/14651858.CD001867.pub3]">RÃ¶sner 2010b</a>; <a href="./references#CD012557-bbs2-0147" title="Vaz de LimaFB , AndrioloRB , da SilveiraDX . Dopaminergic antagonists for alcohol dependence. Cochrane Database of Systematic Reviews2010, Issue 4. Art. No: CD003352. [DOI: 10.1002/14651858.CD003352.pub4]">Vaz de Lima 2010</a>). The best practice in the treatment of AUD should comprise both pharmacotherapy and psychotherapy (<a href="./references#CD012557-bbs2-0079" title="HaberPS , RiordanBC , WinterDT , BarrettL , SaundersJ , HidesL , et al. New Australian guidelines for the treatment of alcohol problems: an overview of recommendations. Medical Journal of Australia2021;215(Suppl 7):S3-32. [PMID: 34601742]">Haber 2021</a>; <a href="./references#CD012557-bbs2-0126" title="RayLA , MeredithLR , KilukBD , WalthersJ , CarrollKM , MagillM . Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders: a systematic review and meta-analysis. JAMA Network Open2020;3(6):e208279. [PMID: 32558914]">Ray 2020</a>). However, in the US, one recent national study that interviewed more than 42,000 adults estimated that only 1.6% of people with AUD received medications approved for this disorder (<a href="./references#CD012557-bbs2-0080" title="HanB , JonesCM , EinsteinEB , PowellPA , ComptonWM . Use of medications for alcohol use disorder in the US: results from the 2019 national survey on drug use and health. JAMA Psychiatry2021;78(8):922-4. [PMID: 34132744]">Han 2021</a>). In Italy, among a sample of 345 people with severe AUD admitted to public services for outpatient treatment of this disorder, less than 30% received the combination of pharmacotherapy and psychotherapy even if they were still drinking during treatment (<a href="./references#CD012557-bbs2-0040" title="AgabioR , BaliaS , GessaGL , PaniPP . Use of medications for the treatment of alcohol dependence: a retrospective study conducted in 2011â2012. Current Drug Research Reviews2021;13(2):154-64. [PMID: 33371866]">Agabio 2021a</a>). </p> </section> <section id="CD012557-sec-0011"> <h3 class="title" id="CD012557-sec-0011">Description of the intervention</h3> <p>Baclofen, also known as betaâ4âchlorophenylâgammaâaminobutyric acid (<a href="./references#CD012557-bbs2-0144" title="SteardoL , LeoA , MaranoE . Efficacy of baclofen in trigeminal neuralgia and some other painful conditions. A clinical trial. European Neurology1984;23(1):51-5.">Steardo 1984</a>), is an agonist of the Î³âaminobutyric acid type B (GABA<sub>B</sub>) receptor (<a href="./references#CD012557-bbs2-0091" title="KentCN , ParkC , LindsleyCW . Classics in chemical neuroscience: baclofen. Chemical Neuroscience2020;11(12):1740-55. [PMID: 32436697]">Kent 2020</a>). The substance was originally approved for use in spasticity associated with neurological conditions and has recently emerged as a treatment of major interest for AUD (<a href="./references#CD012557-bbs2-0035" title="AgabioR , PretiA , GessaGL . Efficacy and tolerability of baclofen in substance use disorders: a systematic review. European Addiction Research2013;19(6):325-45.">Agabio 2013</a>; <a href="./references#CD012557-bbs2-0036" title="AgabioR , ColomboG . GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence. Frontiers in Neuroscience2014;8:140. [DOI: 10.3389/fnins.2014.00140]">Agabio 2014</a>; <a href="./references#CD012557-bbs2-0038" title="AgabioR , SinclairJM , AddoloratoG , AubinHJ , BerahaEM , CaputoF , et al. Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry2018;5(12):957-60. [PMID: 30413394]">Agabio 2018a</a>; <a href="./references#CD012557-bbs2-0045" title="AndradeC . Individualized, high-dose baclofen for reduction in alcohol intake in persons with high levels of consumption. Journal of Clinical Psychiatry2020;81(4):20f13606. [PMID: 32757504]">Andrade 2020</a>; <a href="./references#CD012557-bbs2-0050" title="BrennanJL , LeungJG , GagliardiJP , RivelliSK , MuzykAJ . Clinical effectiveness of baclofen for the treatment of alcohol dependence: a review. Clinical Pharmacology2013;5:99-107. [DOI: 10.2147/CPAA.S32434]">Brennan 2013</a>; <a href="./references#CD012557-bbs2-0053" title="BurnetteEM , NietoSJ , GrodinEN , MeredithLR , HurleyB , MiottoK , et al. Novel agents for the pharmacological treatment of alcohol use disorder. Drugs2022;82(3):251-74. [PMID: PMC8888464]">Burnette 2022</a>; <a href="./references#CD012557-bbs2-0062" title="deBeaurepaireR , SinclairJM , HeydtmannM , AddoloratoG , AubinHJ , BerahaEM , et al. The use of baclofen as a treatment for alcohol use disorder: a clinical practice perspective. Frontiers in Psychiatry2019;9:708. [PMID: 30662411]">de Beaurepaire 2019</a>; <a href="./references#CD012557-bbs2-0115" title="MorleyKC , PerryCJ , WattJ , HurzelerT , LeggioL , LawrenceAJ , et al. New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies. Expert Opinion on Pharmacotherapy2021;22(10):1291-303. [PMID: 33615945]">Morley 2021</a>). Baclofen is available in oral formulations and intrathecal solutions, the latter reserved for treatment of spasticity unresponsive to oral administration of baclofen. The recommended oral daily dose for baclofen ranges from 15 mg to 80 mg, starting from 15 mg a day and increasing by 5 mg every three days (<a href="./references#CD012557-bbs2-0038" title="AgabioR , SinclairJM , AddoloratoG , AubinHJ , BerahaEM , CaputoF , et al. Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry2018;5(12):957-60. [PMID: 30413394]">Agabio 2018a</a>; <a href="./references#CD012557-bbs2-0062" title="deBeaurepaireR , SinclairJM , HeydtmannM , AddoloratoG , AubinHJ , BerahaEM , et al. The use of baclofen as a treatment for alcohol use disorder: a clinical practice perspective. Frontiers in Psychiatry2019;9:708. [PMID: 30662411]">de Beaurepaire 2019</a>). Despite high individual variation in pharmacokinetics, baclofen is rapidly absorbed from the gastrointestinal tract following oral administration. Up to 80% of an oral dose is excreted in the urine, with only a limited hepatic metabolism, making it a useful agent in people with impaired hepatic function, while renal function should be carefully assessed prior to baclofen administration (<a href="./references#CD012557-bbs2-0038" title="AgabioR , SinclairJM , AddoloratoG , AubinHJ , BerahaEM , CaputoF , et al. Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry2018;5(12):957-60. [PMID: 30413394]">Agabio 2018a</a>; <a href="./references#CD012557-bbs2-0050" title="BrennanJL , LeungJG , GagliardiJP , RivelliSK , MuzykAJ . Clinical effectiveness of baclofen for the treatment of alcohol dependence: a review. Clinical Pharmacology2013;5:99-107. [DOI: 10.2147/CPAA.S32434]">Brennan 2013</a>). In addition, baclofen has a short halfâlife of three to four hours and is rapidly cleared from the blood. As a result, baclofen needs to be administered three or four times per day to maintain therapeutic effects (<a href="./references#CD012557-bbs2-0137" title="Schwarz Pharma. KemstroÂ® (oral baclofen tablets) package insert. Monheim (Germany)2003.">Schwarz Pharma 2003</a>). </p> <p>Preclinical studies have found that baclofen reduces the acquisition of alcoholâdrinking behaviour and its maintenance and reinstatement in alcoholâexperienced rats (<a href="./references#CD012557-bbs2-0036" title="AgabioR , ColomboG . GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence. Frontiers in Neuroscience2014;8:140. [DOI: 10.3389/fnins.2014.00140]">Agabio 2014</a>; <a href="./references#CD012557-bbs2-0057" title="ColomboG , GessaGL . Suppressing effect of baclofen on multiple alcohol-related behaviors in laboratory animals. Frontiers in Psychiatry2018;9:475. [PMID: 30323777]">Colombo 2018</a>). Effects on reinstatement were assessed by the modification of the soâcalled 'alcohol deprivation effect', a rodent model for studying relapse behaviour referring to the temporary increase in voluntary alcohol intake after a period of forced abstinence from alcohol in a freeâchoice experiment (<a href="./references#CD012557-bbs2-0109" title="Martin-FardonR , WeissF . Modeling relapse in animals. Current Topics in Behavioral Neurosciences2013;13:403-32.">MartinâFardon 2013</a>). Furthermore, baclofen has been shown to doseâdependently reduce the number of leverâresponses for alcohol and the amount of selfâadministered alcohol in rats under operant selfâadministration conditions (e.g. <a href="./references#CD012557-bbs2-0057" title="ColomboG , GessaGL . Suppressing effect of baclofen on multiple alcohol-related behaviors in laboratory animals. Frontiers in Psychiatry2018;9:475. [PMID: 30323777]">Colombo 2018</a>; <a href="./references#CD012557-bbs2-0100" title="MaccioniP , SerraS , VaccaG , OrrÃ¹A , PesD , AgabioR , et al. Baclofen-induced reduction of alcohol reinforcement in alcohol-preferring rats. Alcohol2005;36(3):161-8.">Maccioni 2005</a>; <a href="./references#CD012557-bbs2-0102" title="MaccioniP , ZaruA , LoiB , LobinaC , CaraiMA , GessaGL , et al. Comparison of the effect of the GABAÎ receptor agonist, baclofen, and the positive allosteric modulator of the GABAB receptor, GS39783, on alcohol self-administration in 3 different lines of alcohol-preferring rats. Alcoholism, Clinical and Experimental Research2012;36(10):1748-66.">Maccioni 2012</a>). In operant selfâadministration experiments, a specific amount of 'work' is required to access alcohol, with predictive validity for human alcohol craving, and providing measures of alcohol consumption and the reinforcing properties of alcohol (<a href="./references#CD012557-bbs2-0036" title="AgabioR , ColomboG . GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence. Frontiers in Neuroscience2014;8:140. [DOI: 10.3389/fnins.2014.00140]">Agabio 2014</a>; <a href="./references#CD012557-bbs2-0057" title="ColomboG , GessaGL . Suppressing effect of baclofen on multiple alcohol-related behaviors in laboratory animals. Frontiers in Psychiatry2018;9:475. [PMID: 30323777]">Colombo 2018</a>). Thereby baclofen was more potent and effective in those rats seeking and taking larger amounts of alcohol (<a href="./references#CD012557-bbs2-0057" title="ColomboG , GessaGL . Suppressing effect of baclofen on multiple alcohol-related behaviors in laboratory animals. Frontiers in Psychiatry2018;9:475. [PMID: 30323777]">Colombo 2018</a>; <a href="./references#CD012557-bbs2-0102" title="MaccioniP , ZaruA , LoiB , LobinaC , CaraiMA , GessaGL , et al. Comparison of the effect of the GABAÎ receptor agonist, baclofen, and the positive allosteric modulator of the GABAB receptor, GS39783, on alcohol self-administration in 3 different lines of alcohol-preferring rats. Alcoholism, Clinical and Experimental Research2012;36(10):1748-66.">Maccioni 2012</a>; <a href="./references#CD012557-bbs2-0149" title="WalkerBM , KoobGF . The gamma-aminobutyric acid-B receptor agonist baclofen attenuates responding for ethanol in ethanol-dependent rats. Alcoholism, Clinical and Experimental Research2007;31(1):11-8.">Walker 2007</a>). </p> <p>A series of case reports found that the administration of baclofen markedly reduced alcohol intake in people with AUD (<a href="./references#CD012557-bbs2-0034" title="AgabioR , MarrasP , AddoloratoG , CarpinielloB , GessaGL . Baclofen suppresses alcohol intake and craving for alcohol in a schizophrenic alcohol-dependent patient: a case report. Journal of Clinical Psychopharmacology2007;27(3):319-20.">Agabio 2007</a>; <a href="./references#CD012557-bbs2-0044" title="AmeisenO . Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol and Alcoholism2005;40(2):147-50.">Ameisen 2005</a>; <a href="./references#CD012557-bbs2-0052" title="BucknamW . Suppression of symptoms of alcohol dependence and craving using high-dose baclofen. Alcohol and Alcoholism2006;2(42):158-60.">Bucknam 2006</a>; <a href="./references#CD012557-bbs2-0025" title="FlanneryBA , GarbuttJC , CodyMW , RennW , GraceK , OsborneM , et al. Baclofen for alcohol dependence: a preliminary open-label study. Alcoholism, Clinical and Experimental Research2004;28(10):1517-23. ">Flannery 2004</a>; <a href="./references#CD012557-bbs2-0092" title="KrupitskyEM , BurakovAM , IvanovVB , KrandashovaGF , LapinIP , GrinenkoAJ , et al. Baclofen administration for the treatment of affective disorders in alcoholic patients. Drug and Alcohol Dependence1993;33(2):157-63. [DOI: 10.1016/0376-8716(93)90057-w]">Krupitsky 1993</a>; <a href="./references#CD012557-bbs2-0121" title="PastorA , JonesD , CurrieJ . High-dose baclofen for treatment-resistant alcohol dependence. Journal of Clinical Psychopharmacology2012;32:266-8.">Pastor 2012</a>). <a href="./references#CD012557-bbs2-0044" title="AmeisenO . Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol and Alcoholism2005;40(2):147-50.">Ameisen 2005</a> described the personal history of a French physician, who conducted an original doseâfinding curve with baclofen with the aim of treating his own AUD (<a href="./references#CD012557-bbs2-0036" title="AgabioR , ColomboG . GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence. Frontiers in Neuroscience2014;8:140. [DOI: 10.3389/fnins.2014.00140]">Agabio 2014</a>; <a href="./references#CD012557-bbs2-0062" title="deBeaurepaireR , SinclairJM , HeydtmannM , AddoloratoG , AubinHJ , BerahaEM , et al. The use of baclofen as a treatment for alcohol use disorder: a clinical practice perspective. Frontiers in Psychiatry2019;9:708. [PMID: 30662411]">de Beaurepaire 2019</a>). He tested oral baclofen, starting with the 'conventional' dose of 30 mg a day and increased the daily dose up to 270 mg after five weeks, experiencing, "complete medicationâinduced suppression of craving" for alcohol with alleviation of comorbid anxiety (<a href="./references#CD012557-bbs2-0044" title="AmeisenO . Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol and Alcoholism2005;40(2):147-50.">Ameisen 2005</a>). </p> <p>While numerous case reports, case series and openâlabel studies have been published indicating the effectiveness of baclofen in people with AUD, randomised controlled trials (RCTs) conducted to date have yielded conflicting results (for an overview see <a href="./references#CD012557-bbs2-0062" title="deBeaurepaireR , SinclairJM , HeydtmannM , AddoloratoG , AubinHJ , BerahaEM , et al. The use of baclofen as a treatment for alcohol use disorder: a clinical practice perspective. Frontiers in Psychiatry2019;9:708. [PMID: 30662411]">de Beaurepaire 2019</a>). The diversity of findings has stimulated the discussion on potential moderators of effectiveness (<a href="./references#CD012557-bbs2-0038" title="AgabioR , SinclairJM , AddoloratoG , AubinHJ , BerahaEM , CaputoF , et al. Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry2018;5(12):957-60. [PMID: 30413394]">Agabio 2018a</a>; <a href="./references#CD012557-bbs2-0062" title="deBeaurepaireR , SinclairJM , HeydtmannM , AddoloratoG , AubinHJ , BerahaEM , et al. The use of baclofen as a treatment for alcohol use disorder: a clinical practice perspective. Frontiers in Psychiatry2019;9:708. [PMID: 30662411]">de Beaurepaire 2019</a>; <a href="./references#CD012557-bbs2-0095" title="LeggioL , GarbuttJC , AddoloratoG . Effectiveness and safety of baclofen in the treatment of alcohol dependent patients. CNS &amp; Neurological Disorders Drug Targets2010;9:33-44.">Leggio 2010</a>; <a href="./references#CD012557-bbs2-0115" title="MorleyKC , PerryCJ , WattJ , HurzelerT , LeggioL , LawrenceAJ , et al. New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies. Expert Opinion on Pharmacotherapy2021;22(10):1291-303. [PMID: 33615945]">Morley 2021</a>). Among others, severity of alcohol dependence (<a href="./references#CD012557-bbs2-0038" title="AgabioR , SinclairJM , AddoloratoG , AubinHJ , BerahaEM , CaputoF , et al. Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry2018;5(12):957-60. [PMID: 30413394]">Agabio 2018a</a>; <a href="./references#CD012557-bbs2-0062" title="deBeaurepaireR , SinclairJM , HeydtmannM , AddoloratoG , AubinHJ , BerahaEM , et al. The use of baclofen as a treatment for alcohol use disorder: a clinical practice perspective. Frontiers in Psychiatry2019;9:708. [PMID: 30662411]">de Beaurepaire 2019</a>), baclofen dosing (<a href="./references#CD012557-bbs2-0038" title="AgabioR , SinclairJM , AddoloratoG , AubinHJ , BerahaEM , CaputoF , et al. Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry2018;5(12):957-60. [PMID: 30413394]">Agabio 2018a</a>; <a href="./references#CD012557-bbs2-0062" title="deBeaurepaireR , SinclairJM , HeydtmannM , AddoloratoG , AubinHJ , BerahaEM , et al. The use of baclofen as a treatment for alcohol use disorder: a clinical practice perspective. Frontiers in Psychiatry2019;9:708. [PMID: 30662411]">de Beaurepaire 2019</a>; <a href="./references#CD012557-bbs2-0146" title="ThompsonA , OwensL , RichardsonP , PirmohamedM . Systematic review: baclofen dosing protocols for alcohol use disorders used in observational studies. European Neuropsychopharmacology2017;27(11):1077-89.">Thompson 2017</a>), and comorbid anxiety (<a href="./references#CD012557-bbs2-0039" title="AgabioR , LeggioL . Baclofen in the treatment of patients with alcohol use disorder and other mental health disorders. Frontiers in Psychiatry2018;9:464. [PMID: 30323774]">Agabio 2018b</a>; <a href="./references#CD012557-bbs2-0041" title="AgabioR , BaldwinDS , AmaroH , LeggioL , SinclairJM . The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: a systematic review and meta-analysis. Neuroscience &amp; Biobehavioral Reviews2021;125:296-313. [PMID: 33454289]">Agabio 2021b</a>; <a href="./references#CD012557-bbs2-0062" title="deBeaurepaireR , SinclairJM , HeydtmannM , AddoloratoG , AubinHJ , BerahaEM , et al. The use of baclofen as a treatment for alcohol use disorder: a clinical practice perspective. Frontiers in Psychiatry2019;9:708. [PMID: 30662411]">de Beaurepaire 2019</a>) have been discussed to moderate the effects of baclofen on alcohol consumption. </p> <p>Although data are mixed regarding baclofen's efficacy in AUD, they are consistent in terms of safety if used as recommended (<a href="./references#CD012557-bbs2-0038" title="AgabioR , SinclairJM , AddoloratoG , AubinHJ , BerahaEM , CaputoF , et al. Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry2018;5(12):957-60. [PMID: 30413394]">Agabio 2018a</a>; <a href="./references#CD012557-bbs2-0050" title="BrennanJL , LeungJG , GagliardiJP , RivelliSK , MuzykAJ . Clinical effectiveness of baclofen for the treatment of alcohol dependence: a review. Clinical Pharmacology2013;5:99-107. [DOI: 10.2147/CPAA.S32434]">Brennan 2013</a>). Extensive information on baclofen's safety is available from its widespread use for the treatment of spasticity for decades. Most adverse events are not severe, are doseârelated and are transient (<a href="./references#CD012557-bbs2-0038" title="AgabioR , SinclairJM , AddoloratoG , AubinHJ , BerahaEM , CaputoF , et al. Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry2018;5(12):957-60. [PMID: 30413394]">Agabio 2018a</a>; <a href="./references#CD012557-bbs2-0062" title="deBeaurepaireR , SinclairJM , HeydtmannM , AddoloratoG , AubinHJ , BerahaEM , et al. The use of baclofen as a treatment for alcohol use disorder: a clinical practice perspective. Frontiers in Psychiatry2019;9:708. [PMID: 30662411]">de Beaurepaire 2019</a>). Sedation, somnolence, weakness, vertigo and psychological disturbances are the most common adverse events (<a href="./references#CD012557-bbs2-0060" title="DarioA , TomeiG . A benefitârisk assessment of baclofen in severe spinal spasticity. Drug Safety2004;27(11):799-818.">Dario 2004</a>). The administration of low doses of baclofen is considered safe in people affected by AUD, while an abrupt interruption and withdrawal from higher doses of baclofen may lead to serious adverse effects (<a href="./references#CD012557-bbs2-0038" title="AgabioR , SinclairJM , AddoloratoG , AubinHJ , BerahaEM , CaputoF , et al. Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry2018;5(12):957-60. [PMID: 30413394]">Agabio 2018a</a>; <a href="./references#CD012557-bbs2-0062" title="deBeaurepaireR , SinclairJM , HeydtmannM , AddoloratoG , AubinHJ , BerahaEM , et al. The use of baclofen as a treatment for alcohol use disorder: a clinical practice perspective. Frontiers in Psychiatry2019;9:708. [PMID: 30662411]">de Beaurepaire 2019</a>). While such events are rare, the lack of noted adverse events may be a result of small sample sizes and low doses of baclofen utilised in available studies (<a href="./references#CD012557-bbs2-0050" title="BrennanJL , LeungJG , GagliardiJP , RivelliSK , MuzykAJ . Clinical effectiveness of baclofen for the treatment of alcohol dependence: a review. Clinical Pharmacology2013;5:99-107. [DOI: 10.2147/CPAA.S32434]">Brennan 2013</a>). In October 2018, the French Medicines Agency (Agence Nationale de SÃ©curitÃ© du MÃ©dicament et des Produits de SantÃ© (ANSM)) approved baclofen for the treatment of AUD at the maximum dose of 80 mg a day (<a href="./references#CD012557-bbs2-0131" title="RollandB , SimonN , FranchittoN , AubinHJ . France grants an approval to baclofen for alcohol dependence. Alcohol and Alcoholism2020;55(1):44-5. [PMID: 31761949]">Rolland 2020</a>). In France, where this medication was frequently prescribed for the treatment of AUD at high doses, an alarming increase of selfâpoisonings with baclofen, including suicide attempts and unintentional overdose, has been reported (e.g. <a href="./references#CD012557-bbs2-0084" title="HollaB , GowdaGS , PrabhuL , BabyS , ViswanathB , ChandP , et al. High doses of baclofen as suicide attempt in patients with alcohol use disorders â a serious concern. Asian Journal of Psychiatry2015;17:99-100.">Holla 2015</a>; <a href="./references#CD012557-bbs2-0099" title="LoggeWB , MorleyKC , HaberPS . GABAB receptors and alcohol use disorders: clinical studies. Current Topics in Behavioral Neurosciences2022;52:195-212. [PMID: 33580440]">Logge 2022</a>; <a href="./references#CD012557-bbs2-0123" title="PelissierF , deHaroL , CardonaF , PicotC , PuskarczykE , SaporiJM , et al. Self-poisoning with baclofen in alcohol-dependent patients: national reports to French Poison Control Centers, 2008â2013. Clinical Toxicology2017;55(4):275-84.">Pelissier 2017</a>; <a href="./references#CD012557-bbs2-0128" title="ReynoardJ , SchmittC , TorrentsR , SimonN . Toxicological considerations in the prescription of baclofen for the treatment of substance use disorders. Expert Opinion on Drug Metabolism &amp; Toxicology2020;16(4):309-17. [PMID: 32149546]">Reynoard 2020</a>) leading to the authorisation of a maximum daily dose of baclofen 80 mg for the treatment of AUD (<a href="./references#CD012557-bbs2-0131" title="RollandB , SimonN , FranchittoN , AubinHJ . France grants an approval to baclofen for alcohol dependence. Alcohol and Alcoholism2020;55(1):44-5. [PMID: 31761949]">Rolland 2020</a>). </p> </section> <section id="CD012557-sec-0012"> <h3 class="title" id="CD012557-sec-0012">How the intervention might work</h3> <p>The mesolimbic dopamine pathway, including dopamine cells in the ventral tegmental area projecting into the nucleus accumbens, is crucial for drug reward and addiction (<a href="./references#CD012557-bbs2-0148" title="VolkowND , WangGJ , FowlerJS , TomasiD , TelangF . Addiction: beyond dopamine reward circuitry. Proceedings of the National Academy of Sciences USA2011;108(37):15037-42.">Volkow 2011</a>; <a href="./references#CD012557-bbs2-0156" title="WiseRA . Roles for nigrostriatal â not just mesocorticolimbicâdopamine in reward and addiction. Trends in Neurosciences2009;32(10):517-24.">Wise 2009</a>). Baclofen's primary mechanism of action for alcohol dependence is presumed to be the reduction of the reinforcing properties of alcohol by suppressing alcoholâstimulated dopamine release in the mesolimbic dopamine system (<a href="./references#CD012557-bbs2-0061" title="deBeaurepaireR . A review of the potential mechanisms of action of baclofen in alcohol use disorder. Frontiers in Psychiatry2018;9:506. [PMID: 30459646]">de Beaurepaire 2018</a>). Agonistic effects of baclofen at GABA<sub>B</sub> receptors located in several brain areas including the mesolimbic circuit (<a href="./references#CD012557-bbs2-0125" title="PitmanKA , PuilE , BorglandSL . GABA(B) modulation of dopamine release in the nucleus accumbens core. European Journal of Neuroscience2014;40(10):3472-80.">Pitman 2014</a>), and the ventral tegmental area, inhibit alcoholâinduced firing of dopaminergic neurons and of alcoholâstimulated dopamine release in the nucleus accumbens, resulting in the reduction of reinforcing properties of alcohol and drugs (<a href="./references#CD012557-bbs2-0036" title="AgabioR , ColomboG . GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence. Frontiers in Neuroscience2014;8:140. [DOI: 10.3389/fnins.2014.00140]">Agabio 2014</a>; <a href="./references#CD012557-bbs2-0101" title="MaccioniP , ColomboG . Role of the GABA(B) receptor in alcohol-seeking and drinking behavior. Alcohol2009;43(7):555-8.">Maccioni 2009</a>; <a href="./references#CD012557-bbs2-0158" title="YoungKA , FranklinTR , RobertsDC , JagannathanK , SuhJJ , WetherillRR , et al. Nipping cue reactivity in the bud: baclofen prevents limbic activation elicited by subliminal drug cues. Journal of Neuroscience2014;34(14):5038-43.">Young 2014</a>). As baclofen did not affect spontaneous motor activity in rats, baclofen's effects are not due to muscleârelaxant or sedative properties of the drug, but can rather be considered as a result of its ability to reduce the appetitive strength of alcohol (<a href="./references#CD012557-bbs2-0056" title="ColomboG , VaccaG , SerraS , BrunettiG , CaraiMA , GessaGL . Baclofen suppresses motivation to consume alcohol in rats. Psychopharmacology2003;167(3):221-4.">Colombo 2003</a>; <a href="./references#CD012557-bbs2-0057" title="ColomboG , GessaGL . Suppressing effect of baclofen on multiple alcohol-related behaviors in laboratory animals. Frontiers in Psychiatry2018;9:475. [PMID: 30323777]">Colombo 2018</a>). In addition, substitutional effects of baclofen to replace alcohol have been discussed (<a href="./references#CD012557-bbs2-0055" title="ChickJ , NuttDJ . Substitution therapy for alcoholism: time for a reappraisal?Journal of Psychopharmacology2012;26(2):205-12.">Chick 2012</a>; <a href="./references#CD012557-bbs2-0130" title="RollandB , BordetR , DeheulS , CottencinO . Baclofen for alcohol-dependence: anticraving or partial substitution?Journal of Clinical Psychopharmacology2013;33(2):280-1.">Rolland 2013</a>). </p> <p>In addition, GABA<sub>B</sub> receptors are highly expressed in limbic structures involved in the mediation of anxiety (<a href="./references#CD012557-bbs2-0059" title="CryanJF , KaupmannK . Don't worry 'B' happy!: a role for GABA(B) receptors in anxiety and depression. Trends in Pharmacological Sciences2005;26:36-43.">Cryan 2005</a>), while activation of GABA<sub>B</sub> receptors in these structures might reduce anxiety (<a href="./references#CD012557-bbs2-0016" title="MorleyKC , BaillieA , LeungS , AddoloratoG , LeggioL , HaberPS . Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol and Alcoholism2014;49(6):654-60. [DOI: 10.1093/alcalc/agu062]">Morley 2014âLD</a>; <a href="./references#CD012557-bbs2-0017" title="MorleyKC , BaillieA , LeungS , AddoloratoG , LeggioL , HaberPS . Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol and Alcoholism2014;49(6):654-60. [DOI: 10.1093/alcalc/agu062]">Morley 2014âMD</a>). Evidence from various clinical studies shows that baclofen may reduce anxiety in people with AUD (<a href="./references#CD012557-bbs2-0024" title="AddoloratoG , CaputoF , CapristoE , DomenicaliM , BernardiM , JaniriM , et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomised controlled study. Alcohol &amp; Alcoholism2002;37:504-8. ">Addolorato 2002</a>; <a href="./references#CD012557-bbs2-0025" title="FlanneryBA , GarbuttJC , CodyMW , RennW , GraceK , OsborneM , et al. Baclofen for alcohol dependence: a preliminary open-label study. Alcoholism, Clinical and Experimental Research2004;28(10):1517-23. ">Flannery 2004</a>; <a href="./references#CD012557-bbs2-0092" title="KrupitskyEM , BurakovAM , IvanovVB , KrandashovaGF , LapinIP , GrinenkoAJ , et al. Baclofen administration for the treatment of affective disorders in alcoholic patients. Drug and Alcohol Dependence1993;33(2):157-63. [DOI: 10.1016/0376-8716(93)90057-w]">Krupitsky 1993</a>; <a href="./references#CD012557-bbs2-0016" title="MorleyKC , BaillieA , LeungS , AddoloratoG , LeggioL , HaberPS . Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol and Alcoholism2014;49(6):654-60. [DOI: 10.1093/alcalc/agu062]">Morley 2014âLD</a>; <a href="./references#CD012557-bbs2-0017" title="MorleyKC , BaillieA , LeungS , AddoloratoG , LeggioL , HaberPS . Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol and Alcoholism2014;49(6):654-60. [DOI: 10.1093/alcalc/agu062]">Morley 2014âMD</a>). Postâhoc analyses in one of the studies found that treatment with baclofen was most effective in people with comorbid anxiety (<a href="./references#CD012557-bbs2-0016" title="MorleyKC , BaillieA , LeungS , AddoloratoG , LeggioL , HaberPS . Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol and Alcoholism2014;49(6):654-60. [DOI: 10.1093/alcalc/agu062]">Morley 2014âLD</a>; <a href="./references#CD012557-bbs2-0019" title="HengS , JamshidiN , BaillieA , LouieE , DoreG , PhungN , et al. Baclofen response in alcohol dependent patients concurrently receiving antidepressants: secondary analysis from the BacALD study. Frontiers in Psychiatry2018;9:576. LoggeW , BaillieAJ , MorrisRW , HaberPS , MorleyKC . Baclofen reduces alcohol cue-induced fMRI brain activation in treatment seeking alcohol dependent individuals. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. LoggeWB , BaillieAJ , HaberPS , MorleyKC . Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Human Psychopharmacology2020;35(2):e2722. LoggeWB , HaberPS , BaillieAJ , KosinskiP , MorrisRW , FraserI , et al. Dose-specific baclofen effects on brain structure, function and treatment responses: neuroimaging findings from the BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):20A-21A. LoggeWB , MorleyKC , HaberPS , BaillieAJ . Executive functioning moderates responses to appetitive cues: a study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism2019;54(1):38-46. LoggeWB , MorrisRW , BaillieAJ , HaberPS , MorleyKC . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berlin)2021;238(5):1291-302. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Baclofen for treatment of alcohol use disorder: secondary analyses and implications of the Australian BacALD trial. Drug and Alcohol Review2019;38:S75. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Exploration of the modulating role of the GABAb receptor polymorphism rs29220 on response to baclofen in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):41A. MorleyKC , BaillieA , FraserI , Furneaux-BateA , DoreG , RobertsM , et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry2018;212(6):362-9. MorleyKC , LagopoulosJ , LoggeW , BaillieA , AdamsC , HaberPS . Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addiction Biology2020;25(1):e12702. MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55. MorleyKC , LoggeWB , FraserI , MorrisRW , BaillieAJ , HaberPS . High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology2021;46:28-36. MorleyKC , LuquinN , BaillieA , FraserI , TrentRJ , DoreG , et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction2018;113(12):2205-13. MorleyKC , MorrisR , LoggeW , BaillieA , FraserI , HaberPS . Baclofen administration attenuates insula response during anticipatory anxiety in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. MorleyKC , RiordanB , LoggeW , BaillieA , HaberPS . Moderation of baclofen on the daily relationship between craving and alcohol use: results from the Australian BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):53A. RomboutsSA , BaillieA , HaberPS , MorleyKC . Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD Trial. Alcohol and Alcoholism2019;54(3):272-8. ">Morley 2018âMD</a>). This result has been confirmed by one recent metaâanalysis (<a href="./references#CD012557-bbs2-0041" title="AgabioR , BaldwinDS , AmaroH , LeggioL , SinclairJM . The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: a systematic review and meta-analysis. Neuroscience &amp; Biobehavioral Reviews2021;125:296-313. [PMID: 33454289]">Agabio 2021b</a>). Thus, besides dampening the reinforcing properties of alcohol through the suppression of alcoholâstimulated dopamine release in the mesolimbic dopamine system, baclofen's effects on drinking might also be related to the presence of anxiety symptoms (<a href="./references#CD012557-bbs2-0036" title="AgabioR , ColomboG . GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence. Frontiers in Neuroscience2014;8:140. [DOI: 10.3389/fnins.2014.00140]">Agabio 2014</a>; <a href="./references#CD012557-bbs2-0041" title="AgabioR , BaldwinDS , AmaroH , LeggioL , SinclairJM . The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: a systematic review and meta-analysis. Neuroscience &amp; Biobehavioral Reviews2021;125:296-313. [PMID: 33454289]">Agabio 2021b</a>). </p> </section> <section id="CD012557-sec-0013"> <h3 class="title" id="CD012557-sec-0013">Why it is important to do this review</h3> <p>While several pharmacological treatments have been approved for the treatment of AUD (see <a href="#CD012557-sec-0009">Background</a>), their clinical use is limited by a number of factors (<a href="./references#CD012557-bbs2-0140" title="SinclairJM , ChambersSE , ShilesCJ , BaldwinDS . Safety and tolerability of pharmacological treatment of alcohol dependence: comprehensive review of evidence. Drug Safety2016;39(7):627-45. [PMID: 27023898]">Sinclair 2016</a>). The aversive agent disulfiram supports abstinence (<a href="./references#CD012557-bbs2-0087" title="JorgensenCH , PedersenB , TonnesenH . The efficacy of disulfiram for the treatment of alcohol use disorder. Alcoholism, Clinical and Experimental Research2011;35:1749-58.">Jorgensen 2011</a>), but due to its safety profile it is a therapeutic option for only selected patient groups with a high selfâefficacy expectation to abstain from drinking after taking disulfiram (<a href="./references#CD012557-bbs2-0117" title="MutschlerJ , GrosshansM , SoykaM , RÃ¶snerS . Current findings and mechanisms of action of disulfiram in the treatment of alcohol dependence. Pharmacopsychiatry2016;49(4):137-41.">Mutschler 2016</a>). Further substances such as the opioidâantagonists, naltrexone and nalmefene, and the glutamate antagonist, acamprosate, appear to be safe and effective in people with AUD, but the strong variation in treatment response (<a href="./references#CD012557-bbs2-0133" title="RÃ¶snerS , Hackl-HerrwerthA , LeuchtS , LehertP , VecchiS , SoykaM . Acamprosate for alcohol dependence. Cochrane Database of Systematic Reviews2010, Issue 9. Art. No: CD004332. [DOI: 10.1002/14651858.CD004332.pub2]">RÃ¶sner 2010a</a>; <a href="./references#CD012557-bbs2-0134" title="RÃ¶snerS , Hackl-HerrwerthA , LeuchtS , VecchiS , SrisurapanontM , SoykaM . Opioid antagonists for alcohol dependence. Cochrane Database of Systematic Reviews2010, Issue 12. Art. No: CD001867. [DOI: 10.1002/14651858.CD001867.pub3]">RÃ¶sner 2010b</a>), indicates that patients might benefit from an extended range of treatment options that allow a further individualisation of pharmacological approaches (<a href="./references#CD012557-bbs2-0157" title="WitkiewitzK , LittenRZ , LeggioL . Advances in the science and treatment of alcohol use disorder. Science Advances2019;5(9):eaax4043. [PMID: 31579824]">Witkiewitz 2019</a>). Baclofen as a treatment option for AUD has received much attention in recent years, initiated by pharmacological selfâexperimentation of Olivier Ameisen (<a href="./references#CD012557-bbs2-0044" title="AmeisenO . Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol and Alcoholism2005;40(2):147-50.">Ameisen 2005</a>), and suggested for people with AUD who do not respond to other medications for AUD (i.e. acamprosate, naltrexone and disulfiram) or have contraindications for the use of other medications (i.e. sever liver disease) (<a href="./references#CD012557-bbs2-0062" title="deBeaurepaireR , SinclairJM , HeydtmannM , AddoloratoG , AubinHJ , BerahaEM , et al. The use of baclofen as a treatment for alcohol use disorder: a clinical practice perspective. Frontiers in Psychiatry2019;9:708. [PMID: 30662411]">de Beaurepaire 2019</a>). Even though numerous case reports and case series confirmed the effectiveness of baclofen in people with AUD, data from RCTs yielded conflicting results (<a href="./references#CD012557-bbs2-0062" title="deBeaurepaireR , SinclairJM , HeydtmannM , AddoloratoG , AubinHJ , BerahaEM , et al. The use of baclofen as a treatment for alcohol use disorder: a clinical practice perspective. Frontiers in Psychiatry2019;9:708. [PMID: 30662411]">de Beaurepaire 2019</a>). </p> <p>The planned review of baclofen to achieve abstinence or to reduce alcohol consumption in people with AUD will provide a systematic integration of the available evidence for health decision makers, therapists and patients, and aims to offer illustrative measures for estimating the therapeutic benefits and risks of baclofen, while indicating gaps in knowledge and methodological demands for future clinical research. In addition, the planned review will evaluate the effects due to the different doses of baclofen considering that, in clinical practice, the daily dose used to help people with AUD to achieve abstinence or reduce alcohol consumption varies between patients over a 10âfold range (<a href="./references#CD012557-bbs2-0038" title="AgabioR , SinclairJM , AddoloratoG , AubinHJ , BerahaEM , CaputoF , et al. Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry2018;5(12):957-60. [PMID: 30413394]">Agabio 2018a</a>). In addition, the planned review will also evaluate two other factors that may influence the effects of baclofen in the treatment of AUD such as the duration of the treatment and the consumption of alcohol at the beginning of treatment (<a href="./references#CD012557-bbs2-0038" title="AgabioR , SinclairJM , AddoloratoG , AubinHJ , BerahaEM , CaputoF , et al. Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry2018;5(12):957-60. [PMID: 30413394]">Agabio 2018a</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012557-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012557-sec-0014"></div> <p>To evaluate the benefits and harms of baclofen on achieving and maintaining abstinence or reducing alcohol consumption in people with AUD compared to placebo, no treatment or any other pharmacological relapse prevention treatment. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012557-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012557-sec-0015"></div> <section id="CD012557-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012557-sec-0017"> <h4 class="title">Types of studies</h4> <p>RCTs of at least four weeks' treatment duration and 12 weeks' overall study duration, comparing baclofen with placebo, no treatment or other pharmacological treatments for achieving alcohol abstinence or reducing consumption in people with AUD. We planned to include studies employing a crossâover design, using data from the first active treatment stage only. </p> </section> <section id="CD012557-sec-0018"> <h4 class="title">Types of participants</h4> <p>Adults (aged 18 years and older), currently with AUD according to Diagnostic and Statistical Manual of Mental Disorders, 3rd edition (DSMâIII; <a href="./references#CD012557-bbs2-0046" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd edition. Washington (DC): American Psychiatric Association, 1980.">APA 1980</a>), Diagnostic and Statistical Manual of Mental Disorders, 3rd edition, revised (DSMâ IIIâR; <a href="./references#CD012557-bbs2-0047" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Revised edition. Washington (DC): American Psychiatric Association, 1987.">APA 1987</a>), Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSMâIVâTR; <a href="./references#CD012557-bbs2-0048" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington (DC): American Psychiatric Association, 2000.">APA 2000</a>), DSMâ5 (<a href="./references#CD012557-bbs2-0049" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Washington (DC): American Psychiatric Association, 2013.">APA 2013</a>), and ICDâ10 (<a href="./references#CD012557-bbs2-0151" title="World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10). Geneva (Switzerland): World Health Organization, 1992.">WHO 1992</a>; WHO 2010). There were no limitations on other participant characteristics such as concomitant substance use disorders or other comorbid psychiatric conditions. We included participants who were still drinking and those in the postdetoxification phase, if the detoxification was completed 28 days or less before starting treatment. We also included studies with participants in methadone maintenance schemes. We excluded studies where baclofen was used to treat alcohol withdrawal. </p> <p>We excluded people younger than 18 years of age and pregnant women because of the substantially different approach required for clinical management of these individuals. </p> </section> <section id="CD012557-sec-0019"> <h4 class="title">Types of interventions</h4> <section id="CD012557-sec-0020"> <h5 class="title">Experimental intervention</h5> <p>We included baclofen at any dose and route of administration. Studies could consider baclofen as monotherapy or in combination with further treatments provided that concomitant treatments were provided equally in both the experimental and control groups. </p> </section> <section id="CD012557-sec-0021"> <h5 class="title">Control intervention</h5> <p>Placebo, no treatment or any other pharmacological relapse prevention treatment, including acamprosate, naltrexone or nalmefene. We did not consider disulfiram as a control intervention due to the psychological mediation of its effects. </p> </section> </section> <section id="CD012557-sec-0022"> <h4 class="title">Types of outcome measures</h4> <section id="CD012557-sec-0023"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012557-list-0001"> <li> <p>Relapse: return to any drinking, measured by the number of people who had returned to any drinking at the end of the study. </p> </li> <li> <p>Frequency of use: measured as mean number or percentage of abstinent days (ratio of the total sum of days with abstinence, related to the entire duration of the study, multiplied by 100; and mean number or percentage of heavy drinking days (HDD)). </p> </li> <li> <p>Amount of use: number of drinks per drinking day or drinking occasion.</p> </li> <li> <p>Adverse events: measured by number of people with at least one adverse event, both subjectively and objectively assessed. </p> </li> <li> <p>Dropouts from treatment: number of participants who did not complete the study protocol.</p> </li> <li> <p>Dropouts from treatment due to adverse events.</p> </li> </ul> </p> <p>We included drinking outcomes irrespective of the source of information, considering, for example, participant selfâreports, breathalyser tests, laboratory tests and collateral reports of others. </p> </section> <section id="CD012557-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012557-list-0002"> <li> <p>Craving, as measured by validated scales.</p> </li> <li> <p>Anxiety, as measured by validated scales.</p> </li> <li> <p>Depression, as measured by validated scales.</p> </li> <li> <p>Frequency of most relevant adverse events.</p> </li> </ul> </p> </section> </section> </section> <section id="CD012557-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <p>The Cochrane Drugs and Alcohol Information Specialist conducted systematic searches for RCTs and controlled clinical studies. There were no language, publication year or publication status restrictions. The date of the search was 22 November 2021. </p> <section id="CD012557-sec-0026"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases:</p> <p> <ul id="CD012557-list-0003"> <li> <p>Cochrane Drugs and Alcohol Group (CDAG) Specialised Register (22 November 2021; <a href="./appendices#CD012557-sec-0168">Appendix 1</a>); </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2021, issue 11) via <a href="https://onlinelibrary.wiley.com/" target="_blank">onlinelibrary.wiley.com</a> (<a href="./appendices#CD012557-sec-0169">Appendix 2</a>); </p> </li> <li> <p>MEDLINE via Ovid (from January 2018 to 22 November 2021; <a href="./appendices#CD012557-sec-0170">Appendix 3</a>); </p> </li> <li> <p>Embase via Ovid (from January 2018 to 30 January 2018; <a href="./appendices#CD012557-sec-0171">Appendix 4</a>); </p> </li> <li> <p>PsycINFO (Ovid; from January 2018 to 22 November 2021; <a href="./appendices#CD012557-sec-0172">Appendix 5</a>); </p> </li> <li> <p>Web of Science (Thomson Reuters; from January 2018 to 22 November 2021; <a href="./appendices#CD012557-sec-0173">Appendix 6</a>); </p> </li> <li> <p>CINAHL (EBSCOhost; from January 2018 to 22 November 2021; <a href="./appendices#CD012557-sec-0174">Appendix 7</a>). </p> </li> </ul> </p> <p>We searched the databases using MeSH and freeâtext terms relating to baclofen and alcohol dependence. We combined the PubMed search with the Cochrane Highly Sensitive Search Strategy for identifying RCTs in MEDLINE: sensitivityâmaximising version (<a href="./references#CD012557-bbs2-0094" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Lefebvre 2011</a>). We revised this strategy appropriately for each database to take account of differences in controlled vocabulary and syntax rules. </p> <p>We searched the following trials registries on 22 November 2021:</p> <p> <ul id="CD012557-list-0004"> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>); </p> </li> <li> <p>WHO International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>). </p> </li> </ul> </p> </section> <section id="CD012557-sec-0027"> <h4 class="title">Searching other resources</h4> <p>We contacted key informants and experts to request any further, potentially relevant studies and seek information about unpublished or incomplete studies. We handsearched the reference lists of included studies and current reviews. We included all eligible studies identified by the search, irrespective of language, publication type or status. </p> </section> </section> <section id="CD012557-sec-0028"> <h3 class="title" id="CD012557-sec-0028">Data collection and analysis</h3> <section id="CD012557-sec-0029"> <h4 class="title">Selection of studies</h4> <p>After removing duplicates, two review authors (RA, SM) independently screened the abstracts of all publications obtained by the search strategy. Two review authors (RA, SM) independently assessed the full text of potentially relevant studies for inclusion. We excluded studies that did not meet eligibility criteria and recorded the reasons in the <a href="./references#CD012557-sec-0189" title="">Characteristics of excluded studies</a> table. We used <a href="./references#CD012557-bbs2-0058" title="Covidence. Melbourne, Australia: Veritas Health Innovation, accessed 30 January 2018. Available at www.covidence.org.">Covidence</a> software for study selection (<a href="./references#CD012557-bbs2-0058" title="Covidence. Melbourne, Australia: Veritas Health Innovation, accessed 30 January 2018. Available at www.covidence.org.">Covidence</a>). We resolved any disagreement by discussion, involving a third review author (RS) in case of persisting disagreements. We documented the search process in sufficient details to complete a PRISMA study flow diagram. </p> </section> <section id="CD012557-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (RA, SM) independently extracted data onto a data extraction form. We resolved any doubts by discussion. We extracted the following information: number and characteristics of participants, setting, type of experimental and control intervention, length of followâup, types of outcomes, country of origin, funding and conflict of interest. We used <a href="./references#CD012557-bbs2-0058" title="Covidence. Melbourne, Australia: Veritas Health Innovation, accessed 30 January 2018. Available at www.covidence.org.">Covidence</a> software for data extraction (<a href="./references#CD012557-bbs2-0058" title="Covidence. Melbourne, Australia: Veritas Health Innovation, accessed 30 January 2018. Available at www.covidence.org.">Covidence</a>). </p> </section> <section id="CD012557-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (RA, SM) independently assessed the risk of bias of the included studies using the criteria recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012557-bbs2-0083" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). The recommended approach for assessing risk of bias in studies included in Cochrane Reviews is a twoâpart tool, addressing the following specific domains: sequence generation and allocation concealment (selection bias), blinding of participants and providers (performance bias), blinding of outcome assessors (detection bias), incomplete outcome data (attrition bias) and selective outcome reporting (reporting bias). The first part of the tool involves describing what was reported to have happened in the study. The second part of the tool involves assigning a judgement relating to the risk of bias for that entry, in terms of low, high or unclear risk. To make these judgements, we used the criteria indicated by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, adapted to the addiction field. See <a href="./appendices#CD012557-sec-0175">Appendix 8</a> for details. </p> <p>We addressed the domains of sequence generation and allocation concealment (avoidance of selection bias) by a single entry for each study. </p> <p>We considered blinding of participants, personnel and outcome assessors (avoidance of performance bias and detection bias), separately for objective outcomes (e.g. relapse measured by urine or breath analysis, duration of abstinence and dropout), and subjective outcomes (e.g. participant selfâreported use of substance, adverse events, craving, psychiatric symptoms). </p> <p>We considered incomplete outcome data (avoidance of attrition bias), for all outcomes except dropout from the treatment, which is very often the primary outcome measure in studies on addiction. </p> </section> <section id="CD012557-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous outcomes by calculating the risk ratio (RR) for each trial with the uncertainty in each result being expressed with 95% confidence intervals (CI). We analysed continuous outcomes by calculating the mean difference (MD) with 95% CIs when the studies used the same instrument for assessing the outcome. We used the standardised mean difference (SMD) when the studies used different instruments. </p> </section> <section id="CD012557-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>If we included multiâarmed studies in the metaâanalyses and one arm was considered more than once in the same comparisons (e.g. two different doses of baclofen compared to the same control group), we divided the control group into two different groups, each group comprising half the participants of the original group to avoid double counting of participants in the control groups. For crossâover studies in metaâanalyses, we planned to use data from the first period only (i.e. before crossâover), to address the risk of carryâover effects. However, we did not include any crossâover studies. </p> </section> <section id="CD012557-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the original investigators to request information on incomplete or missing data from the studies. We included all randomised participants in the statistical analysis, without any imputation of missing data. If standard deviations (SD) were missing, we used the mean of the available SDs of the other included studies (<a href="./references#CD012557-bbs2-0066" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology2006;59:7-10.">Furukawa 2006</a>). </p> </section> <section id="CD012557-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>We analysed heterogeneity using the IÂ² statistic and the ChiÂ² test (<a href="./references#CD012557-bbs2-0081" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327:557-60.">Higgins 2003</a>). We regarded heterogeneity as substantial if the IÂ² statistic was greater than 50% or P less than 0.10 for the ChiÂ² test for heterogeneity (<a href="./references#CD012557-bbs2-0063" title="DeeksJJ , HigginsJP , AltmanDG , editor(s) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Deeks 2017</a>). Following the guidance in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012557-bbs2-0063" title="DeeksJJ , HigginsJP , AltmanDG , editor(s) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Deeks 2017</a>), we distinguished the following values: 0% to 40% denoted no important, 30% to 60% moderate, 50% to 90% substantial and 75% to 100% considerable heterogeneity. If we found considerable heterogeneity (i.e. 75% or above), we explored possible reasons by visually inspecting the forest plot to identify studies that might be contributing to heterogeneity. </p> </section> <section id="CD012557-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>We used visual inspection of funnel plots (plots of the effect estimate from each study against the sample size or effect standard error) to indicate possible publication bias if there were at least 10 studies included in the metaâanalysis (<a href="./references#CD012557-bbs2-0145" title="SterneJA , EggerM , MoherD , BoutronI , editor(s). Chapter 10: Addressing reporting biases. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Sterne 2017</a>). </p> </section> <section id="CD012557-sec-0037"> <h4 class="title">Data synthesis</h4> <p>We combined the outcomes from the individual studies through metaâanalysis where possible (comparability of intervention and outcomes between studies), using a randomâeffects model, because we expected a certain degree of heterogeneity between studies. If the clinical or statistical heterogeneity between studies was too high (i.e. 75% to 100%), we considered not pooling the data. </p> </section> <section id="CD012557-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed subgroup analysis to investigate the sources of heterogeneity and assess any difference in treatment efficacy and safety in different subgroups. In detail, we planned to perform subgroup analyses for the following variables: </p> <p> <ul id="CD012557-list-0005"> <li> <p>daily doses of baclofen;</p> </li> <li> <p>participants with concomitant substance use disorders;</p> </li> <li> <p>comorbid psychiatric conditions;</p> </li> <li> <p>consumption of alcohol at the beginning of treatment;</p> </li> <li> <p>duration of treatment.</p> </li> </ul> </p> <p>According to the daily doses of baclofen, we divided the studies into three subgroups: low doses (up to 30 mg), medium doses (above 30 and 100 mg or less) and high doses (above 100 mg). </p> <p>According to the consumption of alcohol at the beginning of the treatment, we divided the studies into two subgroups: detoxified participants (when participants were abstinent for at least three days before treatment) and nonâdetoxified participants (when participants were still drinking at the beginning of the treatment). </p> <p>According to the duration of treatment, we divided studies into two subgroups: 12âweek studies and longer than 12âweek studies. </p> <p>We were able to perform subgroup analyses for different daily doses of baclofen, detoxified versus nonâdetoxified participants and duration of treatment. </p> <p>Subgroup analyses did not explain heterogeneity, which remained very high in the subgroups were there was one outlying study with results that conflicted with the rest of the studies (<a href="./references#CD012557-bbs2-0014" title="BollingerJ , EdwardsSM , ZywiakWK , TideyJW , SwiftRW , KennaGA , et al. A double-blind, placebo-controlled randomized pilot study of the effects of baclofen on alcohol-tobacco co-use and alcohol cue-reactivity in alcoholic smokers. Clinical and Translational Science2014;7(3):265. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW , et al. Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Erratum for: Neuropsychopharmacology. 2014 Dec;39 Suppl 1:S1-647. Neuropsychopharmacology2015;40(6):1560. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW . Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Neuropsychopharmacology2014;39:S340. LeggioL , ZywiakWH , EdwardsSM , TideyJW , SwiftRM , KennaGA . A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology2015;232(1):233-43. [DOI: 10.1007/s00213-014-3652-9]">Leggio 2015</a>). Participants included in this study were both nicotine and alcohol dependent, the study had the aimed to obtain both smoking and drinking abstinence and the study was conducted in a laboratory setting. As these characteristics could explain the heterogeneity due to the different population of participants compared to those recruited by the other studies, we excluded the study from the metaâanalyses. </p> </section> <section id="CD012557-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>To incorporate our assessment of risk of bias in the review process we first plotted the intervention effect estimates stratified by risk of bias for allocation concealment (selection bias). If differences in the results were present among studies at different risks of selection bias, we planned to perform sensitivity analysis by excluding studies at high risk of bias from the analysis. We also planned to perform sensitivity analysis to assess how sensitive the results were to changes in the assumptions about missing data for relapse, assuming dropout or loss to followâup as not relapsed. We did not perform any sensitivity analyses because there were no such cases. </p> </section> <section id="CD012557-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We assessed the overall certainty of the evidence for the following primary outcomes using GRADE: relapse, frequency of use, amount of use, adverse events and dropout from treatment. The GRADE Working Group developed a system for grading the certainty of evidence that considers issues related to internal validity and external validity, such as directness of results. (<a href="./references#CD012557-bbs2-0072" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(19):1490-4.">GRADE 2004</a>; <a href="./references#CD012557-bbs2-0077" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7560):924-6.">Guyatt 2008</a>; <a href="./references#CD012557-bbs2-0078" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines 1. Introduction â GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64:383-94.">Guyatt 2011</a>; <a href="./references#CD012557-bbs2-0136" title="SchÃ¼nemannHJ , JaeschkeR , CookD , BriaW , El-SolhA , ErnstA . An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. American Journal of Respiratory and Critical Care Medicine2006;174(5):605-14.">SchÃ¼nemann 2006</a>). </p> <p>We presented the main findings of the review in three summary of findings tables: baclofen versus placebo, baclofen versus acamprosate and baclofen versus naltrexone. This is a transparent and simple tabular format that provides key information concerning the certainty of evidence, the magnitude of effect of the interventions examined and the sum of available data on the main outcomes. </p> <p>The GRADE system uses the following criteria for assigning grades of evidence.</p> <p> <ul id="CD012557-list-0006"> <li> <p>High: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> <p>Grading is decreased for the following reasons:</p> <p> <ul id="CD012557-list-0007"> <li> <p>serious (â1) or very serious (â2) study limitations for risk of bias;</p> </li> <li> <p>serious (â1) or very serious (â2) inconsistency between study results;</p> </li> <li> <p>some (â1) or major (â2) uncertainty about directness (the correspondence between the population, the intervention, or the outcomes measured in the studies actually found and those under consideration in our systematic review); </p> </li> <li> <p>serious (â1) or very serious (â2) imprecision of the pooled estimate;</p> </li> <li> <p>publication bias strongly suspected (â1).</p> </li> </ul> </p> <p>We used <a href="./references#CD012557-bbs2-0073" title="GRADEpro GDT. Version accessed 30 January 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a> software to prepare the summary of findings tables (<a href="./references#CD012557-bbs2-0073" title="GRADEpro GDT. Version accessed 30 January 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012557-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012557-sec-0041"></div> <section id="CD012557-sec-0042"> <h3 class="title">Description of studies</h3> <section id="CD012557-sec-0043"> <h4 class="title">Results of the search</h4> <p><a href="#CD012557-fig-0001">Figure 1</a> shows the PRISMA flow diagram for screening, selection and assessment of studies. </p> <div class="figure" id="CD012557-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA study flow diagram." data-id="CD012557-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA study flow diagram.</p> </div> </div> </div> <p>For this update, we identified 161 studies from all possible sources following the removal of duplicates. We excluded 131 studies based on title and abstract and assessed 30 fullâtext articles. We identified four studies meeting our inclusion criteria reported in 22 references. One study compared a single dose of baclofen to placebo (<a href="./references#CD012557-bbs2-0023" title="JauryPH . Baclofen for the treatment of alcohol drinkers (Bacloville). Alcoholism: Clinical and Experimental Research2014;38:215a. RigalL , SidorkiewiczS , TrÃ©luyerJM , PerrodeauE , Le JeunneC , PorcherR , et al. Titrated baclofen for high-risk alcohol consumption: a randomized placebo-controlled trial in out-patients with 1-year follow-up. Addiction2020;115(7):1265-76. ">Rigal 2020</a>), two studies compared two doses of baclofen to placebo (each included as two discrete data sets; <a href="./references#CD012557-bbs2-0009" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âLD</a>; <a href="./references#CD012557-bbs2-0010" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. [PMID: 34155332]NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âMD</a>; <a href="./references#CD012557-bbs2-0018" title="HengS , JamshidiN , BaillieA , LouieE , DoreG , PhungN , et al. Baclofen response in alcohol dependent patients concurrently receiving antidepressants: secondary analysis from the BacALD study. Frontiers in Psychiatry2018;9:576. LoggeW , BaillieAJ , MorrisRW , HaberPS , MorleyKC . Baclofen reduces alcohol cue-induced fMRI brain activation in treatment seeking alcohol dependent individuals. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. LoggeWB , BaillieAJ , HaberPS , MorleyKC . Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Human Psychopharmacology2020;35(2):e2722. LoggeWB , HaberPS , BaillieAJ , KosinskiP , MorrisRW , FraserI , et al. Dose-specific baclofen effects on brain structure, function and treatment responses: neuroimaging findings from the BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):20A-21A. LoggeWB , MorleyKC , HaberPS , BaillieAJ . Executive functioning moderates responses to appetitive cues: a study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism2019;54(1):38-46. LoggeWB , MorrisRW , BaillieAJ , HaberPS , MorleyKC . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berlin)2021;238(5):1291-302. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Baclofen for treatment of alcohol use disorder: secondary analyses and implications of the Australian BacALD trial. Drug and Alcohol Review2019;38:S75. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Exploration of the modulating role of the GABAb receptor polymorphism rs29220 on response to baclofen in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):41A. MorleyKC , BaillieA , FraserI , Furneaux-BateA , DoreG , RobertsM , et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry2018;212(6):362-9. MorleyKC , LagopoulosJ , LoggeW , BaillieA , AdamsC , HaberPS . Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addiction Biology2020;25(1):e12702. MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55. MorleyKC , LoggeWB , FraserI , MorrisRW , BaillieAJ , HaberPS . High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology2021;46:28-36. MorleyKC , LuquinN , BaillieA , FraserI , TrentRJ , DoreG , et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction2018;113(12):2205-13. MorleyKC , MorrisR , LoggeW , BaillieA , FraserI , HaberPS . Baclofen administration attenuates insula response during anticipatory anxiety in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. MorleyKC , RiordanB , LoggeW , BaillieA , HaberPS . Moderation of baclofen on the daily relationship between craving and alcohol use: results from the Australian BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):53A. MorleyLC , LuquinN , BaillieA , FraserI , TrentR , DoreG , et al. Moderation of baclofen response by a GABAb receptor polymorphism. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. RomboutsSA , BaillieA , HaberPS , MorleyKC . Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD trial. Alcohol and Alcoholism2019;54(3):272-8. ">Morley 2018âLD</a>; <a href="./references#CD012557-bbs2-0019" title="HengS , JamshidiN , BaillieA , LouieE , DoreG , PhungN , et al. Baclofen response in alcohol dependent patients concurrently receiving antidepressants: secondary analysis from the BacALD study. Frontiers in Psychiatry2018;9:576. LoggeW , BaillieAJ , MorrisRW , HaberPS , MorleyKC . Baclofen reduces alcohol cue-induced fMRI brain activation in treatment seeking alcohol dependent individuals. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. LoggeWB , BaillieAJ , HaberPS , MorleyKC . Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Human Psychopharmacology2020;35(2):e2722. LoggeWB , HaberPS , BaillieAJ , KosinskiP , MorrisRW , FraserI , et al. Dose-specific baclofen effects on brain structure, function and treatment responses: neuroimaging findings from the BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):20A-21A. LoggeWB , MorleyKC , HaberPS , BaillieAJ . Executive functioning moderates responses to appetitive cues: a study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism2019;54(1):38-46. LoggeWB , MorrisRW , BaillieAJ , HaberPS , MorleyKC . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berlin)2021;238(5):1291-302. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Baclofen for treatment of alcohol use disorder: secondary analyses and implications of the Australian BacALD trial. Drug and Alcohol Review2019;38:S75. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Exploration of the modulating role of the GABAb receptor polymorphism rs29220 on response to baclofen in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):41A. MorleyKC , BaillieA , FraserI , Furneaux-BateA , DoreG , RobertsM , et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry2018;212(6):362-9. MorleyKC , LagopoulosJ , LoggeW , BaillieA , AdamsC , HaberPS . Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addiction Biology2020;25(1):e12702. MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55. MorleyKC , LoggeWB , FraserI , MorrisRW , BaillieAJ , HaberPS . High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology2021;46:28-36. MorleyKC , LuquinN , BaillieA , FraserI , TrentRJ , DoreG , et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction2018;113(12):2205-13. MorleyKC , MorrisR , LoggeW , BaillieA , FraserI , HaberPS . Baclofen administration attenuates insula response during anticipatory anxiety in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. MorleyKC , RiordanB , LoggeW , BaillieA , HaberPS . Moderation of baclofen on the daily relationship between craving and alcohol use: results from the Australian BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):53A. RomboutsSA , BaillieA , HaberPS , MorleyKC . Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD Trial. Alcohol and Alcoholism2019;54(3):272-8. ">Morley 2018âMD</a>), and one study compared a single dose of baclofen to acamprosate and naltrexone (<a href="./references#CD012557-bbs2-0013" title="KumarA , SharmaA , BansalPD , BahetraM , GillHK , KumarR . A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. Indian Journal of Psychiatry2020;62(6):650-8. ">Kumar 2020a</a>). In addition, the authors of a study previously awaiting classification that compared two doses of baclofen to placebo provided data allowing us to include the study (included as two discrete data sets; <a href="./references#CD012557-bbs2-0002" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , BedogniG , CaputoF , et al. Doseâresponse effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism2011;46(3):312-7. [PMID: 21414953]">Addolorato 2011âLD</a>; <a href="./references#CD012557-bbs2-0003" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , BedogniG , CaputoF , et al. Doseâresponse effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism2011;46(3):312-7. [PMID: 21414953]">Addolorato 2011âMD</a>). We excluded three studies (see <a href="./references#CD012557-sec-0189" title="">Characteristics of excluded studies</a> table) and one is awaiting classification (see <a href="./references#CD012557-sec-0190" title="">Characteristics of studies awaiting classification</a> table). Overall, we included five new RCTs. </p> <p>We previously identified 12 studies, eight that compared a single dose of baclofen to placebo (<a href="./references#CD012557-bbs2-0001" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , VonghiaL , MirijelloA , et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet2007;370(9603):1915-22. [DOI: 10.1016/S0140-6736(07)61814-5]">Addolorato 2007</a>; <a href="./references#CD012557-bbs2-0006" title="GarbuttJC , Kampov-PolevoyAB , GallopR , Kalka-JuhlL , FlanneryBA . Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcoholism, Clinical and Experimental Research2010;34(11):1849-57. [DOI: 10.1111/j.1530-0277.2010.01273.x]">Garbutt 2010a</a>; <a href="./references#CD012557-bbs2-0011" title="HauserP , Fuller B HoSB , ThurasP , KernS , DieperinkE . The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. Addiction2017;112(7):1173-83. [DOI: 10.1111/add.13787.]">Hauser 2017</a>; <a href="./references#CD012557-bbs2-0012" title="KrupitskiiEM , RybakovaKV , KiselevAS , AlekseevaYV , BerntsevVA , ChekhlatyiEI , et al. Efficacy and safety of the use of baclofen in the treatment of alcohol dependent (a double-blind, randomized, placebo-controlled pilot study). Neuroscience and Behavioral Physiology2017;47(2):153-62. [DOI: 10.1007/s11055-016-0379-6]KrupitskyEM , RybakovaKV , KiselevAS , AlexeevaYV , BerntsevVA , ChekhlatyEI , et al. Double blind placebo controlled randomized pilot clinical trial of baclofen (BaclosanÂ®) for alcohol dependence. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova2015;115(6):53-62. [DOI: 10.17116/jnevro20151156153-62]">Krupitskii 2017</a>; <a href="./references#CD012557-bbs2-0014" title="BollingerJ , EdwardsSM , ZywiakWK , TideyJW , SwiftRW , KennaGA , et al. A double-blind, placebo-controlled randomized pilot study of the effects of baclofen on alcohol-tobacco co-use and alcohol cue-reactivity in alcoholic smokers. Clinical and Translational Science2014;7(3):265. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW , et al. Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Erratum for: Neuropsychopharmacology. 2014 Dec;39 Suppl 1:S1-647. Neuropsychopharmacology2015;40(6):1560. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW . Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Neuropsychopharmacology2014;39:S340. LeggioL , ZywiakWH , EdwardsSM , TideyJW , SwiftRM , KennaGA . A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology2015;232(1):233-43. [DOI: 10.1007/s00213-014-3652-9]">Leggio 2015</a>; <a href="./references#CD012557-bbs2-0020" title="BeckA , PelzP , LorenzRC , CharletK , GeiselO , HeinzA , et al. Effects of high-dose baclofen on cue reactivity in alcohol dependence: a randomized, placebo-controlled pharmaco-fMRI study. European Neuropsychopharmacology2018;28(11):1206-16. GeiselO , HellwegR , WerneckeKD , WiedemannK , MÃ¼llerCA . Total and acylated ghrelin plasma levels as potential long-term response markers in alcohol-dependent patients receiving high-dose of the GABA-B receptor agonist baclofen. Psychiatry Research2019;272:431-7. GeiselO , SchlemmL , HellwegR , WiedemannK , MÃ¼llerCA . Hypothalamic-pituitary-adrenocortical axis activity in alcohol-dependent patients during treatment with high-dose baclofen. Pharmacopsychiatry2019;52(1):32-7. MullerCA , GeiselO , PelzP , HiglV , KrugerJ , StickelA , et al. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. European Neuropsychopharmacology2015;25(8):1167-77. [DOI: 10.1016/j.euroneuro.2015.04.002]MullerCA , GeiselO , PelzP , HiglV , KrugerJ , StickelA , et al. Individually titrated high-dose baclofen for the treatment of alcohol dependence (BACLAD study) â a randomized controlled trial. European Psychiatry2015;30(S1):1611. [DOI: 10.1016/S0924-9338(15)31243-8]PelzP , GenauckA , GleichT , LorenzRC , HeinzA , MullerCA , et al. Baclofen desensitizes the fronto-striatal reward network in alcohol dependent patients: a randomized, placebo-controlled pharmaco FMRI trial. Alcoholism: Clinical and Experimental Research2018;42:126A. PelzP , GenauckA , LorenzRC , WustenbergC , WackerhagenK , CharletT , et al. Baclofen desensitizes insular gain anticipation in alcohol-dependent patients â a randomized, placebo-controlled, patient-tailored pharmaco fMRI trial. Alcoholism: Clinical and Experimental Research2019;43(Suppl 1):246A. ">Muller 2015</a>; <a href="./references#CD012557-bbs2-0021" title="PonizovskyAM , RoscaP , AronovichE , WeizmanA , GrinshpoonA . Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up. Journal of Substance Abuse Treatment2015;52:24-30. [DOI: 10.1016/j.jsat.2014.11.007]">Ponizovsky 2015</a>; <a href="./references#CD012557-bbs2-0022" title="PouchainD . A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients. The Alpadir study. Exercer-La Revue Francophone De Medecine Generale2018;142:163-5. ReynaudM , AubinHJ , TrinquetF , ZakineB , DanoC , DematteisM , et al. A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients â the ALPADIR Study. Alcohol and Alcoholism2017;52(4):439-46. ">Reynaud 2017</a>), two that compared two doses of baclofen to placebo (each included as two discrete data sets; <a href="./references#CD012557-bbs2-0004" title="BerahaEM , SaleminkE , GoudriaanAE , BakkerA , De JongD , SmitsN , et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology2017;26(12):1950-9. BerahaEM , SaleminkE , KredietE , WiersRW . Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?Journal of Psychopharmacology2018;32(8):867-75. [PMID: 29897022]">Beraha 2016âHD</a>; <a href="./references#CD012557-bbs2-0005" title="BerahaEM , SaleminkE , GoudriaanAE , BakkerA , De JongD , SmitsN , et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology2017;26(12):1950-9. BerahaEM , SaleminkE , KredietE , WiersRW . Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?Journal of Psychopharmacology2018;32(8):867-75. ">Beraha 2016âLD</a>; <a href="./references#CD012557-bbs2-0016" title="MorleyKC , BaillieA , LeungS , AddoloratoG , LeggioL , HaberPS . Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol and Alcoholism2014;49(6):654-60. [DOI: 10.1093/alcalc/agu062]">Morley 2014âLD</a>; <a href="./references#CD012557-bbs2-0017" title="MorleyKC , BaillieA , LeungS , AddoloratoG , LeggioL , HaberPS . Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol and Alcoholism2014;49(6):654-60. [DOI: 10.1093/alcalc/agu062]">Morley 2014âMD</a>), one study that compared a single dose of baclofen to acamprosate (<a href="./references#CD012557-bbs2-0015" title="MishraSN , SwainSP , ShuklaRK , SarkarP . A study of comparative efficacy of baclofen vs acamprosate in reducing alcohol craving and abuse. Orissa Journal of Psychiatry2010;-:48-53. ">Mishra 2010</a>), and one study that compared baclofen to placebo and naltrexone (included as two discrete data sets; <a href="./references#CD012557-bbs2-0007" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b1</a>; <a href="./references#CD012557-bbs2-0008" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b2</a>) in our original review (see <a href="./references#CD012557-sec-0188" title="">Characteristics of included studies</a> table). </p> </section> <section id="CD012557-sec-0044"> <h4 class="title">Included studies</h4> <p>We included 17 RCTs involving 1818 participants (see <a href="./references#CD012557-sec-0188" title="">Characteristics of included studies</a> table). The mean study size was 107 participants, ranging from 30 in <a href="./references#CD012557-bbs2-0014" title="BollingerJ , EdwardsSM , ZywiakWK , TideyJW , SwiftRW , KennaGA , et al. A double-blind, placebo-controlled randomized pilot study of the effects of baclofen on alcohol-tobacco co-use and alcohol cue-reactivity in alcoholic smokers. Clinical and Translational Science2014;7(3):265. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW , et al. Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Erratum for: Neuropsychopharmacology. 2014 Dec;39 Suppl 1:S1-647. Neuropsychopharmacology2015;40(6):1560. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW . Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Neuropsychopharmacology2014;39:S340. LeggioL , ZywiakWH , EdwardsSM , TideyJW , SwiftRM , KennaGA . A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology2015;232(1):233-43. [DOI: 10.1007/s00213-014-3652-9]">Leggio 2015</a> to 320 in <a href="./references#CD012557-bbs2-0022" title="PouchainD . A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients. The Alpadir study. Exercer-La Revue Francophone De Medecine Generale2018;142:163-5. ReynaudM , AubinHJ , TrinquetF , ZakineB , DanoC , DematteisM , et al. A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients â the ALPADIR Study. Alcohol and Alcoholism2017;52(4):439-46. ">Reynaud 2017</a>. Six studies recruited more than 100 participants (<a href="./references#CD012557-bbs2-0005" title="BerahaEM , SaleminkE , GoudriaanAE , BakkerA , De JongD , SmitsN , et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology2017;26(12):1950-9. BerahaEM , SaleminkE , KredietE , WiersRW . Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?Journal of Psychopharmacology2018;32(8):867-75. ">Beraha 2016âLD</a>; <a href="./references#CD012557-bbs2-0005" title="BerahaEM , SaleminkE , GoudriaanAE , BakkerA , De JongD , SmitsN , et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology2017;26(12):1950-9. BerahaEM , SaleminkE , KredietE , WiersRW . Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?Journal of Psychopharmacology2018;32(8):867-75. ">Beraha 2016âLD</a>; <a href="./references#CD012557-bbs2-0009" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âLD</a>; <a href="./references#CD012557-bbs2-0010" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. [PMID: 34155332]NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âMD</a>; <a href="./references#CD012557-bbs2-0011" title="HauserP , Fuller B HoSB , ThurasP , KernS , DieperinkE . The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. Addiction2017;112(7):1173-83. [DOI: 10.1111/add.13787.]">Hauser 2017</a>; <a href="./references#CD012557-bbs2-0018" title="HengS , JamshidiN , BaillieA , LouieE , DoreG , PhungN , et al. Baclofen response in alcohol dependent patients concurrently receiving antidepressants: secondary analysis from the BacALD study. Frontiers in Psychiatry2018;9:576. LoggeW , BaillieAJ , MorrisRW , HaberPS , MorleyKC . Baclofen reduces alcohol cue-induced fMRI brain activation in treatment seeking alcohol dependent individuals. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. LoggeWB , BaillieAJ , HaberPS , MorleyKC . Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Human Psychopharmacology2020;35(2):e2722. LoggeWB , HaberPS , BaillieAJ , KosinskiP , MorrisRW , FraserI , et al. Dose-specific baclofen effects on brain structure, function and treatment responses: neuroimaging findings from the BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):20A-21A. LoggeWB , MorleyKC , HaberPS , BaillieAJ . Executive functioning moderates responses to appetitive cues: a study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism2019;54(1):38-46. LoggeWB , MorrisRW , BaillieAJ , HaberPS , MorleyKC . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berlin)2021;238(5):1291-302. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Baclofen for treatment of alcohol use disorder: secondary analyses and implications of the Australian BacALD trial. Drug and Alcohol Review2019;38:S75. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Exploration of the modulating role of the GABAb receptor polymorphism rs29220 on response to baclofen in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):41A. MorleyKC , BaillieA , FraserI , Furneaux-BateA , DoreG , RobertsM , et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry2018;212(6):362-9. MorleyKC , LagopoulosJ , LoggeW , BaillieA , AdamsC , HaberPS . Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addiction Biology2020;25(1):e12702. MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55. MorleyKC , LoggeWB , FraserI , MorrisRW , BaillieAJ , HaberPS . High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology2021;46:28-36. MorleyKC , LuquinN , BaillieA , FraserI , TrentRJ , DoreG , et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction2018;113(12):2205-13. MorleyKC , MorrisR , LoggeW , BaillieA , FraserI , HaberPS . Baclofen administration attenuates insula response during anticipatory anxiety in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. MorleyKC , RiordanB , LoggeW , BaillieA , HaberPS . Moderation of baclofen on the daily relationship between craving and alcohol use: results from the Australian BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):53A. MorleyLC , LuquinN , BaillieA , FraserI , TrentR , DoreG , et al. Moderation of baclofen response by a GABAb receptor polymorphism. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. RomboutsSA , BaillieA , HaberPS , MorleyKC . Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD trial. Alcohol and Alcoholism2019;54(3):272-8. ">Morley 2018âLD</a>; <a href="./references#CD012557-bbs2-0019" title="HengS , JamshidiN , BaillieA , LouieE , DoreG , PhungN , et al. Baclofen response in alcohol dependent patients concurrently receiving antidepressants: secondary analysis from the BacALD study. Frontiers in Psychiatry2018;9:576. LoggeW , BaillieAJ , MorrisRW , HaberPS , MorleyKC . Baclofen reduces alcohol cue-induced fMRI brain activation in treatment seeking alcohol dependent individuals. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. LoggeWB , BaillieAJ , HaberPS , MorleyKC . Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Human Psychopharmacology2020;35(2):e2722. LoggeWB , HaberPS , BaillieAJ , KosinskiP , MorrisRW , FraserI , et al. Dose-specific baclofen effects on brain structure, function and treatment responses: neuroimaging findings from the BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):20A-21A. LoggeWB , MorleyKC , HaberPS , BaillieAJ . Executive functioning moderates responses to appetitive cues: a study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism2019;54(1):38-46. LoggeWB , MorrisRW , BaillieAJ , HaberPS , MorleyKC . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berlin)2021;238(5):1291-302. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Baclofen for treatment of alcohol use disorder: secondary analyses and implications of the Australian BacALD trial. Drug and Alcohol Review2019;38:S75. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Exploration of the modulating role of the GABAb receptor polymorphism rs29220 on response to baclofen in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):41A. MorleyKC , BaillieA , FraserI , Furneaux-BateA , DoreG , RobertsM , et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry2018;212(6):362-9. MorleyKC , LagopoulosJ , LoggeW , BaillieA , AdamsC , HaberPS . Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addiction Biology2020;25(1):e12702. MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55. MorleyKC , LoggeWB , FraserI , MorrisRW , BaillieAJ , HaberPS . High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology2021;46:28-36. MorleyKC , LuquinN , BaillieA , FraserI , TrentRJ , DoreG , et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction2018;113(12):2205-13. MorleyKC , MorrisR , LoggeW , BaillieA , FraserI , HaberPS . Baclofen administration attenuates insula response during anticipatory anxiety in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. MorleyKC , RiordanB , LoggeW , BaillieA , HaberPS . Moderation of baclofen on the daily relationship between craving and alcohol use: results from the Australian BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):53A. RomboutsSA , BaillieA , HaberPS , MorleyKC . Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD Trial. Alcohol and Alcoholism2019;54(3):272-8. ">Morley 2018âMD</a>; <a href="./references#CD012557-bbs2-0022" title="PouchainD . A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients. The Alpadir study. Exercer-La Revue Francophone De Medecine Generale2018;142:163-5. ReynaudM , AubinHJ , TrinquetF , ZakineB , DanoC , DematteisM , et al. A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients â the ALPADIR Study. Alcohol and Alcoholism2017;52(4):439-46. ">Reynaud 2017</a>; <a href="./references#CD012557-bbs2-0023" title="JauryPH . Baclofen for the treatment of alcohol drinkers (Bacloville). Alcoholism: Clinical and Experimental Research2014;38:215a. RigalL , SidorkiewiczS , TrÃ©luyerJM , PerrodeauE , Le JeunneC , PorcherR , et al. Titrated baclofen for high-risk alcohol consumption: a randomized placebo-controlled trial in out-patients with 1-year follow-up. Addiction2020;115(7):1265-76. ">Rigal 2020</a>). The mean age of participants was 46.5 years, and 69.6% were men. All studies except one recruited participants with a diagnosis of alcohol dependence according to the DSMâIV or ICDâ10 criteria. <a href="./references#CD012557-bbs2-0023" title="JauryPH . Baclofen for the treatment of alcohol drinkers (Bacloville). Alcoholism: Clinical and Experimental Research2014;38:215a. RigalL , SidorkiewiczS , TrÃ©luyerJM , PerrodeauE , Le JeunneC , PorcherR , et al. Titrated baclofen for high-risk alcohol consumption: a randomized placebo-controlled trial in out-patients with 1-year follow-up. Addiction2020;115(7):1265-76. ">Rigal 2020</a> did not require the diagnosis of alcohol dependence and recruited highârisk drinkers according to the WHO definition of atârisk drinking (alcohol consumption greater than 40 g/day or single occasion, greater than 280 g/week, or both for women; greater than 60 g/day or single occasion, greater than 420 g/week, or both for men; <a href="./references#CD012557-bbs2-0152" title="World Health Organization. International guide for monitoring alcohol consumption and related harm. apps.who.int/iris/handle/10665/66529 (accessed 8 December 2022). [www.who.int/iris/handle/10665/66529]">WHO 2000</a>). To be included, these participants also had to voluntarily consult a physician for their alcohol problem and express the desire to achieve abstinence or reduce alcohol consumption. Accordingly, we assumed that these participants met at least three criteria for AUD (alcohol consumption in higher amounts than intended; desire to cut down or control alcohol use; craving; <a href="./references#CD012557-bbs2-0049" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Washington (DC): American Psychiatric Association, 2013.">APA 2013</a>), and we included the study. </p> <p>Five studies took place in the USA (<a href="./references#CD012557-bbs2-0006" title="GarbuttJC , Kampov-PolevoyAB , GallopR , Kalka-JuhlL , FlanneryBA . Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcoholism, Clinical and Experimental Research2010;34(11):1849-57. [DOI: 10.1111/j.1530-0277.2010.01273.x]">Garbutt 2010a</a>; <a href="./references#CD012557-bbs2-0007" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b1</a>; <a href="./references#CD012557-bbs2-0008" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b2</a>; <a href="./references#CD012557-bbs2-0009" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âLD</a>; <a href="./references#CD012557-bbs2-0010" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. [PMID: 34155332]NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âMD</a>; <a href="./references#CD012557-bbs2-0011" title="HauserP , Fuller B HoSB , ThurasP , KernS , DieperinkE . The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. Addiction2017;112(7):1173-83. [DOI: 10.1111/add.13787.]">Hauser 2017</a>; <a href="./references#CD012557-bbs2-0014" title="BollingerJ , EdwardsSM , ZywiakWK , TideyJW , SwiftRW , KennaGA , et al. A double-blind, placebo-controlled randomized pilot study of the effects of baclofen on alcohol-tobacco co-use and alcohol cue-reactivity in alcoholic smokers. Clinical and Translational Science2014;7(3):265. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW , et al. Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Erratum for: Neuropsychopharmacology. 2014 Dec;39 Suppl 1:S1-647. Neuropsychopharmacology2015;40(6):1560. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW . Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Neuropsychopharmacology2014;39:S340. LeggioL , ZywiakWH , EdwardsSM , TideyJW , SwiftRM , KennaGA . A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology2015;232(1):233-43. [DOI: 10.1007/s00213-014-3652-9]">Leggio 2015</a>); two studies in Australia (<a href="./references#CD012557-bbs2-0016" title="MorleyKC , BaillieA , LeungS , AddoloratoG , LeggioL , HaberPS . Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol and Alcoholism2014;49(6):654-60. [DOI: 10.1093/alcalc/agu062]">Morley 2014âLD</a>; <a href="./references#CD012557-bbs2-0017" title="MorleyKC , BaillieA , LeungS , AddoloratoG , LeggioL , HaberPS . Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol and Alcoholism2014;49(6):654-60. [DOI: 10.1093/alcalc/agu062]">Morley 2014âMD</a>; <a href="./references#CD012557-bbs2-0018" title="HengS , JamshidiN , BaillieA , LouieE , DoreG , PhungN , et al. Baclofen response in alcohol dependent patients concurrently receiving antidepressants: secondary analysis from the BacALD study. Frontiers in Psychiatry2018;9:576. LoggeW , BaillieAJ , MorrisRW , HaberPS , MorleyKC . Baclofen reduces alcohol cue-induced fMRI brain activation in treatment seeking alcohol dependent individuals. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. LoggeWB , BaillieAJ , HaberPS , MorleyKC . Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Human Psychopharmacology2020;35(2):e2722. LoggeWB , HaberPS , BaillieAJ , KosinskiP , MorrisRW , FraserI , et al. Dose-specific baclofen effects on brain structure, function and treatment responses: neuroimaging findings from the BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):20A-21A. LoggeWB , MorleyKC , HaberPS , BaillieAJ . Executive functioning moderates responses to appetitive cues: a study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism2019;54(1):38-46. LoggeWB , MorrisRW , BaillieAJ , HaberPS , MorleyKC . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berlin)2021;238(5):1291-302. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Baclofen for treatment of alcohol use disorder: secondary analyses and implications of the Australian BacALD trial. Drug and Alcohol Review2019;38:S75. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Exploration of the modulating role of the GABAb receptor polymorphism rs29220 on response to baclofen in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):41A. MorleyKC , BaillieA , FraserI , Furneaux-BateA , DoreG , RobertsM , et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry2018;212(6):362-9. MorleyKC , LagopoulosJ , LoggeW , BaillieA , AdamsC , HaberPS . Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addiction Biology2020;25(1):e12702. MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55. MorleyKC , LoggeWB , FraserI , MorrisRW , BaillieAJ , HaberPS . High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology2021;46:28-36. MorleyKC , LuquinN , BaillieA , FraserI , TrentRJ , DoreG , et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction2018;113(12):2205-13. MorleyKC , MorrisR , LoggeW , BaillieA , FraserI , HaberPS . Baclofen administration attenuates insula response during anticipatory anxiety in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. MorleyKC , RiordanB , LoggeW , BaillieA , HaberPS . Moderation of baclofen on the daily relationship between craving and alcohol use: results from the Australian BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):53A. MorleyLC , LuquinN , BaillieA , FraserI , TrentR , DoreG , et al. Moderation of baclofen response by a GABAb receptor polymorphism. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. RomboutsSA , BaillieA , HaberPS , MorleyKC . Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD trial. Alcohol and Alcoholism2019;54(3):272-8. ">Morley 2018âLD</a>; <a href="./references#CD012557-bbs2-0019" title="HengS , JamshidiN , BaillieA , LouieE , DoreG , PhungN , et al. Baclofen response in alcohol dependent patients concurrently receiving antidepressants: secondary analysis from the BacALD study. Frontiers in Psychiatry2018;9:576. LoggeW , BaillieAJ , MorrisRW , HaberPS , MorleyKC . Baclofen reduces alcohol cue-induced fMRI brain activation in treatment seeking alcohol dependent individuals. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. LoggeWB , BaillieAJ , HaberPS , MorleyKC . Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Human Psychopharmacology2020;35(2):e2722. LoggeWB , HaberPS , BaillieAJ , KosinskiP , MorrisRW , FraserI , et al. Dose-specific baclofen effects on brain structure, function and treatment responses: neuroimaging findings from the BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):20A-21A. LoggeWB , MorleyKC , HaberPS , BaillieAJ . Executive functioning moderates responses to appetitive cues: a study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism2019;54(1):38-46. LoggeWB , MorrisRW , BaillieAJ , HaberPS , MorleyKC . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berlin)2021;238(5):1291-302. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Baclofen for treatment of alcohol use disorder: secondary analyses and implications of the Australian BacALD trial. Drug and Alcohol Review2019;38:S75. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Exploration of the modulating role of the GABAb receptor polymorphism rs29220 on response to baclofen in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):41A. MorleyKC , BaillieA , FraserI , Furneaux-BateA , DoreG , RobertsM , et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry2018;212(6):362-9. MorleyKC , LagopoulosJ , LoggeW , BaillieA , AdamsC , HaberPS . Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addiction Biology2020;25(1):e12702. MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55. MorleyKC , LoggeWB , FraserI , MorrisRW , BaillieAJ , HaberPS . High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology2021;46:28-36. MorleyKC , LuquinN , BaillieA , FraserI , TrentRJ , DoreG , et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction2018;113(12):2205-13. MorleyKC , MorrisR , LoggeW , BaillieA , FraserI , HaberPS . Baclofen administration attenuates insula response during anticipatory anxiety in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. MorleyKC , RiordanB , LoggeW , BaillieA , HaberPS . Moderation of baclofen on the daily relationship between craving and alcohol use: results from the Australian BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):53A. RomboutsSA , BaillieA , HaberPS , MorleyKC . Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD Trial. Alcohol and Alcoholism2019;54(3):272-8. ">Morley 2018âMD</a>), France (<a href="./references#CD012557-bbs2-0022" title="PouchainD . A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients. The Alpadir study. Exercer-La Revue Francophone De Medecine Generale2018;142:163-5. ReynaudM , AubinHJ , TrinquetF , ZakineB , DanoC , DematteisM , et al. A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients â the ALPADIR Study. Alcohol and Alcoholism2017;52(4):439-46. ">Reynaud 2017</a>; <a href="./references#CD012557-bbs2-0023" title="JauryPH . Baclofen for the treatment of alcohol drinkers (Bacloville). Alcoholism: Clinical and Experimental Research2014;38:215a. RigalL , SidorkiewiczS , TrÃ©luyerJM , PerrodeauE , Le JeunneC , PorcherR , et al. Titrated baclofen for high-risk alcohol consumption: a randomized placebo-controlled trial in out-patients with 1-year follow-up. Addiction2020;115(7):1265-76. ">Rigal 2020</a>), Italy (<a href="./references#CD012557-bbs2-0001" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , VonghiaL , MirijelloA , et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet2007;370(9603):1915-22. [DOI: 10.1016/S0140-6736(07)61814-5]">Addolorato 2007</a>; <a href="./references#CD012557-bbs2-0002" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , BedogniG , CaputoF , et al. Doseâresponse effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism2011;46(3):312-7. [PMID: 21414953]">Addolorato 2011âLD</a>; <a href="./references#CD012557-bbs2-0003" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , BedogniG , CaputoF , et al. Doseâresponse effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism2011;46(3):312-7. [PMID: 21414953]">Addolorato 2011âMD</a>), and India (<a href="./references#CD012557-bbs2-0013" title="KumarA , SharmaA , BansalPD , BahetraM , GillHK , KumarR . A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. Indian Journal of Psychiatry2020;62(6):650-8. ">Kumar 2020a</a>; <a href="./references#CD012557-bbs2-0015" title="MishraSN , SwainSP , ShuklaRK , SarkarP . A study of comparative efficacy of baclofen vs acamprosate in reducing alcohol craving and abuse. Orissa Journal of Psychiatry2010;-:48-53. ">Mishra 2010</a>); and one in Germany (<a href="./references#CD012557-bbs2-0020" title="BeckA , PelzP , LorenzRC , CharletK , GeiselO , HeinzA , et al. Effects of high-dose baclofen on cue reactivity in alcohol dependence: a randomized, placebo-controlled pharmaco-fMRI study. European Neuropsychopharmacology2018;28(11):1206-16. GeiselO , HellwegR , WerneckeKD , WiedemannK , MÃ¼llerCA . Total and acylated ghrelin plasma levels as potential long-term response markers in alcohol-dependent patients receiving high-dose of the GABA-B receptor agonist baclofen. Psychiatry Research2019;272:431-7. GeiselO , SchlemmL , HellwegR , WiedemannK , MÃ¼llerCA . Hypothalamic-pituitary-adrenocortical axis activity in alcohol-dependent patients during treatment with high-dose baclofen. Pharmacopsychiatry2019;52(1):32-7. MullerCA , GeiselO , PelzP , HiglV , KrugerJ , StickelA , et al. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. European Neuropsychopharmacology2015;25(8):1167-77. [DOI: 10.1016/j.euroneuro.2015.04.002]MullerCA , GeiselO , PelzP , HiglV , KrugerJ , StickelA , et al. Individually titrated high-dose baclofen for the treatment of alcohol dependence (BACLAD study) â a randomized controlled trial. European Psychiatry2015;30(S1):1611. [DOI: 10.1016/S0924-9338(15)31243-8]PelzP , GenauckA , GleichT , LorenzRC , HeinzA , MullerCA , et al. Baclofen desensitizes the fronto-striatal reward network in alcohol dependent patients: a randomized, placebo-controlled pharmaco FMRI trial. Alcoholism: Clinical and Experimental Research2018;42:126A. PelzP , GenauckA , LorenzRC , WustenbergC , WackerhagenK , CharletT , et al. Baclofen desensitizes insular gain anticipation in alcohol-dependent patients â a randomized, placebo-controlled, patient-tailored pharmaco fMRI trial. Alcoholism: Clinical and Experimental Research2019;43(Suppl 1):246A. ">Muller 2015</a>), Israel (<a href="./references#CD012557-bbs2-0021" title="PonizovskyAM , RoscaP , AronovichE , WeizmanA , GrinshpoonA . Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up. Journal of Substance Abuse Treatment2015;52:24-30. [DOI: 10.1016/j.jsat.2014.11.007]">Ponizovsky 2015</a>), Russia (<a href="./references#CD012557-bbs2-0012" title="KrupitskiiEM , RybakovaKV , KiselevAS , AlekseevaYV , BerntsevVA , ChekhlatyiEI , et al. Efficacy and safety of the use of baclofen in the treatment of alcohol dependent (a double-blind, randomized, placebo-controlled pilot study). Neuroscience and Behavioral Physiology2017;47(2):153-62. [DOI: 10.1007/s11055-016-0379-6]KrupitskyEM , RybakovaKV , KiselevAS , AlexeevaYV , BerntsevVA , ChekhlatyEI , et al. Double blind placebo controlled randomized pilot clinical trial of baclofen (BaclosanÂ®) for alcohol dependence. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova2015;115(6):53-62. [DOI: 10.17116/jnevro20151156153-62]">Krupitskii 2017</a>), and the Netherlands (<a href="./references#CD012557-bbs2-0004" title="BerahaEM , SaleminkE , GoudriaanAE , BakkerA , De JongD , SmitsN , et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology2017;26(12):1950-9. BerahaEM , SaleminkE , KredietE , WiersRW . Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?Journal of Psychopharmacology2018;32(8):867-75. [PMID: 29897022]">Beraha 2016âHD</a>; <a href="./references#CD012557-bbs2-0005" title="BerahaEM , SaleminkE , GoudriaanAE , BakkerA , De JongD , SmitsN , et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology2017;26(12):1950-9. BerahaEM , SaleminkE , KredietE , WiersRW . Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?Journal of Psychopharmacology2018;32(8):867-75. ">Beraha 2016âLD</a>). </p> <p>All studies excluded people with substance use disorders by substances other than alcohol or nicotine. One trial recruited people dependent by both alcohol and nicotine (<a href="./references#CD012557-bbs2-0014" title="BollingerJ , EdwardsSM , ZywiakWK , TideyJW , SwiftRW , KennaGA , et al. A double-blind, placebo-controlled randomized pilot study of the effects of baclofen on alcohol-tobacco co-use and alcohol cue-reactivity in alcoholic smokers. Clinical and Translational Science2014;7(3):265. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW , et al. Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Erratum for: Neuropsychopharmacology. 2014 Dec;39 Suppl 1:S1-647. Neuropsychopharmacology2015;40(6):1560. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW . Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Neuropsychopharmacology2014;39:S340. LeggioL , ZywiakWH , EdwardsSM , TideyJW , SwiftRM , KennaGA . A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology2015;232(1):233-43. [DOI: 10.1007/s00213-014-3652-9]">Leggio 2015</a>). All studies excluded people with comorbid severe mental disorders but five studies recruited people receiving stable doses of antidepressants (<a href="./references#CD012557-bbs2-0004" title="BerahaEM , SaleminkE , GoudriaanAE , BakkerA , De JongD , SmitsN , et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology2017;26(12):1950-9. BerahaEM , SaleminkE , KredietE , WiersRW . Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?Journal of Psychopharmacology2018;32(8):867-75. [PMID: 29897022]">Beraha 2016âHD</a>; <a href="./references#CD012557-bbs2-0005" title="BerahaEM , SaleminkE , GoudriaanAE , BakkerA , De JongD , SmitsN , et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology2017;26(12):1950-9. BerahaEM , SaleminkE , KredietE , WiersRW . Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?Journal of Psychopharmacology2018;32(8):867-75. ">Beraha 2016âLD</a>; <a href="./references#CD012557-bbs2-0006" title="GarbuttJC , Kampov-PolevoyAB , GallopR , Kalka-JuhlL , FlanneryBA . Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcoholism, Clinical and Experimental Research2010;34(11):1849-57. [DOI: 10.1111/j.1530-0277.2010.01273.x]">Garbutt 2010a</a>; <a href="./references#CD012557-bbs2-0009" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âLD</a>; <a href="./references#CD012557-bbs2-0010" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. [PMID: 34155332]NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âMD</a>; <a href="./references#CD012557-bbs2-0018" title="HengS , JamshidiN , BaillieA , LouieE , DoreG , PhungN , et al. Baclofen response in alcohol dependent patients concurrently receiving antidepressants: secondary analysis from the BacALD study. Frontiers in Psychiatry2018;9:576. LoggeW , BaillieAJ , MorrisRW , HaberPS , MorleyKC . Baclofen reduces alcohol cue-induced fMRI brain activation in treatment seeking alcohol dependent individuals. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. LoggeWB , BaillieAJ , HaberPS , MorleyKC . Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Human Psychopharmacology2020;35(2):e2722. LoggeWB , HaberPS , BaillieAJ , KosinskiP , MorrisRW , FraserI , et al. Dose-specific baclofen effects on brain structure, function and treatment responses: neuroimaging findings from the BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):20A-21A. LoggeWB , MorleyKC , HaberPS , BaillieAJ . Executive functioning moderates responses to appetitive cues: a study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism2019;54(1):38-46. LoggeWB , MorrisRW , BaillieAJ , HaberPS , MorleyKC . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berlin)2021;238(5):1291-302. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Baclofen for treatment of alcohol use disorder: secondary analyses and implications of the Australian BacALD trial. Drug and Alcohol Review2019;38:S75. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Exploration of the modulating role of the GABAb receptor polymorphism rs29220 on response to baclofen in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):41A. MorleyKC , BaillieA , FraserI , Furneaux-BateA , DoreG , RobertsM , et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry2018;212(6):362-9. MorleyKC , LagopoulosJ , LoggeW , BaillieA , AdamsC , HaberPS . Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addiction Biology2020;25(1):e12702. MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55. MorleyKC , LoggeWB , FraserI , MorrisRW , BaillieAJ , HaberPS . High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology2021;46:28-36. MorleyKC , LuquinN , BaillieA , FraserI , TrentRJ , DoreG , et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction2018;113(12):2205-13. MorleyKC , MorrisR , LoggeW , BaillieA , FraserI , HaberPS . Baclofen administration attenuates insula response during anticipatory anxiety in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. MorleyKC , RiordanB , LoggeW , BaillieA , HaberPS . Moderation of baclofen on the daily relationship between craving and alcohol use: results from the Australian BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):53A. MorleyLC , LuquinN , BaillieA , FraserI , TrentR , DoreG , et al. Moderation of baclofen response by a GABAb receptor polymorphism. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. RomboutsSA , BaillieA , HaberPS , MorleyKC . Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD trial. Alcohol and Alcoholism2019;54(3):272-8. ">Morley 2018âLD</a>; <a href="./references#CD012557-bbs2-0019" title="HengS , JamshidiN , BaillieA , LouieE , DoreG , PhungN , et al. Baclofen response in alcohol dependent patients concurrently receiving antidepressants: secondary analysis from the BacALD study. Frontiers in Psychiatry2018;9:576. LoggeW , BaillieAJ , MorrisRW , HaberPS , MorleyKC . Baclofen reduces alcohol cue-induced fMRI brain activation in treatment seeking alcohol dependent individuals. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. LoggeWB , BaillieAJ , HaberPS , MorleyKC . Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Human Psychopharmacology2020;35(2):e2722. LoggeWB , HaberPS , BaillieAJ , KosinskiP , MorrisRW , FraserI , et al. Dose-specific baclofen effects on brain structure, function and treatment responses: neuroimaging findings from the BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):20A-21A. LoggeWB , MorleyKC , HaberPS , BaillieAJ . Executive functioning moderates responses to appetitive cues: a study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism2019;54(1):38-46. LoggeWB , MorrisRW , BaillieAJ , HaberPS , MorleyKC . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berlin)2021;238(5):1291-302. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Baclofen for treatment of alcohol use disorder: secondary analyses and implications of the Australian BacALD trial. Drug and Alcohol Review2019;38:S75. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Exploration of the modulating role of the GABAb receptor polymorphism rs29220 on response to baclofen in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):41A. MorleyKC , BaillieA , FraserI , Furneaux-BateA , DoreG , RobertsM , et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry2018;212(6):362-9. MorleyKC , LagopoulosJ , LoggeW , BaillieA , AdamsC , HaberPS . Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addiction Biology2020;25(1):e12702. MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55. MorleyKC , LoggeWB , FraserI , MorrisRW , BaillieAJ , HaberPS . High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology2021;46:28-36. MorleyKC , LuquinN , BaillieA , FraserI , TrentRJ , DoreG , et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction2018;113(12):2205-13. MorleyKC , MorrisR , LoggeW , BaillieA , FraserI , HaberPS . Baclofen administration attenuates insula response during anticipatory anxiety in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. MorleyKC , RiordanB , LoggeW , BaillieA , HaberPS . Moderation of baclofen on the daily relationship between craving and alcohol use: results from the Australian BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):53A. RomboutsSA , BaillieA , HaberPS , MorleyKC . Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD Trial. Alcohol and Alcoholism2019;54(3):272-8. ">Morley 2018âMD</a>; <a href="./references#CD012557-bbs2-0022" title="PouchainD . A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients. The Alpadir study. Exercer-La Revue Francophone De Medecine Generale2018;142:163-5. ReynaudM , AubinHJ , TrinquetF , ZakineB , DanoC , DematteisM , et al. A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients â the ALPADIR Study. Alcohol and Alcoholism2017;52(4):439-46. ">Reynaud 2017</a>). Three studies recruited people with severe liver disease (i.e. cirrhosis including ChildâPugh, hepatitis B virusâpositive, hepatitis C virusâpositive: <a href="./references#CD012557-bbs2-0001" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , VonghiaL , MirijelloA , et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet2007;370(9603):1915-22. [DOI: 10.1016/S0140-6736(07)61814-5]">Addolorato 2007</a>; chronic HCV: <a href="./references#CD012557-bbs2-0011" title="HauserP , Fuller B HoSB , ThurasP , KernS , DieperinkE . The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. Addiction2017;112(7):1173-83. [DOI: 10.1111/add.13787.]">Hauser 2017</a>; alcoholic liver disease: <a href="./references#CD012557-bbs2-0018" title="HengS , JamshidiN , BaillieA , LouieE , DoreG , PhungN , et al. Baclofen response in alcohol dependent patients concurrently receiving antidepressants: secondary analysis from the BacALD study. Frontiers in Psychiatry2018;9:576. LoggeW , BaillieAJ , MorrisRW , HaberPS , MorleyKC . Baclofen reduces alcohol cue-induced fMRI brain activation in treatment seeking alcohol dependent individuals. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. LoggeWB , BaillieAJ , HaberPS , MorleyKC . Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Human Psychopharmacology2020;35(2):e2722. LoggeWB , HaberPS , BaillieAJ , KosinskiP , MorrisRW , FraserI , et al. Dose-specific baclofen effects on brain structure, function and treatment responses: neuroimaging findings from the BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):20A-21A. LoggeWB , MorleyKC , HaberPS , BaillieAJ . Executive functioning moderates responses to appetitive cues: a study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism2019;54(1):38-46. LoggeWB , MorrisRW , BaillieAJ , HaberPS , MorleyKC . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berlin)2021;238(5):1291-302. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Baclofen for treatment of alcohol use disorder: secondary analyses and implications of the Australian BacALD trial. Drug and Alcohol Review2019;38:S75. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Exploration of the modulating role of the GABAb receptor polymorphism rs29220 on response to baclofen in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):41A. MorleyKC , BaillieA , FraserI , Furneaux-BateA , DoreG , RobertsM , et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry2018;212(6):362-9. MorleyKC , LagopoulosJ , LoggeW , BaillieA , AdamsC , HaberPS . Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addiction Biology2020;25(1):e12702. MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55. MorleyKC , LoggeWB , FraserI , MorrisRW , BaillieAJ , HaberPS . High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology2021;46:28-36. MorleyKC , LuquinN , BaillieA , FraserI , TrentRJ , DoreG , et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction2018;113(12):2205-13. MorleyKC , MorrisR , LoggeW , BaillieA , FraserI , HaberPS . Baclofen administration attenuates insula response during anticipatory anxiety in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. MorleyKC , RiordanB , LoggeW , BaillieA , HaberPS . Moderation of baclofen on the daily relationship between craving and alcohol use: results from the Australian BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):53A. MorleyLC , LuquinN , BaillieA , FraserI , TrentR , DoreG , et al. Moderation of baclofen response by a GABAb receptor polymorphism. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. RomboutsSA , BaillieA , HaberPS , MorleyKC . Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD trial. Alcohol and Alcoholism2019;54(3):272-8. ">Morley 2018âLD</a>; <a href="./references#CD012557-bbs2-0019" title="HengS , JamshidiN , BaillieA , LouieE , DoreG , PhungN , et al. Baclofen response in alcohol dependent patients concurrently receiving antidepressants: secondary analysis from the BacALD study. Frontiers in Psychiatry2018;9:576. LoggeW , BaillieAJ , MorrisRW , HaberPS , MorleyKC . Baclofen reduces alcohol cue-induced fMRI brain activation in treatment seeking alcohol dependent individuals. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. LoggeWB , BaillieAJ , HaberPS , MorleyKC . Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Human Psychopharmacology2020;35(2):e2722. LoggeWB , HaberPS , BaillieAJ , KosinskiP , MorrisRW , FraserI , et al. Dose-specific baclofen effects on brain structure, function and treatment responses: neuroimaging findings from the BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):20A-21A. LoggeWB , MorleyKC , HaberPS , BaillieAJ . Executive functioning moderates responses to appetitive cues: a study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism2019;54(1):38-46. LoggeWB , MorrisRW , BaillieAJ , HaberPS , MorleyKC . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berlin)2021;238(5):1291-302. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Baclofen for treatment of alcohol use disorder: secondary analyses and implications of the Australian BacALD trial. Drug and Alcohol Review2019;38:S75. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Exploration of the modulating role of the GABAb receptor polymorphism rs29220 on response to baclofen in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):41A. MorleyKC , BaillieA , FraserI , Furneaux-BateA , DoreG , RobertsM , et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry2018;212(6):362-9. MorleyKC , LagopoulosJ , LoggeW , BaillieA , AdamsC , HaberPS . Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addiction Biology2020;25(1):e12702. MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55. MorleyKC , LoggeWB , FraserI , MorrisRW , BaillieAJ , HaberPS . High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology2021;46:28-36. MorleyKC , LuquinN , BaillieA , FraserI , TrentRJ , DoreG , et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction2018;113(12):2205-13. MorleyKC , MorrisR , LoggeW , BaillieA , FraserI , HaberPS . Baclofen administration attenuates insula response during anticipatory anxiety in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. MorleyKC , RiordanB , LoggeW , BaillieA , HaberPS . Moderation of baclofen on the daily relationship between craving and alcohol use: results from the Australian BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):53A. RomboutsSA , BaillieA , HaberPS , MorleyKC . Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD Trial. Alcohol and Alcoholism2019;54(3):272-8. ">Morley 2018âMD</a>). </p> <p>Most studies required participants to abstain from alcohol for at least three days before beginning the pharmacological treatment (<a href="./references#CD012557-bbs2-0001" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , VonghiaL , MirijelloA , et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet2007;370(9603):1915-22. [DOI: 10.1016/S0140-6736(07)61814-5]">Addolorato 2007</a>; <a href="./references#CD012557-bbs2-0002" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , BedogniG , CaputoF , et al. Doseâresponse effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism2011;46(3):312-7. [PMID: 21414953]">Addolorato 2011âLD</a>; <a href="./references#CD012557-bbs2-0003" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , BedogniG , CaputoF , et al. Doseâresponse effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism2011;46(3):312-7. [PMID: 21414953]">Addolorato 2011âMD</a>; <a href="./references#CD012557-bbs2-0004" title="BerahaEM , SaleminkE , GoudriaanAE , BakkerA , De JongD , SmitsN , et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology2017;26(12):1950-9. BerahaEM , SaleminkE , KredietE , WiersRW . Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?Journal of Psychopharmacology2018;32(8):867-75. [PMID: 29897022]">Beraha 2016âHD</a>; <a href="./references#CD012557-bbs2-0005" title="BerahaEM , SaleminkE , GoudriaanAE , BakkerA , De JongD , SmitsN , et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology2017;26(12):1950-9. BerahaEM , SaleminkE , KredietE , WiersRW . Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?Journal of Psychopharmacology2018;32(8):867-75. ">Beraha 2016âLD</a>; <a href="./references#CD012557-bbs2-0006" title="GarbuttJC , Kampov-PolevoyAB , GallopR , Kalka-JuhlL , FlanneryBA . Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcoholism, Clinical and Experimental Research2010;34(11):1849-57. [DOI: 10.1111/j.1530-0277.2010.01273.x]">Garbutt 2010a</a>; <a href="./references#CD012557-bbs2-0012" title="KrupitskiiEM , RybakovaKV , KiselevAS , AlekseevaYV , BerntsevVA , ChekhlatyiEI , et al. Efficacy and safety of the use of baclofen in the treatment of alcohol dependent (a double-blind, randomized, placebo-controlled pilot study). Neuroscience and Behavioral Physiology2017;47(2):153-62. [DOI: 10.1007/s11055-016-0379-6]KrupitskyEM , RybakovaKV , KiselevAS , AlexeevaYV , BerntsevVA , ChekhlatyEI , et al. Double blind placebo controlled randomized pilot clinical trial of baclofen (BaclosanÂ®) for alcohol dependence. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova2015;115(6):53-62. [DOI: 10.17116/jnevro20151156153-62]">Krupitskii 2017</a>; <a href="./references#CD012557-bbs2-0013" title="KumarA , SharmaA , BansalPD , BahetraM , GillHK , KumarR . A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. Indian Journal of Psychiatry2020;62(6):650-8. ">Kumar 2020a</a>; <a href="./references#CD012557-bbs2-0016" title="MorleyKC , BaillieA , LeungS , AddoloratoG , LeggioL , HaberPS . Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol and Alcoholism2014;49(6):654-60. [DOI: 10.1093/alcalc/agu062]">Morley 2014âLD</a>; <a href="./references#CD012557-bbs2-0017" title="MorleyKC , BaillieA , LeungS , AddoloratoG , LeggioL , HaberPS . Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol and Alcoholism2014;49(6):654-60. [DOI: 10.1093/alcalc/agu062]">Morley 2014âMD</a>; <a href="./references#CD012557-bbs2-0018" title="HengS , JamshidiN , BaillieA , LouieE , DoreG , PhungN , et al. Baclofen response in alcohol dependent patients concurrently receiving antidepressants: secondary analysis from the BacALD study. Frontiers in Psychiatry2018;9:576. LoggeW , BaillieAJ , MorrisRW , HaberPS , MorleyKC . Baclofen reduces alcohol cue-induced fMRI brain activation in treatment seeking alcohol dependent individuals. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. LoggeWB , BaillieAJ , HaberPS , MorleyKC . Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Human Psychopharmacology2020;35(2):e2722. LoggeWB , HaberPS , BaillieAJ , KosinskiP , MorrisRW , FraserI , et al. Dose-specific baclofen effects on brain structure, function and treatment responses: neuroimaging findings from the BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):20A-21A. LoggeWB , MorleyKC , HaberPS , BaillieAJ . Executive functioning moderates responses to appetitive cues: a study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism2019;54(1):38-46. LoggeWB , MorrisRW , BaillieAJ , HaberPS , MorleyKC . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berlin)2021;238(5):1291-302. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Baclofen for treatment of alcohol use disorder: secondary analyses and implications of the Australian BacALD trial. Drug and Alcohol Review2019;38:S75. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Exploration of the modulating role of the GABAb receptor polymorphism rs29220 on response to baclofen in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):41A. MorleyKC , BaillieA , FraserI , Furneaux-BateA , DoreG , RobertsM , et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry2018;212(6):362-9. MorleyKC , LagopoulosJ , LoggeW , BaillieA , AdamsC , HaberPS . Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addiction Biology2020;25(1):e12702. MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55. MorleyKC , LoggeWB , FraserI , MorrisRW , BaillieAJ , HaberPS . High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology2021;46:28-36. MorleyKC , LuquinN , BaillieA , FraserI , TrentRJ , DoreG , et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction2018;113(12):2205-13. MorleyKC , MorrisR , LoggeW , BaillieA , FraserI , HaberPS . Baclofen administration attenuates insula response during anticipatory anxiety in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. MorleyKC , RiordanB , LoggeW , BaillieA , HaberPS . Moderation of baclofen on the daily relationship between craving and alcohol use: results from the Australian BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):53A. MorleyLC , LuquinN , BaillieA , FraserI , TrentR , DoreG , et al. Moderation of baclofen response by a GABAb receptor polymorphism. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. RomboutsSA , BaillieA , HaberPS , MorleyKC . Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD trial. Alcohol and Alcoholism2019;54(3):272-8. ">Morley 2018âLD</a>; <a href="./references#CD012557-bbs2-0019" title="HengS , JamshidiN , BaillieA , LouieE , DoreG , PhungN , et al. Baclofen response in alcohol dependent patients concurrently receiving antidepressants: secondary analysis from the BacALD study. Frontiers in Psychiatry2018;9:576. LoggeW , BaillieAJ , MorrisRW , HaberPS , MorleyKC . Baclofen reduces alcohol cue-induced fMRI brain activation in treatment seeking alcohol dependent individuals. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. LoggeWB , BaillieAJ , HaberPS , MorleyKC . Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Human Psychopharmacology2020;35(2):e2722. LoggeWB , HaberPS , BaillieAJ , KosinskiP , MorrisRW , FraserI , et al. Dose-specific baclofen effects on brain structure, function and treatment responses: neuroimaging findings from the BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):20A-21A. LoggeWB , MorleyKC , HaberPS , BaillieAJ . Executive functioning moderates responses to appetitive cues: a study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism2019;54(1):38-46. LoggeWB , MorrisRW , BaillieAJ , HaberPS , MorleyKC . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berlin)2021;238(5):1291-302. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Baclofen for treatment of alcohol use disorder: secondary analyses and implications of the Australian BacALD trial. Drug and Alcohol Review2019;38:S75. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Exploration of the modulating role of the GABAb receptor polymorphism rs29220 on response to baclofen in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):41A. MorleyKC , BaillieA , FraserI , Furneaux-BateA , DoreG , RobertsM , et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry2018;212(6):362-9. MorleyKC , LagopoulosJ , LoggeW , BaillieA , AdamsC , HaberPS . Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addiction Biology2020;25(1):e12702. MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55. MorleyKC , LoggeWB , FraserI , MorrisRW , BaillieAJ , HaberPS . High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology2021;46:28-36. MorleyKC , LuquinN , BaillieA , FraserI , TrentRJ , DoreG , et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction2018;113(12):2205-13. MorleyKC , MorrisR , LoggeW , BaillieA , FraserI , HaberPS . Baclofen administration attenuates insula response during anticipatory anxiety in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. MorleyKC , RiordanB , LoggeW , BaillieA , HaberPS . Moderation of baclofen on the daily relationship between craving and alcohol use: results from the Australian BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):53A. RomboutsSA , BaillieA , HaberPS , MorleyKC . Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD Trial. Alcohol and Alcoholism2019;54(3):272-8. ">Morley 2018âMD</a>; <a href="./references#CD012557-bbs2-0020" title="BeckA , PelzP , LorenzRC , CharletK , GeiselO , HeinzA , et al. Effects of high-dose baclofen on cue reactivity in alcohol dependence: a randomized, placebo-controlled pharmaco-fMRI study. European Neuropsychopharmacology2018;28(11):1206-16. GeiselO , HellwegR , WerneckeKD , WiedemannK , MÃ¼llerCA . Total and acylated ghrelin plasma levels as potential long-term response markers in alcohol-dependent patients receiving high-dose of the GABA-B receptor agonist baclofen. Psychiatry Research2019;272:431-7. GeiselO , SchlemmL , HellwegR , WiedemannK , MÃ¼llerCA . Hypothalamic-pituitary-adrenocortical axis activity in alcohol-dependent patients during treatment with high-dose baclofen. Pharmacopsychiatry2019;52(1):32-7. MullerCA , GeiselO , PelzP , HiglV , KrugerJ , StickelA , et al. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. European Neuropsychopharmacology2015;25(8):1167-77. [DOI: 10.1016/j.euroneuro.2015.04.002]MullerCA , GeiselO , PelzP , HiglV , KrugerJ , StickelA , et al. Individually titrated high-dose baclofen for the treatment of alcohol dependence (BACLAD study) â a randomized controlled trial. European Psychiatry2015;30(S1):1611. [DOI: 10.1016/S0924-9338(15)31243-8]PelzP , GenauckA , GleichT , LorenzRC , HeinzA , MullerCA , et al. Baclofen desensitizes the fronto-striatal reward network in alcohol dependent patients: a randomized, placebo-controlled pharmaco FMRI trial. Alcoholism: Clinical and Experimental Research2018;42:126A. PelzP , GenauckA , LorenzRC , WustenbergC , WackerhagenK , CharletT , et al. Baclofen desensitizes insular gain anticipation in alcohol-dependent patients â a randomized, placebo-controlled, patient-tailored pharmaco fMRI trial. Alcoholism: Clinical and Experimental Research2019;43(Suppl 1):246A. ">Muller 2015</a>; <a href="./references#CD012557-bbs2-0022" title="PouchainD . A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients. The Alpadir study. Exercer-La Revue Francophone De Medecine Generale2018;142:163-5. ReynaudM , AubinHJ , TrinquetF , ZakineB , DanoC , DematteisM , et al. A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients â the ALPADIR Study. Alcohol and Alcoholism2017;52(4):439-46. ">Reynaud 2017</a>). In these studies, abstinence ranged from three to 28 days (<a href="./references#CD012557-bbs2-0004" title="BerahaEM , SaleminkE , GoudriaanAE , BakkerA , De JongD , SmitsN , et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology2017;26(12):1950-9. BerahaEM , SaleminkE , KredietE , WiersRW . Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?Journal of Psychopharmacology2018;32(8):867-75. [PMID: 29897022]">Beraha 2016âHD</a>; <a href="./references#CD012557-bbs2-0005" title="BerahaEM , SaleminkE , GoudriaanAE , BakkerA , De JongD , SmitsN , et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology2017;26(12):1950-9. BerahaEM , SaleminkE , KredietE , WiersRW . Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?Journal of Psychopharmacology2018;32(8):867-75. ">Beraha 2016âLD</a>). Seven studies recruited people who were still drinking at the beginning of the pharmacological treatment (<a href="./references#CD012557-bbs2-0007" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b1</a>; <a href="./references#CD012557-bbs2-0008" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b2</a>; <a href="./references#CD012557-bbs2-0009" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âLD</a>; <a href="./references#CD012557-bbs2-0010" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. [PMID: 34155332]NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âMD</a>; <a href="./references#CD012557-bbs2-0011" title="HauserP , Fuller B HoSB , ThurasP , KernS , DieperinkE . The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. Addiction2017;112(7):1173-83. [DOI: 10.1111/add.13787.]">Hauser 2017</a>; <a href="./references#CD012557-bbs2-0014" title="BollingerJ , EdwardsSM , ZywiakWK , TideyJW , SwiftRW , KennaGA , et al. A double-blind, placebo-controlled randomized pilot study of the effects of baclofen on alcohol-tobacco co-use and alcohol cue-reactivity in alcoholic smokers. Clinical and Translational Science2014;7(3):265. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW , et al. Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Erratum for: Neuropsychopharmacology. 2014 Dec;39 Suppl 1:S1-647. Neuropsychopharmacology2015;40(6):1560. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW . Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Neuropsychopharmacology2014;39:S340. LeggioL , ZywiakWH , EdwardsSM , TideyJW , SwiftRM , KennaGA . A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology2015;232(1):233-43. [DOI: 10.1007/s00213-014-3652-9]">Leggio 2015</a>; <a href="./references#CD012557-bbs2-0015" title="MishraSN , SwainSP , ShuklaRK , SarkarP . A study of comparative efficacy of baclofen vs acamprosate in reducing alcohol craving and abuse. Orissa Journal of Psychiatry2010;-:48-53. ">Mishra 2010</a>; <a href="./references#CD012557-bbs2-0021" title="PonizovskyAM , RoscaP , AronovichE , WeizmanA , GrinshpoonA . Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up. Journal of Substance Abuse Treatment2015;52:24-30. [DOI: 10.1016/j.jsat.2014.11.007]">Ponizovsky 2015</a>; <a href="./references#CD012557-bbs2-0023" title="JauryPH . Baclofen for the treatment of alcohol drinkers (Bacloville). Alcoholism: Clinical and Experimental Research2014;38:215a. RigalL , SidorkiewiczS , TrÃ©luyerJM , PerrodeauE , Le JeunneC , PorcherR , et al. Titrated baclofen for high-risk alcohol consumption: a randomized placebo-controlled trial in out-patients with 1-year follow-up. Addiction2020;115(7):1265-76. ">Rigal 2020</a>). </p> <p>Most studies were had a duration of 12 weeks (<a href="./references#CD012557-bbs2-0001" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , VonghiaL , MirijelloA , et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet2007;370(9603):1915-22. [DOI: 10.1016/S0140-6736(07)61814-5]">Addolorato 2007</a>; <a href="./references#CD012557-bbs2-0002" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , BedogniG , CaputoF , et al. Doseâresponse effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism2011;46(3):312-7. [PMID: 21414953]">Addolorato 2011âLD</a>; <a href="./references#CD012557-bbs2-0003" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , BedogniG , CaputoF , et al. Doseâresponse effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism2011;46(3):312-7. [PMID: 21414953]">Addolorato 2011âMD</a>; <a href="./references#CD012557-bbs2-0006" title="GarbuttJC , Kampov-PolevoyAB , GallopR , Kalka-JuhlL , FlanneryBA . Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcoholism, Clinical and Experimental Research2010;34(11):1849-57. [DOI: 10.1111/j.1530-0277.2010.01273.x]">Garbutt 2010a</a>; <a href="./references#CD012557-bbs2-0007" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b1</a>; <a href="./references#CD012557-bbs2-0008" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b2</a>; <a href="./references#CD012557-bbs2-0011" title="HauserP , Fuller B HoSB , ThurasP , KernS , DieperinkE . The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. Addiction2017;112(7):1173-83. [DOI: 10.1111/add.13787.]">Hauser 2017</a>; <a href="./references#CD012557-bbs2-0012" title="KrupitskiiEM , RybakovaKV , KiselevAS , AlekseevaYV , BerntsevVA , ChekhlatyiEI , et al. Efficacy and safety of the use of baclofen in the treatment of alcohol dependent (a double-blind, randomized, placebo-controlled pilot study). Neuroscience and Behavioral Physiology2017;47(2):153-62. [DOI: 10.1007/s11055-016-0379-6]KrupitskyEM , RybakovaKV , KiselevAS , AlexeevaYV , BerntsevVA , ChekhlatyEI , et al. Double blind placebo controlled randomized pilot clinical trial of baclofen (BaclosanÂ®) for alcohol dependence. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova2015;115(6):53-62. [DOI: 10.17116/jnevro20151156153-62]">Krupitskii 2017</a>; <a href="./references#CD012557-bbs2-0014" title="BollingerJ , EdwardsSM , ZywiakWK , TideyJW , SwiftRW , KennaGA , et al. A double-blind, placebo-controlled randomized pilot study of the effects of baclofen on alcohol-tobacco co-use and alcohol cue-reactivity in alcoholic smokers. Clinical and Translational Science2014;7(3):265. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW , et al. Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Erratum for: Neuropsychopharmacology. 2014 Dec;39 Suppl 1:S1-647. Neuropsychopharmacology2015;40(6):1560. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW . Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Neuropsychopharmacology2014;39:S340. LeggioL , ZywiakWH , EdwardsSM , TideyJW , SwiftRM , KennaGA . A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology2015;232(1):233-43. [DOI: 10.1007/s00213-014-3652-9]">Leggio 2015</a>; <a href="./references#CD012557-bbs2-0015" title="MishraSN , SwainSP , ShuklaRK , SarkarP . A study of comparative efficacy of baclofen vs acamprosate in reducing alcohol craving and abuse. Orissa Journal of Psychiatry2010;-:48-53. ">Mishra 2010</a>; <a href="./references#CD012557-bbs2-0016" title="MorleyKC , BaillieA , LeungS , AddoloratoG , LeggioL , HaberPS . Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol and Alcoholism2014;49(6):654-60. [DOI: 10.1093/alcalc/agu062]">Morley 2014âLD</a>; <a href="./references#CD012557-bbs2-0017" title="MorleyKC , BaillieA , LeungS , AddoloratoG , LeggioL , HaberPS . Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol and Alcoholism2014;49(6):654-60. [DOI: 10.1093/alcalc/agu062]">Morley 2014âMD</a>; <a href="./references#CD012557-bbs2-0018" title="HengS , JamshidiN , BaillieA , LouieE , DoreG , PhungN , et al. Baclofen response in alcohol dependent patients concurrently receiving antidepressants: secondary analysis from the BacALD study. Frontiers in Psychiatry2018;9:576. LoggeW , BaillieAJ , MorrisRW , HaberPS , MorleyKC . Baclofen reduces alcohol cue-induced fMRI brain activation in treatment seeking alcohol dependent individuals. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. LoggeWB , BaillieAJ , HaberPS , MorleyKC . Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Human Psychopharmacology2020;35(2):e2722. LoggeWB , HaberPS , BaillieAJ , KosinskiP , MorrisRW , FraserI , et al. Dose-specific baclofen effects on brain structure, function and treatment responses: neuroimaging findings from the BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):20A-21A. LoggeWB , MorleyKC , HaberPS , BaillieAJ . Executive functioning moderates responses to appetitive cues: a study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism2019;54(1):38-46. LoggeWB , MorrisRW , BaillieAJ , HaberPS , MorleyKC . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berlin)2021;238(5):1291-302. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Baclofen for treatment of alcohol use disorder: secondary analyses and implications of the Australian BacALD trial. Drug and Alcohol Review2019;38:S75. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Exploration of the modulating role of the GABAb receptor polymorphism rs29220 on response to baclofen in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):41A. MorleyKC , BaillieA , FraserI , Furneaux-BateA , DoreG , RobertsM , et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry2018;212(6):362-9. MorleyKC , LagopoulosJ , LoggeW , BaillieA , AdamsC , HaberPS . Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addiction Biology2020;25(1):e12702. MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55. MorleyKC , LoggeWB , FraserI , MorrisRW , BaillieAJ , HaberPS . High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology2021;46:28-36. MorleyKC , LuquinN , BaillieA , FraserI , TrentRJ , DoreG , et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction2018;113(12):2205-13. MorleyKC , MorrisR , LoggeW , BaillieA , FraserI , HaberPS . Baclofen administration attenuates insula response during anticipatory anxiety in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. MorleyKC , RiordanB , LoggeW , BaillieA , HaberPS . Moderation of baclofen on the daily relationship between craving and alcohol use: results from the Australian BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):53A. MorleyLC , LuquinN , BaillieA , FraserI , TrentR , DoreG , et al. Moderation of baclofen response by a GABAb receptor polymorphism. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. RomboutsSA , BaillieA , HaberPS , MorleyKC . Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD trial. Alcohol and Alcoholism2019;54(3):272-8. ">Morley 2018âLD</a>; <a href="./references#CD012557-bbs2-0019" title="HengS , JamshidiN , BaillieA , LouieE , DoreG , PhungN , et al. Baclofen response in alcohol dependent patients concurrently receiving antidepressants: secondary analysis from the BacALD study. Frontiers in Psychiatry2018;9:576. LoggeW , BaillieAJ , MorrisRW , HaberPS , MorleyKC . Baclofen reduces alcohol cue-induced fMRI brain activation in treatment seeking alcohol dependent individuals. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. LoggeWB , BaillieAJ , HaberPS , MorleyKC . Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Human Psychopharmacology2020;35(2):e2722. LoggeWB , HaberPS , BaillieAJ , KosinskiP , MorrisRW , FraserI , et al. Dose-specific baclofen effects on brain structure, function and treatment responses: neuroimaging findings from the BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):20A-21A. LoggeWB , MorleyKC , HaberPS , BaillieAJ . Executive functioning moderates responses to appetitive cues: a study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism2019;54(1):38-46. LoggeWB , MorrisRW , BaillieAJ , HaberPS , MorleyKC . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berlin)2021;238(5):1291-302. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Baclofen for treatment of alcohol use disorder: secondary analyses and implications of the Australian BacALD trial. Drug and Alcohol Review2019;38:S75. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Exploration of the modulating role of the GABAb receptor polymorphism rs29220 on response to baclofen in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):41A. MorleyKC , BaillieA , FraserI , Furneaux-BateA , DoreG , RobertsM , et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry2018;212(6):362-9. MorleyKC , LagopoulosJ , LoggeW , BaillieA , AdamsC , HaberPS . Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addiction Biology2020;25(1):e12702. MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55. MorleyKC , LoggeWB , FraserI , MorrisRW , BaillieAJ , HaberPS . High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology2021;46:28-36. MorleyKC , LuquinN , BaillieA , FraserI , TrentRJ , DoreG , et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction2018;113(12):2205-13. MorleyKC , MorrisR , LoggeW , BaillieA , FraserI , HaberPS . Baclofen administration attenuates insula response during anticipatory anxiety in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. MorleyKC , RiordanB , LoggeW , BaillieA , HaberPS . Moderation of baclofen on the daily relationship between craving and alcohol use: results from the Australian BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):53A. RomboutsSA , BaillieA , HaberPS , MorleyKC . Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD Trial. Alcohol and Alcoholism2019;54(3):272-8. ">Morley 2018âMD</a>; <a href="./references#CD012557-bbs2-0020" title="BeckA , PelzP , LorenzRC , CharletK , GeiselO , HeinzA , et al. Effects of high-dose baclofen on cue reactivity in alcohol dependence: a randomized, placebo-controlled pharmaco-fMRI study. European Neuropsychopharmacology2018;28(11):1206-16. GeiselO , HellwegR , WerneckeKD , WiedemannK , MÃ¼llerCA . Total and acylated ghrelin plasma levels as potential long-term response markers in alcohol-dependent patients receiving high-dose of the GABA-B receptor agonist baclofen. Psychiatry Research2019;272:431-7. GeiselO , SchlemmL , HellwegR , WiedemannK , MÃ¼llerCA . Hypothalamic-pituitary-adrenocortical axis activity in alcohol-dependent patients during treatment with high-dose baclofen. Pharmacopsychiatry2019;52(1):32-7. MullerCA , GeiselO , PelzP , HiglV , KrugerJ , StickelA , et al. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. European Neuropsychopharmacology2015;25(8):1167-77. [DOI: 10.1016/j.euroneuro.2015.04.002]MullerCA , GeiselO , PelzP , HiglV , KrugerJ , StickelA , et al. Individually titrated high-dose baclofen for the treatment of alcohol dependence (BACLAD study) â a randomized controlled trial. European Psychiatry2015;30(S1):1611. [DOI: 10.1016/S0924-9338(15)31243-8]PelzP , GenauckA , GleichT , LorenzRC , HeinzA , MullerCA , et al. Baclofen desensitizes the fronto-striatal reward network in alcohol dependent patients: a randomized, placebo-controlled pharmaco FMRI trial. Alcoholism: Clinical and Experimental Research2018;42:126A. PelzP , GenauckA , LorenzRC , WustenbergC , WackerhagenK , CharletT , et al. Baclofen desensitizes insular gain anticipation in alcohol-dependent patients â a randomized, placebo-controlled, patient-tailored pharmaco fMRI trial. Alcoholism: Clinical and Experimental Research2019;43(Suppl 1):246A. ">Muller 2015</a>; <a href="./references#CD012557-bbs2-0021" title="PonizovskyAM , RoscaP , AronovichE , WeizmanA , GrinshpoonA . Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up. Journal of Substance Abuse Treatment2015;52:24-30. [DOI: 10.1016/j.jsat.2014.11.007]">Ponizovsky 2015</a>), while five studies were longer than 12 weeks (16 weeks: <a href="./references#CD012557-bbs2-0004" title="BerahaEM , SaleminkE , GoudriaanAE , BakkerA , De JongD , SmitsN , et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology2017;26(12):1950-9. BerahaEM , SaleminkE , KredietE , WiersRW . Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?Journal of Psychopharmacology2018;32(8):867-75. [PMID: 29897022]">Beraha 2016âHD</a>; <a href="./references#CD012557-bbs2-0005" title="BerahaEM , SaleminkE , GoudriaanAE , BakkerA , De JongD , SmitsN , et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology2017;26(12):1950-9. BerahaEM , SaleminkE , KredietE , WiersRW . Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?Journal of Psychopharmacology2018;32(8):867-75. ">Beraha 2016âLD</a>; <a href="./references#CD012557-bbs2-0009" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âLD</a>; <a href="./references#CD012557-bbs2-0010" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. [PMID: 34155332]NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âMD</a>; 24 weeks: <a href="./references#CD012557-bbs2-0013" title="KumarA , SharmaA , BansalPD , BahetraM , GillHK , KumarR . A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. Indian Journal of Psychiatry2020;62(6):650-8. ">Kumar 2020a</a>; 26 weeks: <a href="./references#CD012557-bbs2-0022" title="PouchainD . A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients. The Alpadir study. Exercer-La Revue Francophone De Medecine Generale2018;142:163-5. ReynaudM , AubinHJ , TrinquetF , ZakineB , DanoC , DematteisM , et al. A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients â the ALPADIR Study. Alcohol and Alcoholism2017;52(4):439-46. ">Reynaud 2017</a>; 48 weeks: <a href="./references#CD012557-bbs2-0023" title="JauryPH . Baclofen for the treatment of alcohol drinkers (Bacloville). Alcoholism: Clinical and Experimental Research2014;38:215a. RigalL , SidorkiewiczS , TrÃ©luyerJM , PerrodeauE , Le JeunneC , PorcherR , et al. Titrated baclofen for high-risk alcohol consumption: a randomized placebo-controlled trial in out-patients with 1-year follow-up. Addiction2020;115(7):1265-76. ">Rigal 2020</a>). The mean duration of the interventions was 16.1 weeks (range 12 to 48 weeks). </p> <section id="CD012557-sec-0045"> <h5 class="title">Interventions</h5> <p>The studies administered baclofen in daily doses ranging from 30 mg to 300 mg. Ten studies administered low daily doses (<a href="./references#CD012557-bbs2-0001" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , VonghiaL , MirijelloA , et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet2007;370(9603):1915-22. [DOI: 10.1016/S0140-6736(07)61814-5]">Addolorato 2007</a>; <a href="./references#CD012557-bbs2-0002" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , BedogniG , CaputoF , et al. Doseâresponse effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism2011;46(3):312-7. [PMID: 21414953]">Addolorato 2011âLD</a>; <a href="./references#CD012557-bbs2-0005" title="BerahaEM , SaleminkE , GoudriaanAE , BakkerA , De JongD , SmitsN , et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology2017;26(12):1950-9. BerahaEM , SaleminkE , KredietE , WiersRW . Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?Journal of Psychopharmacology2018;32(8):867-75. ">Beraha 2016âLD</a>; <a href="./references#CD012557-bbs2-0006" title="GarbuttJC , Kampov-PolevoyAB , GallopR , Kalka-JuhlL , FlanneryBA . Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcoholism, Clinical and Experimental Research2010;34(11):1849-57. [DOI: 10.1111/j.1530-0277.2010.01273.x]">Garbutt 2010a</a>; <a href="./references#CD012557-bbs2-0007" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b1</a>; <a href="./references#CD012557-bbs2-0008" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b2</a>; <a href="./references#CD012557-bbs2-0009" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âLD</a>; <a href="./references#CD012557-bbs2-0011" title="HauserP , Fuller B HoSB , ThurasP , KernS , DieperinkE . The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. Addiction2017;112(7):1173-83. [DOI: 10.1111/add.13787.]">Hauser 2017</a>; <a href="./references#CD012557-bbs2-0015" title="MishraSN , SwainSP , ShuklaRK , SarkarP . A study of comparative efficacy of baclofen vs acamprosate in reducing alcohol craving and abuse. Orissa Journal of Psychiatry2010;-:48-53. ">Mishra 2010</a>; <a href="./references#CD012557-bbs2-0016" title="MorleyKC , BaillieA , LeungS , AddoloratoG , LeggioL , HaberPS . Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol and Alcoholism2014;49(6):654-60. [DOI: 10.1093/alcalc/agu062]">Morley 2014âLD</a>; <a href="./references#CD012557-bbs2-0018" title="HengS , JamshidiN , BaillieA , LouieE , DoreG , PhungN , et al. Baclofen response in alcohol dependent patients concurrently receiving antidepressants: secondary analysis from the BacALD study. Frontiers in Psychiatry2018;9:576. LoggeW , BaillieAJ , MorrisRW , HaberPS , MorleyKC . Baclofen reduces alcohol cue-induced fMRI brain activation in treatment seeking alcohol dependent individuals. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. LoggeWB , BaillieAJ , HaberPS , MorleyKC . Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Human Psychopharmacology2020;35(2):e2722. LoggeWB , HaberPS , BaillieAJ , KosinskiP , MorrisRW , FraserI , et al. Dose-specific baclofen effects on brain structure, function and treatment responses: neuroimaging findings from the BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):20A-21A. LoggeWB , MorleyKC , HaberPS , BaillieAJ . Executive functioning moderates responses to appetitive cues: a study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism2019;54(1):38-46. LoggeWB , MorrisRW , BaillieAJ , HaberPS , MorleyKC . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berlin)2021;238(5):1291-302. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Baclofen for treatment of alcohol use disorder: secondary analyses and implications of the Australian BacALD trial. Drug and Alcohol Review2019;38:S75. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Exploration of the modulating role of the GABAb receptor polymorphism rs29220 on response to baclofen in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):41A. MorleyKC , BaillieA , FraserI , Furneaux-BateA , DoreG , RobertsM , et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry2018;212(6):362-9. MorleyKC , LagopoulosJ , LoggeW , BaillieA , AdamsC , HaberPS . Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addiction Biology2020;25(1):e12702. MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55. MorleyKC , LoggeWB , FraserI , MorrisRW , BaillieAJ , HaberPS . High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology2021;46:28-36. MorleyKC , LuquinN , BaillieA , FraserI , TrentRJ , DoreG , et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction2018;113(12):2205-13. MorleyKC , MorrisR , LoggeW , BaillieA , FraserI , HaberPS . Baclofen administration attenuates insula response during anticipatory anxiety in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. MorleyKC , RiordanB , LoggeW , BaillieA , HaberPS . Moderation of baclofen on the daily relationship between craving and alcohol use: results from the Australian BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):53A. MorleyLC , LuquinN , BaillieA , FraserI , TrentR , DoreG , et al. Moderation of baclofen response by a GABAb receptor polymorphism. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. RomboutsSA , BaillieA , HaberPS , MorleyKC . Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD trial. Alcohol and Alcoholism2019;54(3):272-8. ">Morley 2018âLD</a>), eight studies medium daily doses (<a href="./references#CD012557-bbs2-0003" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , BedogniG , CaputoF , et al. Doseâresponse effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism2011;46(3):312-7. [PMID: 21414953]">Addolorato 2011âMD</a>; <a href="./references#CD012557-bbs2-0010" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. [PMID: 34155332]NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âMD</a>; <a href="./references#CD012557-bbs2-0012" title="KrupitskiiEM , RybakovaKV , KiselevAS , AlekseevaYV , BerntsevVA , ChekhlatyiEI , et al. Efficacy and safety of the use of baclofen in the treatment of alcohol dependent (a double-blind, randomized, placebo-controlled pilot study). Neuroscience and Behavioral Physiology2017;47(2):153-62. [DOI: 10.1007/s11055-016-0379-6]KrupitskyEM , RybakovaKV , KiselevAS , AlexeevaYV , BerntsevVA , ChekhlatyEI , et al. Double blind placebo controlled randomized pilot clinical trial of baclofen (BaclosanÂ®) for alcohol dependence. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova2015;115(6):53-62. [DOI: 10.17116/jnevro20151156153-62]">Krupitskii 2017</a>; <a href="./references#CD012557-bbs2-0013" title="KumarA , SharmaA , BansalPD , BahetraM , GillHK , KumarR . A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. Indian Journal of Psychiatry2020;62(6):650-8. ">Kumar 2020a</a>; <a href="./references#CD012557-bbs2-0014" title="BollingerJ , EdwardsSM , ZywiakWK , TideyJW , SwiftRW , KennaGA , et al. A double-blind, placebo-controlled randomized pilot study of the effects of baclofen on alcohol-tobacco co-use and alcohol cue-reactivity in alcoholic smokers. Clinical and Translational Science2014;7(3):265. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW , et al. Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Erratum for: Neuropsychopharmacology. 2014 Dec;39 Suppl 1:S1-647. Neuropsychopharmacology2015;40(6):1560. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW . Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Neuropsychopharmacology2014;39:S340. LeggioL , ZywiakWH , EdwardsSM , TideyJW , SwiftRM , KennaGA . A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology2015;232(1):233-43. [DOI: 10.1007/s00213-014-3652-9]">Leggio 2015</a>; <a href="./references#CD012557-bbs2-0017" title="MorleyKC , BaillieA , LeungS , AddoloratoG , LeggioL , HaberPS . Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol and Alcoholism2014;49(6):654-60. [DOI: 10.1093/alcalc/agu062]">Morley 2014âMD</a>; <a href="./references#CD012557-bbs2-0019" title="HengS , JamshidiN , BaillieA , LouieE , DoreG , PhungN , et al. Baclofen response in alcohol dependent patients concurrently receiving antidepressants: secondary analysis from the BacALD study. Frontiers in Psychiatry2018;9:576. LoggeW , BaillieAJ , MorrisRW , HaberPS , MorleyKC . Baclofen reduces alcohol cue-induced fMRI brain activation in treatment seeking alcohol dependent individuals. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. LoggeWB , BaillieAJ , HaberPS , MorleyKC . Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Human Psychopharmacology2020;35(2):e2722. LoggeWB , HaberPS , BaillieAJ , KosinskiP , MorrisRW , FraserI , et al. Dose-specific baclofen effects on brain structure, function and treatment responses: neuroimaging findings from the BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):20A-21A. LoggeWB , MorleyKC , HaberPS , BaillieAJ . Executive functioning moderates responses to appetitive cues: a study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism2019;54(1):38-46. LoggeWB , MorrisRW , BaillieAJ , HaberPS , MorleyKC . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berlin)2021;238(5):1291-302. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Baclofen for treatment of alcohol use disorder: secondary analyses and implications of the Australian BacALD trial. Drug and Alcohol Review2019;38:S75. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Exploration of the modulating role of the GABAb receptor polymorphism rs29220 on response to baclofen in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):41A. MorleyKC , BaillieA , FraserI , Furneaux-BateA , DoreG , RobertsM , et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry2018;212(6):362-9. MorleyKC , LagopoulosJ , LoggeW , BaillieA , AdamsC , HaberPS . Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addiction Biology2020;25(1):e12702. MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55. MorleyKC , LoggeWB , FraserI , MorrisRW , BaillieAJ , HaberPS . High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology2021;46:28-36. MorleyKC , LuquinN , BaillieA , FraserI , TrentRJ , DoreG , et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction2018;113(12):2205-13. MorleyKC , MorrisR , LoggeW , BaillieA , FraserI , HaberPS . Baclofen administration attenuates insula response during anticipatory anxiety in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. MorleyKC , RiordanB , LoggeW , BaillieA , HaberPS . Moderation of baclofen on the daily relationship between craving and alcohol use: results from the Australian BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):53A. RomboutsSA , BaillieA , HaberPS , MorleyKC . Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD Trial. Alcohol and Alcoholism2019;54(3):272-8. ">Morley 2018âMD</a>; <a href="./references#CD012557-bbs2-0021" title="PonizovskyAM , RoscaP , AronovichE , WeizmanA , GrinshpoonA . Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up. Journal of Substance Abuse Treatment2015;52:24-30. [DOI: 10.1016/j.jsat.2014.11.007]">Ponizovsky 2015</a>), and four studies high daily doses of baclofen (<a href="./references#CD012557-bbs2-0004" title="BerahaEM , SaleminkE , GoudriaanAE , BakkerA , De JongD , SmitsN , et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology2017;26(12):1950-9. BerahaEM , SaleminkE , KredietE , WiersRW . Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?Journal of Psychopharmacology2018;32(8):867-75. [PMID: 29897022]">Beraha 2016âHD</a>; <a href="./references#CD012557-bbs2-0020" title="BeckA , PelzP , LorenzRC , CharletK , GeiselO , HeinzA , et al. Effects of high-dose baclofen on cue reactivity in alcohol dependence: a randomized, placebo-controlled pharmaco-fMRI study. European Neuropsychopharmacology2018;28(11):1206-16. GeiselO , HellwegR , WerneckeKD , WiedemannK , MÃ¼llerCA . Total and acylated ghrelin plasma levels as potential long-term response markers in alcohol-dependent patients receiving high-dose of the GABA-B receptor agonist baclofen. Psychiatry Research2019;272:431-7. GeiselO , SchlemmL , HellwegR , WiedemannK , MÃ¼llerCA . Hypothalamic-pituitary-adrenocortical axis activity in alcohol-dependent patients during treatment with high-dose baclofen. Pharmacopsychiatry2019;52(1):32-7. MullerCA , GeiselO , PelzP , HiglV , KrugerJ , StickelA , et al. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. European Neuropsychopharmacology2015;25(8):1167-77. [DOI: 10.1016/j.euroneuro.2015.04.002]MullerCA , GeiselO , PelzP , HiglV , KrugerJ , StickelA , et al. Individually titrated high-dose baclofen for the treatment of alcohol dependence (BACLAD study) â a randomized controlled trial. European Psychiatry2015;30(S1):1611. [DOI: 10.1016/S0924-9338(15)31243-8]PelzP , GenauckA , GleichT , LorenzRC , HeinzA , MullerCA , et al. Baclofen desensitizes the fronto-striatal reward network in alcohol dependent patients: a randomized, placebo-controlled pharmaco FMRI trial. Alcoholism: Clinical and Experimental Research2018;42:126A. PelzP , GenauckA , LorenzRC , WustenbergC , WackerhagenK , CharletT , et al. Baclofen desensitizes insular gain anticipation in alcohol-dependent patients â a randomized, placebo-controlled, patient-tailored pharmaco fMRI trial. Alcoholism: Clinical and Experimental Research2019;43(Suppl 1):246A. ">Muller 2015</a>; <a href="./references#CD012557-bbs2-0022" title="PouchainD . A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients. The Alpadir study. Exercer-La Revue Francophone De Medecine Generale2018;142:163-5. ReynaudM , AubinHJ , TrinquetF , ZakineB , DanoC , DematteisM , et al. A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients â the ALPADIR Study. Alcohol and Alcoholism2017;52(4):439-46. ">Reynaud 2017</a>; <a href="./references#CD012557-bbs2-0023" title="JauryPH . Baclofen for the treatment of alcohol drinkers (Bacloville). Alcoholism: Clinical and Experimental Research2014;38:215a. RigalL , SidorkiewiczS , TrÃ©luyerJM , PerrodeauE , Le JeunneC , PorcherR , et al. Titrated baclofen for high-risk alcohol consumption: a randomized placebo-controlled trial in out-patients with 1-year follow-up. Addiction2020;115(7):1265-76. ">Rigal 2020</a>). </p> <p>Most studies administered fixed doses of baclofen, starting with a daily dose of 5 mg, three times a day, and gradually increasing up to 30 mg/day to 80 mg/day. Four studies administered flexible doses of baclofen starting from low daily doses and progressively increasing up to 300 mg, according to the beneficial and unwanted (or both) effects (<a href="./references#CD012557-bbs2-0004" title="BerahaEM , SaleminkE , GoudriaanAE , BakkerA , De JongD , SmitsN , et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology2017;26(12):1950-9. BerahaEM , SaleminkE , KredietE , WiersRW . Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?Journal of Psychopharmacology2018;32(8):867-75. [PMID: 29897022]">Beraha 2016âHD</a>; <a href="./references#CD012557-bbs2-0020" title="BeckA , PelzP , LorenzRC , CharletK , GeiselO , HeinzA , et al. Effects of high-dose baclofen on cue reactivity in alcohol dependence: a randomized, placebo-controlled pharmaco-fMRI study. European Neuropsychopharmacology2018;28(11):1206-16. GeiselO , HellwegR , WerneckeKD , WiedemannK , MÃ¼llerCA . Total and acylated ghrelin plasma levels as potential long-term response markers in alcohol-dependent patients receiving high-dose of the GABA-B receptor agonist baclofen. Psychiatry Research2019;272:431-7. GeiselO , SchlemmL , HellwegR , WiedemannK , MÃ¼llerCA . Hypothalamic-pituitary-adrenocortical axis activity in alcohol-dependent patients during treatment with high-dose baclofen. Pharmacopsychiatry2019;52(1):32-7. MullerCA , GeiselO , PelzP , HiglV , KrugerJ , StickelA , et al. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. European Neuropsychopharmacology2015;25(8):1167-77. [DOI: 10.1016/j.euroneuro.2015.04.002]MullerCA , GeiselO , PelzP , HiglV , KrugerJ , StickelA , et al. Individually titrated high-dose baclofen for the treatment of alcohol dependence (BACLAD study) â a randomized controlled trial. European Psychiatry2015;30(S1):1611. [DOI: 10.1016/S0924-9338(15)31243-8]PelzP , GenauckA , GleichT , LorenzRC , HeinzA , MullerCA , et al. Baclofen desensitizes the fronto-striatal reward network in alcohol dependent patients: a randomized, placebo-controlled pharmaco FMRI trial. Alcoholism: Clinical and Experimental Research2018;42:126A. PelzP , GenauckA , LorenzRC , WustenbergC , WackerhagenK , CharletT , et al. Baclofen desensitizes insular gain anticipation in alcohol-dependent patients â a randomized, placebo-controlled, patient-tailored pharmaco fMRI trial. Alcoholism: Clinical and Experimental Research2019;43(Suppl 1):246A. ">Muller 2015</a>; <a href="./references#CD012557-bbs2-0022" title="PouchainD . A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients. The Alpadir study. Exercer-La Revue Francophone De Medecine Generale2018;142:163-5. ReynaudM , AubinHJ , TrinquetF , ZakineB , DanoC , DematteisM , et al. A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients â the ALPADIR Study. Alcohol and Alcoholism2017;52(4):439-46. ">Reynaud 2017</a>; <a href="./references#CD012557-bbs2-0023" title="JauryPH . Baclofen for the treatment of alcohol drinkers (Bacloville). Alcoholism: Clinical and Experimental Research2014;38:215a. RigalL , SidorkiewiczS , TrÃ©luyerJM , PerrodeauE , Le JeunneC , PorcherR , et al. Titrated baclofen for high-risk alcohol consumption: a randomized placebo-controlled trial in out-patients with 1-year follow-up. Addiction2020;115(7):1265-76. ">Rigal 2020</a>). </p> <p>In all but one study (<a href="./references#CD012557-bbs2-0015" title="MishraSN , SwainSP , ShuklaRK , SarkarP . A study of comparative efficacy of baclofen vs acamprosate in reducing alcohol craving and abuse. Orissa Journal of Psychiatry2010;-:48-53. ">Mishra 2010</a>), participants in both the baclofen and placebo groups received psychosocial treatment or counselling of various intensity. </p> </section> <section id="CD012557-sec-0046"> <h5 class="title">Comparisons</h5> <p>Fifteen RCTs compared baclofen with placebo (<a href="./references#CD012557-bbs2-0001" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , VonghiaL , MirijelloA , et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet2007;370(9603):1915-22. [DOI: 10.1016/S0140-6736(07)61814-5]">Addolorato 2007</a>; <a href="./references#CD012557-bbs2-0002" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , BedogniG , CaputoF , et al. Doseâresponse effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism2011;46(3):312-7. [PMID: 21414953]">Addolorato 2011âLD</a>; <a href="./references#CD012557-bbs2-0003" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , BedogniG , CaputoF , et al. Doseâresponse effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism2011;46(3):312-7. [PMID: 21414953]">Addolorato 2011âMD</a>; <a href="./references#CD012557-bbs2-0004" title="BerahaEM , SaleminkE , GoudriaanAE , BakkerA , De JongD , SmitsN , et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology2017;26(12):1950-9. BerahaEM , SaleminkE , KredietE , WiersRW . Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?Journal of Psychopharmacology2018;32(8):867-75. [PMID: 29897022]">Beraha 2016âHD</a>; <a href="./references#CD012557-bbs2-0005" title="BerahaEM , SaleminkE , GoudriaanAE , BakkerA , De JongD , SmitsN , et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology2017;26(12):1950-9. BerahaEM , SaleminkE , KredietE , WiersRW . Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?Journal of Psychopharmacology2018;32(8):867-75. ">Beraha 2016âLD</a>; <a href="./references#CD012557-bbs2-0006" title="GarbuttJC , Kampov-PolevoyAB , GallopR , Kalka-JuhlL , FlanneryBA . Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcoholism, Clinical and Experimental Research2010;34(11):1849-57. [DOI: 10.1111/j.1530-0277.2010.01273.x]">Garbutt 2010a</a>; <a href="./references#CD012557-bbs2-0007" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b1</a>; <a href="./references#CD012557-bbs2-0009" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âLD</a>; <a href="./references#CD012557-bbs2-0010" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. [PMID: 34155332]NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âMD</a>; <a href="./references#CD012557-bbs2-0011" title="HauserP , Fuller B HoSB , ThurasP , KernS , DieperinkE . The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. Addiction2017;112(7):1173-83. [DOI: 10.1111/add.13787.]">Hauser 2017</a>; <a href="./references#CD012557-bbs2-0012" title="KrupitskiiEM , RybakovaKV , KiselevAS , AlekseevaYV , BerntsevVA , ChekhlatyiEI , et al. Efficacy and safety of the use of baclofen in the treatment of alcohol dependent (a double-blind, randomized, placebo-controlled pilot study). Neuroscience and Behavioral Physiology2017;47(2):153-62. [DOI: 10.1007/s11055-016-0379-6]KrupitskyEM , RybakovaKV , KiselevAS , AlexeevaYV , BerntsevVA , ChekhlatyEI , et al. Double blind placebo controlled randomized pilot clinical trial of baclofen (BaclosanÂ®) for alcohol dependence. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova2015;115(6):53-62. [DOI: 10.17116/jnevro20151156153-62]">Krupitskii 2017</a>; <a href="./references#CD012557-bbs2-0014" title="BollingerJ , EdwardsSM , ZywiakWK , TideyJW , SwiftRW , KennaGA , et al. A double-blind, placebo-controlled randomized pilot study of the effects of baclofen on alcohol-tobacco co-use and alcohol cue-reactivity in alcoholic smokers. Clinical and Translational Science2014;7(3):265. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW , et al. Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Erratum for: Neuropsychopharmacology. 2014 Dec;39 Suppl 1:S1-647. Neuropsychopharmacology2015;40(6):1560. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW . Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Neuropsychopharmacology2014;39:S340. LeggioL , ZywiakWH , EdwardsSM , TideyJW , SwiftRM , KennaGA . A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology2015;232(1):233-43. [DOI: 10.1007/s00213-014-3652-9]">Leggio 2015</a>; <a href="./references#CD012557-bbs2-0016" title="MorleyKC , BaillieA , LeungS , AddoloratoG , LeggioL , HaberPS . Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol and Alcoholism2014;49(6):654-60. [DOI: 10.1093/alcalc/agu062]">Morley 2014âLD</a>; <a href="./references#CD012557-bbs2-0017" title="MorleyKC , BaillieA , LeungS , AddoloratoG , LeggioL , HaberPS . Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol and Alcoholism2014;49(6):654-60. [DOI: 10.1093/alcalc/agu062]">Morley 2014âMD</a>; <a href="./references#CD012557-bbs2-0018" title="HengS , JamshidiN , BaillieA , LouieE , DoreG , PhungN , et al. Baclofen response in alcohol dependent patients concurrently receiving antidepressants: secondary analysis from the BacALD study. Frontiers in Psychiatry2018;9:576. LoggeW , BaillieAJ , MorrisRW , HaberPS , MorleyKC . Baclofen reduces alcohol cue-induced fMRI brain activation in treatment seeking alcohol dependent individuals. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. LoggeWB , BaillieAJ , HaberPS , MorleyKC . Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Human Psychopharmacology2020;35(2):e2722. LoggeWB , HaberPS , BaillieAJ , KosinskiP , MorrisRW , FraserI , et al. Dose-specific baclofen effects on brain structure, function and treatment responses: neuroimaging findings from the BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):20A-21A. LoggeWB , MorleyKC , HaberPS , BaillieAJ . Executive functioning moderates responses to appetitive cues: a study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism2019;54(1):38-46. LoggeWB , MorrisRW , BaillieAJ , HaberPS , MorleyKC . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berlin)2021;238(5):1291-302. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Baclofen for treatment of alcohol use disorder: secondary analyses and implications of the Australian BacALD trial. Drug and Alcohol Review2019;38:S75. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Exploration of the modulating role of the GABAb receptor polymorphism rs29220 on response to baclofen in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):41A. MorleyKC , BaillieA , FraserI , Furneaux-BateA , DoreG , RobertsM , et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry2018;212(6):362-9. MorleyKC , LagopoulosJ , LoggeW , BaillieA , AdamsC , HaberPS . Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addiction Biology2020;25(1):e12702. MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55. MorleyKC , LoggeWB , FraserI , MorrisRW , BaillieAJ , HaberPS . High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology2021;46:28-36. MorleyKC , LuquinN , BaillieA , FraserI , TrentRJ , DoreG , et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction2018;113(12):2205-13. MorleyKC , MorrisR , LoggeW , BaillieA , FraserI , HaberPS . Baclofen administration attenuates insula response during anticipatory anxiety in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. MorleyKC , RiordanB , LoggeW , BaillieA , HaberPS . Moderation of baclofen on the daily relationship between craving and alcohol use: results from the Australian BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):53A. MorleyLC , LuquinN , BaillieA , FraserI , TrentR , DoreG , et al. Moderation of baclofen response by a GABAb receptor polymorphism. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. RomboutsSA , BaillieA , HaberPS , MorleyKC . Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD trial. Alcohol and Alcoholism2019;54(3):272-8. ">Morley 2018âLD</a>; <a href="./references#CD012557-bbs2-0019" title="HengS , JamshidiN , BaillieA , LouieE , DoreG , PhungN , et al. Baclofen response in alcohol dependent patients concurrently receiving antidepressants: secondary analysis from the BacALD study. Frontiers in Psychiatry2018;9:576. LoggeW , BaillieAJ , MorrisRW , HaberPS , MorleyKC . Baclofen reduces alcohol cue-induced fMRI brain activation in treatment seeking alcohol dependent individuals. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. LoggeWB , BaillieAJ , HaberPS , MorleyKC . Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Human Psychopharmacology2020;35(2):e2722. LoggeWB , HaberPS , BaillieAJ , KosinskiP , MorrisRW , FraserI , et al. Dose-specific baclofen effects on brain structure, function and treatment responses: neuroimaging findings from the BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):20A-21A. LoggeWB , MorleyKC , HaberPS , BaillieAJ . Executive functioning moderates responses to appetitive cues: a study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism2019;54(1):38-46. LoggeWB , MorrisRW , BaillieAJ , HaberPS , MorleyKC . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berlin)2021;238(5):1291-302. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Baclofen for treatment of alcohol use disorder: secondary analyses and implications of the Australian BacALD trial. Drug and Alcohol Review2019;38:S75. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Exploration of the modulating role of the GABAb receptor polymorphism rs29220 on response to baclofen in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):41A. MorleyKC , BaillieA , FraserI , Furneaux-BateA , DoreG , RobertsM , et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry2018;212(6):362-9. MorleyKC , LagopoulosJ , LoggeW , BaillieA , AdamsC , HaberPS . Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addiction Biology2020;25(1):e12702. MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55. MorleyKC , LoggeWB , FraserI , MorrisRW , BaillieAJ , HaberPS . High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology2021;46:28-36. MorleyKC , LuquinN , BaillieA , FraserI , TrentRJ , DoreG , et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction2018;113(12):2205-13. MorleyKC , MorrisR , LoggeW , BaillieA , FraserI , HaberPS . Baclofen administration attenuates insula response during anticipatory anxiety in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. MorleyKC , RiordanB , LoggeW , BaillieA , HaberPS . Moderation of baclofen on the daily relationship between craving and alcohol use: results from the Australian BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):53A. RomboutsSA , BaillieA , HaberPS , MorleyKC . Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD Trial. Alcohol and Alcoholism2019;54(3):272-8. ">Morley 2018âMD</a>; <a href="./references#CD012557-bbs2-0020" title="BeckA , PelzP , LorenzRC , CharletK , GeiselO , HeinzA , et al. Effects of high-dose baclofen on cue reactivity in alcohol dependence: a randomized, placebo-controlled pharmaco-fMRI study. European Neuropsychopharmacology2018;28(11):1206-16. GeiselO , HellwegR , WerneckeKD , WiedemannK , MÃ¼llerCA . Total and acylated ghrelin plasma levels as potential long-term response markers in alcohol-dependent patients receiving high-dose of the GABA-B receptor agonist baclofen. Psychiatry Research2019;272:431-7. GeiselO , SchlemmL , HellwegR , WiedemannK , MÃ¼llerCA . Hypothalamic-pituitary-adrenocortical axis activity in alcohol-dependent patients during treatment with high-dose baclofen. Pharmacopsychiatry2019;52(1):32-7. MullerCA , GeiselO , PelzP , HiglV , KrugerJ , StickelA , et al. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. European Neuropsychopharmacology2015;25(8):1167-77. [DOI: 10.1016/j.euroneuro.2015.04.002]MullerCA , GeiselO , PelzP , HiglV , KrugerJ , StickelA , et al. Individually titrated high-dose baclofen for the treatment of alcohol dependence (BACLAD study) â a randomized controlled trial. European Psychiatry2015;30(S1):1611. [DOI: 10.1016/S0924-9338(15)31243-8]PelzP , GenauckA , GleichT , LorenzRC , HeinzA , MullerCA , et al. Baclofen desensitizes the fronto-striatal reward network in alcohol dependent patients: a randomized, placebo-controlled pharmaco FMRI trial. Alcoholism: Clinical and Experimental Research2018;42:126A. PelzP , GenauckA , LorenzRC , WustenbergC , WackerhagenK , CharletT , et al. Baclofen desensitizes insular gain anticipation in alcohol-dependent patients â a randomized, placebo-controlled, patient-tailored pharmaco fMRI trial. Alcoholism: Clinical and Experimental Research2019;43(Suppl 1):246A. ">Muller 2015</a>; <a href="./references#CD012557-bbs2-0021" title="PonizovskyAM , RoscaP , AronovichE , WeizmanA , GrinshpoonA . Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up. Journal of Substance Abuse Treatment2015;52:24-30. [DOI: 10.1016/j.jsat.2014.11.007]">Ponizovsky 2015</a>; <a href="./references#CD012557-bbs2-0022" title="PouchainD . A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients. The Alpadir study. Exercer-La Revue Francophone De Medecine Generale2018;142:163-5. ReynaudM , AubinHJ , TrinquetF , ZakineB , DanoC , DematteisM , et al. A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients â the ALPADIR Study. Alcohol and Alcoholism2017;52(4):439-46. ">Reynaud 2017</a>; <a href="./references#CD012557-bbs2-0023" title="JauryPH . Baclofen for the treatment of alcohol drinkers (Bacloville). Alcoholism: Clinical and Experimental Research2014;38:215a. RigalL , SidorkiewiczS , TrÃ©luyerJM , PerrodeauE , Le JeunneC , PorcherR , et al. Titrated baclofen for high-risk alcohol consumption: a randomized placebo-controlled trial in out-patients with 1-year follow-up. Addiction2020;115(7):1265-76. ">Rigal 2020</a>); two RCTs compared baclofen to naltrexone (<a href="./references#CD012557-bbs2-0008" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b2</a>; <a href="./references#CD012557-bbs2-0013" title="KumarA , SharmaA , BansalPD , BahetraM , GillHK , KumarR . A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. Indian Journal of Psychiatry2020;62(6):650-8. ">Kumar 2020a</a>); and two RCTs compared baclofen to acamprosate (<a href="./references#CD012557-bbs2-0013" title="KumarA , SharmaA , BansalPD , BahetraM , GillHK , KumarR . A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. Indian Journal of Psychiatry2020;62(6):650-8. ">Kumar 2020a</a>; <a href="./references#CD012557-bbs2-0015" title="MishraSN , SwainSP , ShuklaRK , SarkarP . A study of comparative efficacy of baclofen vs acamprosate in reducing alcohol craving and abuse. Orissa Journal of Psychiatry2010;-:48-53. ">Mishra 2010</a>). </p> <p>Ten RCTs compared one dose of baclofen to placebo (<a href="./references#CD012557-bbs2-0001" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , VonghiaL , MirijelloA , et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet2007;370(9603):1915-22. [DOI: 10.1016/S0140-6736(07)61814-5]">Addolorato 2007</a>; <a href="./references#CD012557-bbs2-0006" title="GarbuttJC , Kampov-PolevoyAB , GallopR , Kalka-JuhlL , FlanneryBA . Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcoholism, Clinical and Experimental Research2010;34(11):1849-57. [DOI: 10.1111/j.1530-0277.2010.01273.x]">Garbutt 2010a</a>; <a href="./references#CD012557-bbs2-0011" title="HauserP , Fuller B HoSB , ThurasP , KernS , DieperinkE . The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. Addiction2017;112(7):1173-83. [DOI: 10.1111/add.13787.]">Hauser 2017</a>; <a href="./references#CD012557-bbs2-0012" title="KrupitskiiEM , RybakovaKV , KiselevAS , AlekseevaYV , BerntsevVA , ChekhlatyiEI , et al. Efficacy and safety of the use of baclofen in the treatment of alcohol dependent (a double-blind, randomized, placebo-controlled pilot study). Neuroscience and Behavioral Physiology2017;47(2):153-62. [DOI: 10.1007/s11055-016-0379-6]KrupitskyEM , RybakovaKV , KiselevAS , AlexeevaYV , BerntsevVA , ChekhlatyEI , et al. Double blind placebo controlled randomized pilot clinical trial of baclofen (BaclosanÂ®) for alcohol dependence. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova2015;115(6):53-62. [DOI: 10.17116/jnevro20151156153-62]">Krupitskii 2017</a>; <a href="./references#CD012557-bbs2-0014" title="BollingerJ , EdwardsSM , ZywiakWK , TideyJW , SwiftRW , KennaGA , et al. A double-blind, placebo-controlled randomized pilot study of the effects of baclofen on alcohol-tobacco co-use and alcohol cue-reactivity in alcoholic smokers. Clinical and Translational Science2014;7(3):265. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW , et al. Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Erratum for: Neuropsychopharmacology. 2014 Dec;39 Suppl 1:S1-647. Neuropsychopharmacology2015;40(6):1560. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW . Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Neuropsychopharmacology2014;39:S340. LeggioL , ZywiakWH , EdwardsSM , TideyJW , SwiftRM , KennaGA . A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology2015;232(1):233-43. [DOI: 10.1007/s00213-014-3652-9]">Leggio 2015</a>; <a href="./references#CD012557-bbs2-0015" title="MishraSN , SwainSP , ShuklaRK , SarkarP . A study of comparative efficacy of baclofen vs acamprosate in reducing alcohol craving and abuse. Orissa Journal of Psychiatry2010;-:48-53. ">Mishra 2010</a>; <a href="./references#CD012557-bbs2-0020" title="BeckA , PelzP , LorenzRC , CharletK , GeiselO , HeinzA , et al. Effects of high-dose baclofen on cue reactivity in alcohol dependence: a randomized, placebo-controlled pharmaco-fMRI study. European Neuropsychopharmacology2018;28(11):1206-16. GeiselO , HellwegR , WerneckeKD , WiedemannK , MÃ¼llerCA . Total and acylated ghrelin plasma levels as potential long-term response markers in alcohol-dependent patients receiving high-dose of the GABA-B receptor agonist baclofen. Psychiatry Research2019;272:431-7. GeiselO , SchlemmL , HellwegR , WiedemannK , MÃ¼llerCA . Hypothalamic-pituitary-adrenocortical axis activity in alcohol-dependent patients during treatment with high-dose baclofen. Pharmacopsychiatry2019;52(1):32-7. MullerCA , GeiselO , PelzP , HiglV , KrugerJ , StickelA , et al. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. European Neuropsychopharmacology2015;25(8):1167-77. [DOI: 10.1016/j.euroneuro.2015.04.002]MullerCA , GeiselO , PelzP , HiglV , KrugerJ , StickelA , et al. Individually titrated high-dose baclofen for the treatment of alcohol dependence (BACLAD study) â a randomized controlled trial. European Psychiatry2015;30(S1):1611. [DOI: 10.1016/S0924-9338(15)31243-8]PelzP , GenauckA , GleichT , LorenzRC , HeinzA , MullerCA , et al. Baclofen desensitizes the fronto-striatal reward network in alcohol dependent patients: a randomized, placebo-controlled pharmaco FMRI trial. Alcoholism: Clinical and Experimental Research2018;42:126A. PelzP , GenauckA , LorenzRC , WustenbergC , WackerhagenK , CharletT , et al. Baclofen desensitizes insular gain anticipation in alcohol-dependent patients â a randomized, placebo-controlled, patient-tailored pharmaco fMRI trial. Alcoholism: Clinical and Experimental Research2019;43(Suppl 1):246A. ">Muller 2015</a>; <a href="./references#CD012557-bbs2-0021" title="PonizovskyAM , RoscaP , AronovichE , WeizmanA , GrinshpoonA . Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up. Journal of Substance Abuse Treatment2015;52:24-30. [DOI: 10.1016/j.jsat.2014.11.007]">Ponizovsky 2015</a>; <a href="./references#CD012557-bbs2-0022" title="PouchainD . A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients. The Alpadir study. Exercer-La Revue Francophone De Medecine Generale2018;142:163-5. ReynaudM , AubinHJ , TrinquetF , ZakineB , DanoC , DematteisM , et al. A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients â the ALPADIR Study. Alcohol and Alcoholism2017;52(4):439-46. ">Reynaud 2017</a>; <a href="./references#CD012557-bbs2-0023" title="JauryPH . Baclofen for the treatment of alcohol drinkers (Bacloville). Alcoholism: Clinical and Experimental Research2014;38:215a. RigalL , SidorkiewiczS , TrÃ©luyerJM , PerrodeauE , Le JeunneC , PorcherR , et al. Titrated baclofen for high-risk alcohol consumption: a randomized placebo-controlled trial in out-patients with 1-year follow-up. Addiction2020;115(7):1265-76. ">Rigal 2020</a>); five RCTs compared two doses of baclofen to placebo (<a href="./references#CD012557-bbs2-0002" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , BedogniG , CaputoF , et al. Doseâresponse effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism2011;46(3):312-7. [PMID: 21414953]">Addolorato 2011âLD</a>; <a href="./references#CD012557-bbs2-0003" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , BedogniG , CaputoF , et al. Doseâresponse effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism2011;46(3):312-7. [PMID: 21414953]">Addolorato 2011âMD</a>; <a href="./references#CD012557-bbs2-0004" title="BerahaEM , SaleminkE , GoudriaanAE , BakkerA , De JongD , SmitsN , et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology2017;26(12):1950-9. BerahaEM , SaleminkE , KredietE , WiersRW . Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?Journal of Psychopharmacology2018;32(8):867-75. [PMID: 29897022]">Beraha 2016âHD</a>; <a href="./references#CD012557-bbs2-0005" title="BerahaEM , SaleminkE , GoudriaanAE , BakkerA , De JongD , SmitsN , et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology2017;26(12):1950-9. BerahaEM , SaleminkE , KredietE , WiersRW . Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?Journal of Psychopharmacology2018;32(8):867-75. ">Beraha 2016âLD</a>; <a href="./references#CD012557-bbs2-0009" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âLD</a>; <a href="./references#CD012557-bbs2-0010" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. [PMID: 34155332]NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âMD</a>; <a href="./references#CD012557-bbs2-0016" title="MorleyKC , BaillieA , LeungS , AddoloratoG , LeggioL , HaberPS . Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol and Alcoholism2014;49(6):654-60. [DOI: 10.1093/alcalc/agu062]">Morley 2014âLD</a>; <a href="./references#CD012557-bbs2-0017" title="MorleyKC , BaillieA , LeungS , AddoloratoG , LeggioL , HaberPS . Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol and Alcoholism2014;49(6):654-60. [DOI: 10.1093/alcalc/agu062]">Morley 2014âMD</a>; <a href="./references#CD012557-bbs2-0018" title="HengS , JamshidiN , BaillieA , LouieE , DoreG , PhungN , et al. Baclofen response in alcohol dependent patients concurrently receiving antidepressants: secondary analysis from the BacALD study. Frontiers in Psychiatry2018;9:576. LoggeW , BaillieAJ , MorrisRW , HaberPS , MorleyKC . Baclofen reduces alcohol cue-induced fMRI brain activation in treatment seeking alcohol dependent individuals. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. LoggeWB , BaillieAJ , HaberPS , MorleyKC . Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Human Psychopharmacology2020;35(2):e2722. LoggeWB , HaberPS , BaillieAJ , KosinskiP , MorrisRW , FraserI , et al. Dose-specific baclofen effects on brain structure, function and treatment responses: neuroimaging findings from the BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):20A-21A. LoggeWB , MorleyKC , HaberPS , BaillieAJ . Executive functioning moderates responses to appetitive cues: a study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism2019;54(1):38-46. LoggeWB , MorrisRW , BaillieAJ , HaberPS , MorleyKC . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berlin)2021;238(5):1291-302. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Baclofen for treatment of alcohol use disorder: secondary analyses and implications of the Australian BacALD trial. Drug and Alcohol Review2019;38:S75. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Exploration of the modulating role of the GABAb receptor polymorphism rs29220 on response to baclofen in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):41A. MorleyKC , BaillieA , FraserI , Furneaux-BateA , DoreG , RobertsM , et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry2018;212(6):362-9. MorleyKC , LagopoulosJ , LoggeW , BaillieA , AdamsC , HaberPS . Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addiction Biology2020;25(1):e12702. MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55. MorleyKC , LoggeWB , FraserI , MorrisRW , BaillieAJ , HaberPS . High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology2021;46:28-36. MorleyKC , LuquinN , BaillieA , FraserI , TrentRJ , DoreG , et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction2018;113(12):2205-13. MorleyKC , MorrisR , LoggeW , BaillieA , FraserI , HaberPS . Baclofen administration attenuates insula response during anticipatory anxiety in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. MorleyKC , RiordanB , LoggeW , BaillieA , HaberPS . Moderation of baclofen on the daily relationship between craving and alcohol use: results from the Australian BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):53A. MorleyLC , LuquinN , BaillieA , FraserI , TrentR , DoreG , et al. Moderation of baclofen response by a GABAb receptor polymorphism. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. RomboutsSA , BaillieA , HaberPS , MorleyKC . Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD trial. Alcohol and Alcoholism2019;54(3):272-8. ">Morley 2018âLD</a>; <a href="./references#CD012557-bbs2-0019" title="HengS , JamshidiN , BaillieA , LouieE , DoreG , PhungN , et al. Baclofen response in alcohol dependent patients concurrently receiving antidepressants: secondary analysis from the BacALD study. Frontiers in Psychiatry2018;9:576. LoggeW , BaillieAJ , MorrisRW , HaberPS , MorleyKC . Baclofen reduces alcohol cue-induced fMRI brain activation in treatment seeking alcohol dependent individuals. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. LoggeWB , BaillieAJ , HaberPS , MorleyKC . Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Human Psychopharmacology2020;35(2):e2722. LoggeWB , HaberPS , BaillieAJ , KosinskiP , MorrisRW , FraserI , et al. Dose-specific baclofen effects on brain structure, function and treatment responses: neuroimaging findings from the BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):20A-21A. LoggeWB , MorleyKC , HaberPS , BaillieAJ . Executive functioning moderates responses to appetitive cues: a study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism2019;54(1):38-46. LoggeWB , MorrisRW , BaillieAJ , HaberPS , MorleyKC . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berlin)2021;238(5):1291-302. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Baclofen for treatment of alcohol use disorder: secondary analyses and implications of the Australian BacALD trial. Drug and Alcohol Review2019;38:S75. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Exploration of the modulating role of the GABAb receptor polymorphism rs29220 on response to baclofen in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):41A. MorleyKC , BaillieA , FraserI , Furneaux-BateA , DoreG , RobertsM , et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry2018;212(6):362-9. MorleyKC , LagopoulosJ , LoggeW , BaillieA , AdamsC , HaberPS . Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addiction Biology2020;25(1):e12702. MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55. MorleyKC , LoggeWB , FraserI , MorrisRW , BaillieAJ , HaberPS . High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology2021;46:28-36. MorleyKC , LuquinN , BaillieA , FraserI , TrentRJ , DoreG , et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction2018;113(12):2205-13. MorleyKC , MorrisR , LoggeW , BaillieA , FraserI , HaberPS . Baclofen administration attenuates insula response during anticipatory anxiety in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. MorleyKC , RiordanB , LoggeW , BaillieA , HaberPS . Moderation of baclofen on the daily relationship between craving and alcohol use: results from the Australian BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):53A. RomboutsSA , BaillieA , HaberPS , MorleyKC . Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD Trial. Alcohol and Alcoholism2019;54(3):272-8. ">Morley 2018âMD</a>); one RCT compared baclofen to placebo and another medication (<a href="./references#CD012557-bbs2-0007" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b1</a>; <a href="./references#CD012557-bbs2-0008" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b2</a>); and one RCT compared baclofen to two other medications (<a href="./references#CD012557-bbs2-0013" title="KumarA , SharmaA , BansalPD , BahetraM , GillHK , KumarR . A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. Indian Journal of Psychiatry2020;62(6):650-8. ">Kumar 2020a</a>). We found no studies comparing baclofen to no treatment. </p> </section> </section> <section id="CD012557-sec-0047"> <h4 class="title">Excluded studies</h4> <p>We excluded three studies: <a href="./references#CD012557-bbs2-0076" title="GuptaM , VermaP , RastogiR , AroraS , ElwadhiD . Randomized open-label trial of baclofen for relapse prevention in alcohol dependence. American Journal of Drug and Alcohol Abuse2017;43(3):324-31. [PMID: 27808555]">Gupta 2017</a> because the inactive medication used in the control group (benfothiamine) has an effect on both alcohol consumption and anxiety (<a href="./references#CD012557-bbs2-0107" title="ManzardoAM , HeJ , PojeA , PenickEC , CampbellJ , ButlerMG . Double-blind, randomized placebo-controlled clinical trial of benfotiamine for severe alcohol dependence. Drug and Alcohol Dependence2013;133(2):562-70. [PMID: 23992649]">Manzardo 2013</a>; <a href="./references#CD012557-bbs2-0108" title="ManzardoAM , PendletonT , PojeA , PenickEC , ButlerMG . Change in psychiatric symptomatology after benfotiamine treatment in males is related to lifetime alcoholism severity. Drug and Alcohol Dependence2015;152:257-63. [PMID: 25908323]">Manzardo 2015</a>); <a href="./references#CD012557-bbs2-0088" title="JoseNA , YadavP , KapoorA , MahlaVP . Comparison between baclofen and topiramate in alcohol dependence: a prospective study. Indian Journal of Psychiatry2019;28(1):44-50. [CTRI: 2016/01/006525]">Jose 2019</a> because its duration was less than 12 weeks and <a href="./references#CD012557-bbs2-0093" title="KumarR , KumarKJ , BenegalV , RoopeshBN , RaviGS . Integrated intervention program for alcoholism improves impulsiveness and disadvantageous reward processing/risk-taking. Indian Journal of Psychiatry2020;62(4):384-91.">Kumar 2020b</a> because both groups received baclofen. The previous version of this review excluded four studies (<a href="./references#CD012557-bbs2-0024" title="AddoloratoG , CaputoF , CapristoE , DomenicaliM , BernardiM , JaniriM , et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomised controlled study. Alcohol &amp; Alcoholism2002;37:504-8. ">Addolorato 2002</a>; <a href="./references#CD012557-bbs2-0025" title="FlanneryBA , GarbuttJC , CodyMW , RennW , GraceK , OsborneM , et al. Baclofen for alcohol dependence: a preliminary open-label study. Alcoholism, Clinical and Experimental Research2004;28(10):1517-23. ">Flannery 2004</a>; <a href="./references#CD012557-bbs2-0029" title="LeggioL , KennaG , ZywiakW , EdwardsS , FricchioneS , TaveresT . Baclofen as a novel pharmacotherapy for alcohol dependence: preliminary findings from a human laboratory double-blind placebo-controlled randomized study. Neuropsychopharmacology2011;36:187. ">Leggio 2011</a>; <a href="./references#CD012557-bbs2-0030" title="LeggioL , ZywiakWH , McGearyJE , EdwardsS , FricchioneSR , ShoaffJR , et al. A human laboratory pilot study with baclofen in alcoholic individuals. Pharmacology, Biochemistry, and Behavior2013;103(4):784-91. [DOI: 10.1016/j.pbb.2012.11.013]">Leggio 2013</a>). In total, we excluded seven studies. For more details, see <a href="./references#CD012557-sec-0189" title="">Characteristics of excluded studies</a> table. </p> <section id="CD012557-sec-0048"> <h5 class="title">Studies awaiting classification</h5> <p>One new study is awaiting classification as it was a conference abstract providing insufficient information regarding the design and length of the study (<a href="./references#CD012557-bbs2-0090" title="KarthikS , HollaB , BharathRD , VenkatasubramanianG , BenegalV . Baclofen is more efficacious than oral naltrexone in individuals with severe alcohol dependence for maintaining abstinence â a preliminary report. European Psychiatry2018;48(Suppl 1):S335.">Karthik 2018</a>). We moved some references awaiting classification in the previous version of this review to the included studies as primary or secondary references (<a href="./references#CD012557-bbs2-0002" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , BedogniG , CaputoF , et al. Doseâresponse effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism2011;46(3):312-7. [PMID: 21414953]">Addolorato 2011âLD</a>; <a href="./references#CD012557-bbs2-0003" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , BedogniG , CaputoF , et al. Doseâresponse effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism2011;46(3):312-7. [PMID: 21414953]">Addolorato 2011âMD</a>; <a href="./references#CD012557-bbs2-0064" title="FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW . Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Neuropsychopharmacology2014;39:S340.">Farokhnia 2014</a>; <a href="./references#CD012557-bbs2-0086" title="JauryPH . Baclofen for the treatment of alcohol drinkers (Bacloville). Alcoholism: Clinical and Experimental Research2014;38:215a.">Jaury 2014</a>; <a href="./references#CD012557-bbs2-0114" title="MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55.">Morley 2013</a>). In this review update, two studies are awaiting classification (<a href="./references#CD012557-bbs2-0090" title="KarthikS , HollaB , BharathRD , VenkatasubramanianG , BenegalV . Baclofen is more efficacious than oral naltrexone in individuals with severe alcohol dependence for maintaining abstinence â a preliminary report. European Psychiatry2018;48(Suppl 1):S335.">Karthik 2018</a>; <a href="./references#CD012557-bbs2-0138" title="SharmaV , SharmaR , ChaturvediM , BharadwajB . A doseâresponse effect of baclofen in reducing daily alcohol intake in alcohol-dependent subjects. Journal of Gastroenterology and Hepatology2012;27:263. [DOI: 10.1111/jgh.12006]">Sharma 2012</a>; see <a href="./references#CD012557-sec-0190" title="">Characteristics of studies awaiting classification</a> table). </p> </section> <section id="CD012557-sec-0049"> <h5 class="title">Ongoing studies</h5> <p>We identified no new ongoing studies. Among the two studies considered ongoing in the previous version of this review, one (<a href="https://www.clinicaltrials.gov/ct2/show/NCT01980706" target="_blank">NCT01980706</a>) was moved to the included studies section (<a href="./references#CD012557-bbs2-0009" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âLD</a>; <a href="./references#CD012557-bbs2-0010" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. [PMID: 34155332]NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âMD</a>), and one remains in the ongoing studies section (<a href="./references#CD012557-bbs2-0033" title="CTRI/2011/11/002154. Efficacy and safety of baclofen GRS for treatment of alcohol dependence, a 12 week study. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3752 (first received 21 November 2011). ">CTRI/2011/11/002154</a>). See <a href="./references#CD012557-sec-0191" title="">Characteristics of ongoing studies</a> table. </p> </section> </section> </section> <section id="CD012557-sec-0050"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD012557-fig-0002">Figure 2</a> and <a href="#CD012557-fig-0003">Figure 3</a>. For a detailed description of the reasons supporting our judgements, see the risk of bias table in the <a href="./references#CD012557-sec-0188" title="">Characteristics of included studies</a> table. </p> <div class="figure" id="CD012557-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD012557-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD012557-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD012557-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD012557-sec-0051"> <h4 class="title">Allocation</h4> <section id="CD012557-sec-0052"> <h5 class="title">Random sequence generation</h5> <p>We judged 14 studies at low risk of bias. The study authors did not report any information about methods of sequence random generation for the other three studies, so we judged them at unclear risk of bias (<a href="./references#CD012557-bbs2-0001" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , VonghiaL , MirijelloA , et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet2007;370(9603):1915-22. [DOI: 10.1016/S0140-6736(07)61814-5]">Addolorato 2007</a>; <a href="./references#CD012557-bbs2-0007" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b1</a>; <a href="./references#CD012557-bbs2-0008" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b2</a>). </p> </section> <section id="CD012557-sec-0053"> <h5 class="title">Allocation concealment</h5> <p>We judged 12 studies at low risk of bias. The other five studies did not report methods of allocation concealment, so we judged them at unclear risk of bias (<a href="./references#CD012557-bbs2-0006" title="GarbuttJC , Kampov-PolevoyAB , GallopR , Kalka-JuhlL , FlanneryBA . Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcoholism, Clinical and Experimental Research2010;34(11):1849-57. [DOI: 10.1111/j.1530-0277.2010.01273.x]">Garbutt 2010a</a>; <a href="./references#CD012557-bbs2-0007" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b1</a>; <a href="./references#CD012557-bbs2-0008" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b2</a>; <a href="./references#CD012557-bbs2-0013" title="KumarA , SharmaA , BansalPD , BahetraM , GillHK , KumarR . A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. Indian Journal of Psychiatry2020;62(6):650-8. ">Kumar 2020a</a>; <a href="./references#CD012557-bbs2-0014" title="BollingerJ , EdwardsSM , ZywiakWK , TideyJW , SwiftRW , KennaGA , et al. A double-blind, placebo-controlled randomized pilot study of the effects of baclofen on alcohol-tobacco co-use and alcohol cue-reactivity in alcoholic smokers. Clinical and Translational Science2014;7(3):265. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW , et al. Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Erratum for: Neuropsychopharmacology. 2014 Dec;39 Suppl 1:S1-647. Neuropsychopharmacology2015;40(6):1560. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW . Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Neuropsychopharmacology2014;39:S340. LeggioL , ZywiakWH , EdwardsSM , TideyJW , SwiftRM , KennaGA . A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology2015;232(1):233-43. [DOI: 10.1007/s00213-014-3652-9]">Leggio 2015</a>; <a href="./references#CD012557-bbs2-0015" title="MishraSN , SwainSP , ShuklaRK , SarkarP . A study of comparative efficacy of baclofen vs acamprosate in reducing alcohol craving and abuse. Orissa Journal of Psychiatry2010;-:48-53. ">Mishra 2010</a>). </p> </section> </section> <section id="CD012557-sec-0054"> <h4 class="title">Blinding</h4> <section id="CD012557-sec-0055"> <h5 class="title">Performance bias</h5> <p>We judged 13 studies at low risk of bias for objective outcomes and two at high risk (<a href="./references#CD012557-bbs2-0013" title="KumarA , SharmaA , BansalPD , BahetraM , GillHK , KumarR . A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. Indian Journal of Psychiatry2020;62(6):650-8. ">Kumar 2020a</a>; <a href="./references#CD012557-bbs2-0015" title="MishraSN , SwainSP , ShuklaRK , SarkarP . A study of comparative efficacy of baclofen vs acamprosate in reducing alcohol craving and abuse. Orissa Journal of Psychiatry2010;-:48-53. ">Mishra 2010</a>). Two studies did not provide information about blinding, so we judged them at unclear risk of bias (<a href="./references#CD012557-bbs2-0006" title="GarbuttJC , Kampov-PolevoyAB , GallopR , Kalka-JuhlL , FlanneryBA . Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcoholism, Clinical and Experimental Research2010;34(11):1849-57. [DOI: 10.1111/j.1530-0277.2010.01273.x]">Garbutt 2010a</a>; <a href="./references#CD012557-bbs2-0007" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b1</a>; <a href="./references#CD012557-bbs2-0008" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b2</a>). </p> <p>We judged 13 studies at low risk of bias for subjective outcomes and two at high risk (<a href="./references#CD012557-bbs2-0013" title="KumarA , SharmaA , BansalPD , BahetraM , GillHK , KumarR . A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. Indian Journal of Psychiatry2020;62(6):650-8. ">Kumar 2020a</a>; <a href="./references#CD012557-bbs2-0015" title="MishraSN , SwainSP , ShuklaRK , SarkarP . A study of comparative efficacy of baclofen vs acamprosate in reducing alcohol craving and abuse. Orissa Journal of Psychiatry2010;-:48-53. ">Mishra 2010</a>). Two studies did not report methods for blinding, so we judged them at unclear risk of bias (<a href="./references#CD012557-bbs2-0006" title="GarbuttJC , Kampov-PolevoyAB , GallopR , Kalka-JuhlL , FlanneryBA . Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcoholism, Clinical and Experimental Research2010;34(11):1849-57. [DOI: 10.1111/j.1530-0277.2010.01273.x]">Garbutt 2010a</a>; <a href="./references#CD012557-bbs2-0007" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b1</a>; <a href="./references#CD012557-bbs2-0008" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b2</a>). </p> </section> <section id="CD012557-sec-0056"> <h5 class="title">Detection bias</h5> <p>For objective outcomes, we considered 16 studies at low risk of bias and one study at unclear risk (<a href="./references#CD012557-bbs2-0007" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b1</a>; <a href="./references#CD012557-bbs2-0008" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b2</a>). </p> <p>For subjective outcomes, we considered 12 studies at low risk of bias and three studies at high risk of bias (<a href="./references#CD012557-bbs2-0006" title="GarbuttJC , Kampov-PolevoyAB , GallopR , Kalka-JuhlL , FlanneryBA . Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcoholism, Clinical and Experimental Research2010;34(11):1849-57. [DOI: 10.1111/j.1530-0277.2010.01273.x]">Garbutt 2010a</a>; <a href="./references#CD012557-bbs2-0013" title="KumarA , SharmaA , BansalPD , BahetraM , GillHK , KumarR . A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. Indian Journal of Psychiatry2020;62(6):650-8. ">Kumar 2020a</a>; <a href="./references#CD012557-bbs2-0015" title="MishraSN , SwainSP , ShuklaRK , SarkarP . A study of comparative efficacy of baclofen vs acamprosate in reducing alcohol craving and abuse. Orissa Journal of Psychiatry2010;-:48-53. ">Mishra 2010</a>). Two studies did not report sufficient information, so we judged them at unclear risk of bias (<a href="./references#CD012557-bbs2-0007" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b1</a>; <a href="./references#CD012557-bbs2-0008" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b2</a>; <a href="./references#CD012557-bbs2-0011" title="HauserP , Fuller B HoSB , ThurasP , KernS , DieperinkE . The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. Addiction2017;112(7):1173-83. [DOI: 10.1111/add.13787.]">Hauser 2017</a>). </p> </section> </section> <section id="CD012557-sec-0057"> <h4 class="title">Incomplete outcome data</h4> <p>We judged 11 studies at low risk of bias and two studies at high risk of bias (<a href="./references#CD012557-bbs2-0002" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , BedogniG , CaputoF , et al. Doseâresponse effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism2011;46(3):312-7. [PMID: 21414953]">Addolorato 2011âLD</a>; <a href="./references#CD012557-bbs2-0003" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , BedogniG , CaputoF , et al. Doseâresponse effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism2011;46(3):312-7. [PMID: 21414953]">Addolorato 2011âMD</a>; <a href="./references#CD012557-bbs2-0013" title="KumarA , SharmaA , BansalPD , BahetraM , GillHK , KumarR . A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. Indian Journal of Psychiatry2020;62(6):650-8. ">Kumar 2020a</a>). Four studies did not report numbers and reasons of dropouts or missing data for each group, so we judged them at unclear risk of bias (<a href="./references#CD012557-bbs2-0012" title="KrupitskiiEM , RybakovaKV , KiselevAS , AlekseevaYV , BerntsevVA , ChekhlatyiEI , et al. Efficacy and safety of the use of baclofen in the treatment of alcohol dependent (a double-blind, randomized, placebo-controlled pilot study). Neuroscience and Behavioral Physiology2017;47(2):153-62. [DOI: 10.1007/s11055-016-0379-6]KrupitskyEM , RybakovaKV , KiselevAS , AlexeevaYV , BerntsevVA , ChekhlatyEI , et al. Double blind placebo controlled randomized pilot clinical trial of baclofen (BaclosanÂ®) for alcohol dependence. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova2015;115(6):53-62. [DOI: 10.17116/jnevro20151156153-62]">Krupitskii 2017</a>; <a href="./references#CD012557-bbs2-0014" title="BollingerJ , EdwardsSM , ZywiakWK , TideyJW , SwiftRW , KennaGA , et al. A double-blind, placebo-controlled randomized pilot study of the effects of baclofen on alcohol-tobacco co-use and alcohol cue-reactivity in alcoholic smokers. Clinical and Translational Science2014;7(3):265. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW , et al. Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Erratum for: Neuropsychopharmacology. 2014 Dec;39 Suppl 1:S1-647. Neuropsychopharmacology2015;40(6):1560. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW . Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Neuropsychopharmacology2014;39:S340. LeggioL , ZywiakWH , EdwardsSM , TideyJW , SwiftRM , KennaGA . A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology2015;232(1):233-43. [DOI: 10.1007/s00213-014-3652-9]">Leggio 2015</a>; <a href="./references#CD012557-bbs2-0015" title="MishraSN , SwainSP , ShuklaRK , SarkarP . A study of comparative efficacy of baclofen vs acamprosate in reducing alcohol craving and abuse. Orissa Journal of Psychiatry2010;-:48-53. ">Mishra 2010</a>; <a href="./references#CD012557-bbs2-0016" title="MorleyKC , BaillieA , LeungS , AddoloratoG , LeggioL , HaberPS . Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol and Alcoholism2014;49(6):654-60. [DOI: 10.1093/alcalc/agu062]">Morley 2014âLD</a>; <a href="./references#CD012557-bbs2-0017" title="MorleyKC , BaillieA , LeungS , AddoloratoG , LeggioL , HaberPS . Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol and Alcoholism2014;49(6):654-60. [DOI: 10.1093/alcalc/agu062]">Morley 2014âMD</a>). </p> </section> <section id="CD012557-sec-0058"> <h4 class="title">Selective reporting</h4> <p>We judged four studies at low risk of bias and two studies at high risk of bias (<a href="./references#CD012557-bbs2-0002" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , BedogniG , CaputoF , et al. Doseâresponse effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism2011;46(3):312-7. [PMID: 21414953]">Addolorato 2011âLD</a>; <a href="./references#CD012557-bbs2-0003" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , BedogniG , CaputoF , et al. Doseâresponse effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism2011;46(3):312-7. [PMID: 21414953]">Addolorato 2011âMD</a>; <a href="./references#CD012557-bbs2-0015" title="MishraSN , SwainSP , ShuklaRK , SarkarP . A study of comparative efficacy of baclofen vs acamprosate in reducing alcohol craving and abuse. Orissa Journal of Psychiatry2010;-:48-53. ">Mishra 2010</a>). Eleven studies did not provide enough information, so we judged them at unclear risk of bias (<a href="./references#CD012557-bbs2-0006" title="GarbuttJC , Kampov-PolevoyAB , GallopR , Kalka-JuhlL , FlanneryBA . Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcoholism, Clinical and Experimental Research2010;34(11):1849-57. [DOI: 10.1111/j.1530-0277.2010.01273.x]">Garbutt 2010a</a>; <a href="./references#CD012557-bbs2-0007" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b1</a>; <a href="./references#CD012557-bbs2-0008" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b2</a>; <a href="./references#CD012557-bbs2-0011" title="HauserP , Fuller B HoSB , ThurasP , KernS , DieperinkE . The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. Addiction2017;112(7):1173-83. [DOI: 10.1111/add.13787.]">Hauser 2017</a>; <a href="./references#CD012557-bbs2-0012" title="KrupitskiiEM , RybakovaKV , KiselevAS , AlekseevaYV , BerntsevVA , ChekhlatyiEI , et al. Efficacy and safety of the use of baclofen in the treatment of alcohol dependent (a double-blind, randomized, placebo-controlled pilot study). Neuroscience and Behavioral Physiology2017;47(2):153-62. [DOI: 10.1007/s11055-016-0379-6]KrupitskyEM , RybakovaKV , KiselevAS , AlexeevaYV , BerntsevVA , ChekhlatyEI , et al. Double blind placebo controlled randomized pilot clinical trial of baclofen (BaclosanÂ®) for alcohol dependence. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova2015;115(6):53-62. [DOI: 10.17116/jnevro20151156153-62]">Krupitskii 2017</a>; <a href="./references#CD012557-bbs2-0013" title="KumarA , SharmaA , BansalPD , BahetraM , GillHK , KumarR . A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. Indian Journal of Psychiatry2020;62(6):650-8. ">Kumar 2020a</a>; <a href="./references#CD012557-bbs2-0016" title="MorleyKC , BaillieA , LeungS , AddoloratoG , LeggioL , HaberPS . Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol and Alcoholism2014;49(6):654-60. [DOI: 10.1093/alcalc/agu062]">Morley 2014âLD</a>; <a href="./references#CD012557-bbs2-0017" title="MorleyKC , BaillieA , LeungS , AddoloratoG , LeggioL , HaberPS . Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol and Alcoholism2014;49(6):654-60. [DOI: 10.1093/alcalc/agu062]">Morley 2014âMD</a>; <a href="./references#CD012557-bbs2-0018" title="HengS , JamshidiN , BaillieA , LouieE , DoreG , PhungN , et al. Baclofen response in alcohol dependent patients concurrently receiving antidepressants: secondary analysis from the BacALD study. Frontiers in Psychiatry2018;9:576. LoggeW , BaillieAJ , MorrisRW , HaberPS , MorleyKC . Baclofen reduces alcohol cue-induced fMRI brain activation in treatment seeking alcohol dependent individuals. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. LoggeWB , BaillieAJ , HaberPS , MorleyKC . Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Human Psychopharmacology2020;35(2):e2722. LoggeWB , HaberPS , BaillieAJ , KosinskiP , MorrisRW , FraserI , et al. Dose-specific baclofen effects on brain structure, function and treatment responses: neuroimaging findings from the BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):20A-21A. LoggeWB , MorleyKC , HaberPS , BaillieAJ . Executive functioning moderates responses to appetitive cues: a study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism2019;54(1):38-46. LoggeWB , MorrisRW , BaillieAJ , HaberPS , MorleyKC . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berlin)2021;238(5):1291-302. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Baclofen for treatment of alcohol use disorder: secondary analyses and implications of the Australian BacALD trial. Drug and Alcohol Review2019;38:S75. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Exploration of the modulating role of the GABAb receptor polymorphism rs29220 on response to baclofen in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):41A. MorleyKC , BaillieA , FraserI , Furneaux-BateA , DoreG , RobertsM , et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry2018;212(6):362-9. MorleyKC , LagopoulosJ , LoggeW , BaillieA , AdamsC , HaberPS . Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addiction Biology2020;25(1):e12702. MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55. MorleyKC , LoggeWB , FraserI , MorrisRW , BaillieAJ , HaberPS . High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology2021;46:28-36. MorleyKC , LuquinN , BaillieA , FraserI , TrentRJ , DoreG , et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction2018;113(12):2205-13. MorleyKC , MorrisR , LoggeW , BaillieA , FraserI , HaberPS . Baclofen administration attenuates insula response during anticipatory anxiety in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. MorleyKC , RiordanB , LoggeW , BaillieA , HaberPS . Moderation of baclofen on the daily relationship between craving and alcohol use: results from the Australian BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):53A. MorleyLC , LuquinN , BaillieA , FraserI , TrentR , DoreG , et al. Moderation of baclofen response by a GABAb receptor polymorphism. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. RomboutsSA , BaillieA , HaberPS , MorleyKC . Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD trial. Alcohol and Alcoholism2019;54(3):272-8. ">Morley 2018âLD</a>; <a href="./references#CD012557-bbs2-0019" title="HengS , JamshidiN , BaillieA , LouieE , DoreG , PhungN , et al. Baclofen response in alcohol dependent patients concurrently receiving antidepressants: secondary analysis from the BacALD study. Frontiers in Psychiatry2018;9:576. LoggeW , BaillieAJ , MorrisRW , HaberPS , MorleyKC . Baclofen reduces alcohol cue-induced fMRI brain activation in treatment seeking alcohol dependent individuals. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. LoggeWB , BaillieAJ , HaberPS , MorleyKC . Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Human Psychopharmacology2020;35(2):e2722. LoggeWB , HaberPS , BaillieAJ , KosinskiP , MorrisRW , FraserI , et al. Dose-specific baclofen effects on brain structure, function and treatment responses: neuroimaging findings from the BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):20A-21A. LoggeWB , MorleyKC , HaberPS , BaillieAJ . Executive functioning moderates responses to appetitive cues: a study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism2019;54(1):38-46. LoggeWB , MorrisRW , BaillieAJ , HaberPS , MorleyKC . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berlin)2021;238(5):1291-302. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Baclofen for treatment of alcohol use disorder: secondary analyses and implications of the Australian BacALD trial. Drug and Alcohol Review2019;38:S75. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Exploration of the modulating role of the GABAb receptor polymorphism rs29220 on response to baclofen in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):41A. MorleyKC , BaillieA , FraserI , Furneaux-BateA , DoreG , RobertsM , et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry2018;212(6):362-9. MorleyKC , LagopoulosJ , LoggeW , BaillieA , AdamsC , HaberPS . Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addiction Biology2020;25(1):e12702. MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55. MorleyKC , LoggeWB , FraserI , MorrisRW , BaillieAJ , HaberPS . High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology2021;46:28-36. MorleyKC , LuquinN , BaillieA , FraserI , TrentRJ , DoreG , et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction2018;113(12):2205-13. MorleyKC , MorrisR , LoggeW , BaillieA , FraserI , HaberPS . Baclofen administration attenuates insula response during anticipatory anxiety in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. MorleyKC , RiordanB , LoggeW , BaillieA , HaberPS . Moderation of baclofen on the daily relationship between craving and alcohol use: results from the Australian BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):53A. RomboutsSA , BaillieA , HaberPS , MorleyKC . Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD Trial. Alcohol and Alcoholism2019;54(3):272-8. ">Morley 2018âMD</a>; <a href="./references#CD012557-bbs2-0020" title="BeckA , PelzP , LorenzRC , CharletK , GeiselO , HeinzA , et al. Effects of high-dose baclofen on cue reactivity in alcohol dependence: a randomized, placebo-controlled pharmaco-fMRI study. European Neuropsychopharmacology2018;28(11):1206-16. GeiselO , HellwegR , WerneckeKD , WiedemannK , MÃ¼llerCA . Total and acylated ghrelin plasma levels as potential long-term response markers in alcohol-dependent patients receiving high-dose of the GABA-B receptor agonist baclofen. Psychiatry Research2019;272:431-7. GeiselO , SchlemmL , HellwegR , WiedemannK , MÃ¼llerCA . Hypothalamic-pituitary-adrenocortical axis activity in alcohol-dependent patients during treatment with high-dose baclofen. Pharmacopsychiatry2019;52(1):32-7. MullerCA , GeiselO , PelzP , HiglV , KrugerJ , StickelA , et al. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. European Neuropsychopharmacology2015;25(8):1167-77. [DOI: 10.1016/j.euroneuro.2015.04.002]MullerCA , GeiselO , PelzP , HiglV , KrugerJ , StickelA , et al. Individually titrated high-dose baclofen for the treatment of alcohol dependence (BACLAD study) â a randomized controlled trial. European Psychiatry2015;30(S1):1611. [DOI: 10.1016/S0924-9338(15)31243-8]PelzP , GenauckA , GleichT , LorenzRC , HeinzA , MullerCA , et al. Baclofen desensitizes the fronto-striatal reward network in alcohol dependent patients: a randomized, placebo-controlled pharmaco FMRI trial. Alcoholism: Clinical and Experimental Research2018;42:126A. PelzP , GenauckA , LorenzRC , WustenbergC , WackerhagenK , CharletT , et al. Baclofen desensitizes insular gain anticipation in alcohol-dependent patients â a randomized, placebo-controlled, patient-tailored pharmaco fMRI trial. Alcoholism: Clinical and Experimental Research2019;43(Suppl 1):246A. ">Muller 2015</a>; <a href="./references#CD012557-bbs2-0021" title="PonizovskyAM , RoscaP , AronovichE , WeizmanA , GrinshpoonA . Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up. Journal of Substance Abuse Treatment2015;52:24-30. [DOI: 10.1016/j.jsat.2014.11.007]">Ponizovsky 2015</a>; <a href="./references#CD012557-bbs2-0022" title="PouchainD . A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients. The Alpadir study. Exercer-La Revue Francophone De Medecine Generale2018;142:163-5. ReynaudM , AubinHJ , TrinquetF , ZakineB , DanoC , DematteisM , et al. A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients â the ALPADIR Study. Alcohol and Alcoholism2017;52(4):439-46. ">Reynaud 2017</a>; <a href="./references#CD012557-bbs2-0023" title="JauryPH . Baclofen for the treatment of alcohol drinkers (Bacloville). Alcoholism: Clinical and Experimental Research2014;38:215a. RigalL , SidorkiewiczS , TrÃ©luyerJM , PerrodeauE , Le JeunneC , PorcherR , et al. Titrated baclofen for high-risk alcohol consumption: a randomized placebo-controlled trial in out-patients with 1-year follow-up. Addiction2020;115(7):1265-76. ">Rigal 2020</a>). </p> </section> <section id="CD012557-sec-0059"> <h4 class="title">Other potential sources of bias</h4> <p>We identified no other sources of bias.</p> </section> </section> <section id="CD012557-sec-0060"> <h3 class="title" id="CD012557-sec-0060">Effects of interventions</h3> <p>See: <a href="./full#CD012557-tbl-0001"><b>Summary of findings 1</b> Summary of findings table â Baclofen compared to placebo for alcohol use disorder</a>; <a href="./full#CD012557-tbl-0002"><b>Summary of findings 2</b> Summary of findings table â Baclofen compared to acamprosate for alcohol use disorder</a>; <a href="./full#CD012557-tbl-0003"><b>Summary of findings 3</b> Summary of findings table â Baclofen compared to naltrexone for alcohol use disorder</a> </p> <p>For the comparison baclofen versus placebo, we first conducted the analyses including from all studies and found considerable heterogeneity in the rates of abstinent days (17 studies, 1303 participants; IÂ² = 94%) and HDDs at the end of treatment (14 studies, 870 participants; IÂ² = 98%). Conducting the subgroup analyses, we still found considerable heterogeneity in all subgroups where one outlying study was included (<a href="./references#CD012557-bbs2-0014" title="BollingerJ , EdwardsSM , ZywiakWK , TideyJW , SwiftRW , KennaGA , et al. A double-blind, placebo-controlled randomized pilot study of the effects of baclofen on alcohol-tobacco co-use and alcohol cue-reactivity in alcoholic smokers. Clinical and Translational Science2014;7(3):265. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW , et al. Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Erratum for: Neuropsychopharmacology. 2014 Dec;39 Suppl 1:S1-647. Neuropsychopharmacology2015;40(6):1560. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW . Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Neuropsychopharmacology2014;39:S340. LeggioL , ZywiakWH , EdwardsSM , TideyJW , SwiftRM , KennaGA . A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology2015;232(1):233-43. [DOI: 10.1007/s00213-014-3652-9]">Leggio 2015</a>). Accordingly, we excluded this study from all analyses and, for each primary outcome, provided its results separately. </p> <p>We found sufficient data for conducting subgroup analyses according to the daily doses of baclofen, consumption of alcohol at the beginning of treatment and duration of treatment. We conducted subgroup analyses for the primary outcomes (relapse, frequency of use (rate of abstinent days), amount of use (rate of HDDs, drink per drinking days), adverse events (number of participants with at least one adverse event), dropouts from treatment, and dropouts from treatment due to adverse events). </p> <p>We did not conduct subgroup analyses according to the presence or not of comorbid substance use disorders or other mental disorders (or both) because all studies excluded people with substance use disorders of substances other than alcohol or nicotine and people with other comorbid severe mental disorders. </p> <section id="CD012557-sec-0061"> <h4 class="title">Comparison 1: baclofen versus placebo</h4> <section id="CD012557-sec-0062"> <h5 class="title">1.1 Relapse: return to any drinking at end of treatment</h5> <p>Twelve studies involving 1057 participants reported relapse. Baclofen reduced the risk of relapse compared to placebo (RR 0.87, 95% CI 0.77 to 0.99; moderateâcertainty evidence; <a href="./references#CD012557-fig-0009" title="">Analysis 1.1</a>; <a href="#CD012557-fig-0004">Figure 4</a>; <a href="./full#CD012557-tbl-0001">summary of findings Table 1</a>). There was substantial heterogeneity (ChiÂ² = 40.60, degrees of freedom (df) = 11 (P &lt; 0.001); IÂ² = 73%). The study excluded from this metaâanalysis found no difference in relapse between baclofen and placebo (RR â0.53, 95% CI â3.11 to 2.05; 30 participants; <a href="./references#CD012557-bbs2-0014" title="BollingerJ , EdwardsSM , ZywiakWK , TideyJW , SwiftRW , KennaGA , et al. A double-blind, placebo-controlled randomized pilot study of the effects of baclofen on alcohol-tobacco co-use and alcohol cue-reactivity in alcoholic smokers. Clinical and Translational Science2014;7(3):265. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW , et al. Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Erratum for: Neuropsychopharmacology. 2014 Dec;39 Suppl 1:S1-647. Neuropsychopharmacology2015;40(6):1560. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW . Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Neuropsychopharmacology2014;39:S340. LeggioL , ZywiakWH , EdwardsSM , TideyJW , SwiftRM , KennaGA . A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology2015;232(1):233-43. [DOI: 10.1007/s00213-014-3652-9]">Leggio 2015</a>). </p> <div class="figure" id="CD012557-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="original image" data-id="CD012557-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <section id="CD012557-sec-0063"> <h6 class="title">1.1.1 Subgroup analyses: daily doses of baclofen</h6> <p>We found no differences between baclofen and placebo among studies using low, medium or high doses (low: RR 0.82, 95% CI 0.64 to 1.04; considerable heterogeneity (ChiÂ² = 32.98, df = 5 (P &lt; 0.001); IÂ² = 85%); 6 studies, 463 participants; medium: RR 0.73, 95% CI 0.37 to 1.45; considerable heterogeneity (ChiÂ² = 11.20, df = 2 (P = 0.004); IÂ² = 82%); 3 studies, 129 participants; high: RR 0.90, 95% CI 0.71 to 1.15; moderate heterogeneity (ChiÂ² = 4.78, df = 2 (P = 0.09); IÂ² = 58%); 3 studies, 465 participants; <a href="./references#CD012557-fig-0043" title="">Analysis 2.1</a>). </p> </section> <section id="CD012557-sec-0064"> <h6 class="title">1.1.2 Subgroup analyses: duration of treatment</h6> <p>We found no differences between baclofen and placebo among 12âweek studies and longer than 12âweek studies (12 weeks: RR 0.63, 95% CI 0.40 to 1.00; considerable heterogeneity (ChiÂ² = 54.47, df = 6 (P &lt; 0.001); IÂ² = 89%); 7 studies, 466 participants; longer than 12 weeks: RR 0.98, 95% CI 0.93 to 1.03; IÂ² = 0%; 5 studies, 591 participants; <a href="./references#CD012557-fig-0050" title="">Analysis 3.1</a>). </p> </section> <section id="CD012557-sec-0065"> <h6 class="title">1.1.3 Subgroup analyses: consumption of alcohol at beginning of treatment</h6> <p>Baclofen reduced the risk of relapse compared to placebo among studies with detoxified participants (RR 0.73, 95% CI 0.55 to 0.95; considerable heterogeneity (ChiÂ² = 33.42, df = 8 (P &lt; 0.001); IÂ² = 76%); 9 studies, 757 participants; <a href="./references#CD012557-fig-0057" title="">Analysis 4.1</a>). There were no differences between baclofen and placebo among studies with nonâdetoxified participants (RR 1.00, 95% CI 0.94 to 1.06; IÂ² = 0%; 3 studies, 300 participants; <a href="./references#CD012557-fig-0057" title="">Analysis 4.1</a>). </p> </section> </section> <section id="CD012557-sec-0066"> <h5 class="title">1.2 Frequency of use: percentage of days abstinent at end of treatment</h5> <p>We identified 16 studies involving 1273 participants reporting percentage of days abstinent at the end of treatment. Baclofen increased the rate of abstinent days compared to placebo (MD 9.07%, 95% CI 3.30 to 14.85; highâcertainty evidence; <a href="./references#CD012557-fig-0010" title="">Analysis 1.2</a>; <a href="#CD012557-fig-0005">Figure 5</a>; <a href="./full#CD012557-tbl-0001">summary of findings Table 1</a>). There was substantial heterogeneity (ChiÂ² = 43.69, df = 15 (P = 0.001); IÂ² = 66%). The study excluded from this metaâanalysis found that placebo increased the rate of abstinent days compared to baclofen (MD â19.00 days, 95% CI â21.18 to â16.82; 30 participants; <a href="./references#CD012557-bbs2-0014" title="BollingerJ , EdwardsSM , ZywiakWK , TideyJW , SwiftRW , KennaGA , et al. A double-blind, placebo-controlled randomized pilot study of the effects of baclofen on alcohol-tobacco co-use and alcohol cue-reactivity in alcoholic smokers. Clinical and Translational Science2014;7(3):265. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW , et al. Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Erratum for: Neuropsychopharmacology. 2014 Dec;39 Suppl 1:S1-647. Neuropsychopharmacology2015;40(6):1560. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW . Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Neuropsychopharmacology2014;39:S340. LeggioL , ZywiakWH , EdwardsSM , TideyJW , SwiftRM , KennaGA . A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology2015;232(1):233-43. [DOI: 10.1007/s00213-014-3652-9]">Leggio 2015</a>). </p> <div class="figure" id="CD012557-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="original image" data-id="CD012557-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <section id="CD012557-sec-0067"> <h6 class="title">1.2.1 Subgroup analyses: daily doses of baclofen</h6> <p>Baclofen increased the rate of abstinent days compared to placebo among studies using low and high doses (low: MD 10.59%, 95% CI 0.77 to 20.41; substantial heterogeneity (ChiÂ² = 19.68, df = 7 (P = 0.006); IÂ² = 64%); 8 studies, 583 participants; high: MD 11.09%, 95% CI 4.39 to 17.80; IÂ² = 6%; 3 studies, 465 participants; <a href="./references#CD012557-fig-0044" title="">Analysis 2.2</a>). We found no differences between baclofen and placebo among studies using medium doses (MD 7.14%, 95% CI â3.10 to 17.38; moderate heterogeneity (ChiÂ² = 8.39, df = 4 (P = 0.08); IÂ² = 52%); 5 studies, 225 participants; <a href="./references#CD012557-fig-0044" title="">Analysis 2.2</a>). </p> </section> <section id="CD012557-sec-0068"> <h6 class="title">1.2.2 Subgroup analyses: duration of treatment</h6> <p>Baclofen increased the rate of abstinent days compared to placebo among 12âweek studies and longer than 12âweek studies (12 weeks: MD 10.90, 95% CI 3.17 to 18.62; substantial heterogeneity (ChiÂ² = 33.61, df = 10 (P = 0.001); IÂ² = 70%); 11 studies, 682 participants; longer than 12 weeks: MD 8.05, 95% CI 1.09 to 15.01; IÂ² = 18%; 5 studies, 591 participants; <a href="./references#CD012557-fig-0051" title="">Analysis 3.2</a>). </p> </section> <section id="CD012557-sec-0069"> <h6 class="title">1.2.3 Subgroup analyses: consumption of alcohol at beginning of treatment</h6> <p>Baclofen increased the rate of abstinent days compared to placebo among studies with detoxified participants (MD 11.76, 95% CI 3.22 to 20.29; moderate heterogeneity (ChiÂ² = 19.42, df = 9 (P = 0.02); IÂ² = 54%); 10 studies, 549 participants; <a href="./references#CD012557-fig-0058" title="">Analysis 4.2</a>). There was no difference between baclofen and placebo among studies with nonâdetoxified participants (MD 6.03, 95% CI â1.59 to 13.64; substantial heterogeneity (ChiÂ² = 16.88, df = 5 (P = 0.005); IÂ² = 70%); 6 studies, 724 participants; <a href="./references#CD012557-fig-0058" title="">Analysis 4.2</a>). </p> </section> </section> <section id="CD012557-sec-0070"> <h5 class="title">1.3 Frequency of use: heavy drinking days at end of treatment</h5> <p>We identified 13 studies involving 840 participants reporting HDDs at the end of treatment. There was no difference between baclofen and placebo (SMD â0.18, 95% CI â0.48 to 0.11; moderateâcertainty evidence; <a href="./references#CD012557-fig-0011" title="">Analysis 1.3</a>; <a href="#CD012557-fig-0006">Figure 6</a>; <a href="./full#CD012557-tbl-0001">summary of findings Table 1</a>). There was substantial heterogeneity (ChiÂ² = 41.40.55, df = 12 (P &lt; 0.001); IÂ² = 71%). The study excluded from this metaâanalysis found no difference between baclofen and placebo (MD â2.00, 95% CI â13.22 to 9.22; 30 participants; <a href="./references#CD012557-bbs2-0014" title="BollingerJ , EdwardsSM , ZywiakWK , TideyJW , SwiftRW , KennaGA , et al. A double-blind, placebo-controlled randomized pilot study of the effects of baclofen on alcohol-tobacco co-use and alcohol cue-reactivity in alcoholic smokers. Clinical and Translational Science2014;7(3):265. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW , et al. Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Erratum for: Neuropsychopharmacology. 2014 Dec;39 Suppl 1:S1-647. Neuropsychopharmacology2015;40(6):1560. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW . Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Neuropsychopharmacology2014;39:S340. LeggioL , ZywiakWH , EdwardsSM , TideyJW , SwiftRM , KennaGA . A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology2015;232(1):233-43. [DOI: 10.1007/s00213-014-3652-9]">Leggio 2015</a>). </p> <div class="figure" id="CD012557-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="original image" data-id="CD012557-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <section id="CD012557-sec-0071"> <h6 class="title">1.3.1 Subgroup analyses: daily doses of baclofen</h6> <p>We found no difference between baclofen and placebo among the studies low, medium and high doses (low: SMD 0.10, 95% CI â0.15 to 0.34; IÂ² = 0%; 6 studies, 278 participants; medium: SMD â0.47, 95% CI â1.15 to 0.20; considerable heterogeneity (ChiÂ² = 28.68, df = 5 (P &lt; 0.001); IÂ² = 83%); 6 studies, 242 participants; high: SMD â0.21, 95% CI â0.43 to 0.01; 1 study, 320 participants; <a href="./references#CD012557-fig-0045" title="">Analysis 2.3</a>). </p> </section> <section id="CD012557-sec-0072"> <h6 class="title">1.3.2 Subgroup analyses: duration of treatment</h6> <p>We found no difference between baclofen and placebo among 12âweek and longer than 12âweek studies (12 weeks: SMD â0.07, 95% CI â0.27 to 0.13; IÂ² = 0%; 10 studies, 400 participants; longer than 12 weeks: SMD â0.54, 95% CI â1.68 to 0.60; considerable heterogeneity (ChiÂ² = 36.40, df = 2 (P &lt; 0.001); IÂ² = 95%); 3 studies, 440 participants; <a href="./references#CD012557-fig-0052" title="">Analysis 3.3</a>). </p> </section> <section id="CD012557-sec-0073"> <h6 class="title">1.3.3 Subgroup analyses: consumption of alcohol at beginning of treatment</h6> <p>We found no difference between baclofen and placebo among the studies with detoxified and nonâdetoxified participants (toxified: SMD â0.08, 95% CI â0.32 to 0.16; IÂ² = 0%; 8 studies, 296 participants; nonâdetoxified: SMD â0.34, 95% CI â0.98 to 0.30; considerable heterogeneity (ChiÂ² = 37.90, df = 4 (P &lt; 0.001); IÂ² = 89%); 5 studies, 544 participants; <a href="./references#CD012557-fig-0059" title="">Analysis 4.3</a>). </p> </section> </section> <section id="CD012557-sec-0074"> <h5 class="title">1.4 Amount of use: drinks per drinking days at end of treatment</h5> <p>We identified nine studies involving 392 participants reporting drinks per drinking days at the end of treatment. There were no differences between baclofen and placebo (MD â0.45, 95% CI â1.20 to 0.30; moderateâcertainty evidence; <a href="./references#CD012557-fig-0012" title="">Analysis 1.4</a>; <a href="./full#CD012557-tbl-0001">summary of findings Table 1</a>). There was no important heterogeneity (ChiÂ² = 11.65, df = 8 (P = 0.17); IÂ² = 31%). The study excluded from this metaâanalysis found no difference between baclofen and placebo (MD â0.53, 95% CI â3.11 to 2.05; 30 participants; <a href="./references#CD012557-bbs2-0014" title="BollingerJ , EdwardsSM , ZywiakWK , TideyJW , SwiftRW , KennaGA , et al. A double-blind, placebo-controlled randomized pilot study of the effects of baclofen on alcohol-tobacco co-use and alcohol cue-reactivity in alcoholic smokers. Clinical and Translational Science2014;7(3):265. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW , et al. Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Erratum for: Neuropsychopharmacology. 2014 Dec;39 Suppl 1:S1-647. Neuropsychopharmacology2015;40(6):1560. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW . Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Neuropsychopharmacology2014;39:S340. LeggioL , ZywiakWH , EdwardsSM , TideyJW , SwiftRM , KennaGA . A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology2015;232(1):233-43. [DOI: 10.1007/s00213-014-3652-9]">Leggio 2015</a>). </p> <section id="CD012557-sec-0075"> <h6 class="title">1.4.1 Subgroup analyses: daily doses of baclofen</h6> <p>We found no differences between baclofen and placebo among studies using low and medium doses (low: MD â0.06, 95% CI â1.33 to 1.22; moderate heterogeneity (ChiÂ² = 7.39, df = 4 (P = 0.12); IÂ² = 46%); 5 studies, 242 participants; medium: MD â0.64, 95% CI â1.95 to 0.68; IÂ² = 27%; 4 studies, 150 participants; <a href="./references#CD012557-fig-0046" title="">Analysis 2.4</a>). No study using high doses provided data on this outcome. </p> </section> <section id="CD012557-sec-0076"> <h6 class="title">1.4.2 Subgroup analyses: duration of treatment</h6> <p>We found no difference between baclofen and placebo among 12âweek and longer than 12âweek studies (12 weeks: MD â0.36, 95% CI â1.29 to 0.57; moderate heterogeneity (ChiÂ² = 11.07, df = 6 (P = 0.09); IÂ² = 46%); 7 studies, 272 participants; longer than 12 weeks: MD â0.49, 95% CI â2.31 to 1.32; IÂ² = 0%; 2 studies, 120 participants; <a href="./references#CD012557-fig-0053" title="">Analysis 3.4</a>). </p> </section> <section id="CD012557-sec-0077"> <h6 class="title">1.4.3 Subgroup analyses: consumption of alcohol at beginning of treatment</h6> <p>We found no differences between baclofen and placebo among studies with detoxified and nonâdetoxified participants (detoxified: MD â0.36, 95% CI â1.29 to 0.57; moderate heterogeneity (ChiÂ² = 11.07, df = 6 (P = 0.09); IÂ² = 46%); 7 studies, 272 participants; nonâdetoxified: MD â0.49, 95% CI â2.31 to 1.32; IÂ² = 0%; 2 studies, 120 participants; <a href="./references#CD012557-fig-0060" title="">Analysis 4.4</a>). </p> </section> </section> <section id="CD012557-sec-0078"> <h5 class="title">1.5 Adverse events: number of participants with at least one adverse event at end of treatment </h5> <p>We identified 10 studies involving 738 participants reporting the number of participants with at least one adverse event at the end of treatment. There was no difference between baclofen and placebo (RR 1.05, 95% CI 0.99 to 1.11; highâcertainty evidence; <a href="./references#CD012557-fig-0013" title="">Analysis 1.5</a>; <a href="./full#CD012557-tbl-0001">summary of findings Table 1</a>). There was no important heterogeneity (ChiÂ² = 7.06, df = 9 (P = 0.63); IÂ² = 0%). The study excluded from this metaâanalysis found no difference between baclofen and placebo (RR 1.15, 95% CI 0.91 to 1.44; 30 participants; <a href="./references#CD012557-bbs2-0014" title="BollingerJ , EdwardsSM , ZywiakWK , TideyJW , SwiftRW , KennaGA , et al. A double-blind, placebo-controlled randomized pilot study of the effects of baclofen on alcohol-tobacco co-use and alcohol cue-reactivity in alcoholic smokers. Clinical and Translational Science2014;7(3):265. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW , et al. Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Erratum for: Neuropsychopharmacology. 2014 Dec;39 Suppl 1:S1-647. Neuropsychopharmacology2015;40(6):1560. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW . Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Neuropsychopharmacology2014;39:S340. LeggioL , ZywiakWH , EdwardsSM , TideyJW , SwiftRM , KennaGA . A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology2015;232(1):233-43. [DOI: 10.1007/s00213-014-3652-9]">Leggio 2015</a>). </p> <section id="CD012557-sec-0079"> <h6 class="title">1.5.1 Subgroup analyses: daily doses of baclofen</h6> <p>We identified no differences between baclofen and placebo among studies using low, medium and high doses (low: RR 1.23, 95% CI 0.92 to 1.64; IÂ² = 0%; 5 studies, 260 participants; medium: RR 0.90, 95% CI 0.63 to 1.28; IÂ² = 0%; 4 studies, 162 participants; high: RR 1.05, 95% CI 0.99 to 1.11; 1 study, 316 participants; <a href="./references#CD012557-fig-0047" title="">Analysis 2.5</a>). </p> </section> <section id="CD012557-sec-0080"> <h6 class="title">1.5.2 Subgroup analyses: duration of treatment</h6> <p>We found no differences between baclofen and placebo among 12âweek and longer than 12âweek studies (12 weeks: RR 0.99, 95% CI 0.70 to 1.39; IÂ² = 0%; 7 studies, 302 participants; longer than 12 weeks: RR 1.05, 95% CI 1.00 to 1.11; IÂ² = 0%; 3 studies, 436 participants; <a href="./references#CD012557-fig-0054" title="">Analysis 3.5</a>). </p> </section> <section id="CD012557-sec-0081"> <h6 class="title">1.5.3 Subgroup analyses: consumption of alcohol at beginning of treatment</h6> <p>We found no differences between baclofen and placebo among studies with detoxified and nonâdetoxified participants (detoxified: RR 1.05, 95% CI 0.99 to 1.11; IÂ² = 0%; 7 studies, 578 participants; nonâdetoxified: RR 1.11, 95% CI 0.84 to 1.45; IÂ² = 0%; 3 studies, 160 participants; <a href="./references#CD012557-fig-0061" title="">Analysis 4.5</a>). </p> </section> </section> <section id="CD012557-sec-0082"> <h5 class="title">1.6 Dropouts at end of treatment</h5> <p>We identified 17 studies involving 1563 participants reporting dropouts at the end of treatment. There was no difference between baclofen and placebo (RR 0.88, 95% CI 0.74 to 1.03; highâcertainty evidence; <a href="./references#CD012557-fig-0014" title="">Analysis 1.6</a>; <a href="#CD012557-fig-0007">Figure 7</a>; <a href="./full#CD012557-tbl-0001">summary of findings Table 1</a>). There was no important heterogeneity (ChiÂ² = 19.55, df = 16 (P = 0.24); IÂ² = 18%). The study excluded from this metaâanalysis found no difference between baclofen and placebo (RR 0.50, 95% CI 0.11 to 2.33; 30 participants; <a href="./references#CD012557-bbs2-0014" title="BollingerJ , EdwardsSM , ZywiakWK , TideyJW , SwiftRW , KennaGA , et al. A double-blind, placebo-controlled randomized pilot study of the effects of baclofen on alcohol-tobacco co-use and alcohol cue-reactivity in alcoholic smokers. Clinical and Translational Science2014;7(3):265. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW , et al. Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Erratum for: Neuropsychopharmacology. 2014 Dec;39 Suppl 1:S1-647. Neuropsychopharmacology2015;40(6):1560. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW . Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Neuropsychopharmacology2014;39:S340. LeggioL , ZywiakWH , EdwardsSM , TideyJW , SwiftRM , KennaGA . A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology2015;232(1):233-43. [DOI: 10.1007/s00213-014-3652-9]">Leggio 2015</a>). </p> <div class="figure" id="CD012557-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="original image" data-id="CD012557-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <section id="CD012557-sec-0083"> <h6 class="title">1.6.1 Subgroup analyses: daily doses of baclofen</h6> <p>We found no differences between baclofen and placebo among studies using low and medium doses (low: RR 0.96, 95% CI 0.70 to 1.32; IÂ² = 16%; 8 studies, 564 participants; medium: RR 1.03, 95% CI 0.65 to 1.61; IÂ² = 19%; 5 studies, 214 participants). Baclofen decreased the number of dropouts at the end of treatment compared with placebo among the studies using high doses (RR 0.76, 95% CI 0.67 to 0.87; IÂ² = 0%; 4 studies, 785 participants; <a href="./references#CD012557-fig-0048" title="">Analysis 2.6</a>). </p> </section> <section id="CD012557-sec-0084"> <h6 class="title">1.6.2 Subgroup analyses: duration of treatment</h6> <p>We found no differences between baclofen and placebo among 12âweek studies (RR 0.98, 95% CI 0.73 to 1.31; IÂ² = 13%; 11 studies, 652 participants; <a href="./references#CD012557-fig-0055" title="">Analysis 3.6</a>). Baclofen decreased the number of dropouts at the end of treatment compared with placebo in longer than 12âweek studies (RR 0.78, 95% CI 0.69 to 0.88; IÂ² = 0%; 6 studies, 911 participants; <a href="./references#CD012557-fig-0055" title="">Analysis 3.6</a>). </p> </section> <section id="CD012557-sec-0085"> <h6 class="title">1.6.3 Subgroup analyses: consumption of alcohol at beginning of treatment</h6> <p>There were no differences between baclofen and placebo among studies with detoxified and nonâdetoxified participants (detoxified: RR 0.87, 95% CI 0.71 to 1.07; IÂ² = 0%; 12 studies, 879 participants; nonâdetoxified: RR 0.93, 95% CI 0.69 to 1.28; moderate heterogeneity (ChiÂ² = 8.28, df = 4 (P = 0.08); IÂ² = 52%); 5 studies, 684 participants; <a href="./references#CD012557-fig-0062" title="">Analysis 4.6</a>). </p> </section> </section> <section id="CD012557-sec-0086"> <h5 class="title">1.7 Dropouts from treatment due to adverse events</h5> <p>We identified 16 studies involving 1499 participants reporting dropouts from treatment due to adverse events. There was no difference between baclofen and placebo (RR 1.39, 95% CI 0.89 to 2.18; highâcertainty evidence; <a href="./references#CD012557-fig-0015" title="">Analysis 1.7</a> and <a href="#CD012557-fig-0008">Figure 8</a>; <a href="./full#CD012557-tbl-0001">summary of findings Table 1</a>). There was no important heterogeneity (ChiÂ² = 7.55, df = 10 (P = 0.67); IÂ² = 0%). The study excluded from this metaâanalysis found zero events in both groups (RR not estimable; <a href="./references#CD012557-bbs2-0014" title="BollingerJ , EdwardsSM , ZywiakWK , TideyJW , SwiftRW , KennaGA , et al. A double-blind, placebo-controlled randomized pilot study of the effects of baclofen on alcohol-tobacco co-use and alcohol cue-reactivity in alcoholic smokers. Clinical and Translational Science2014;7(3):265. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW , et al. Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Erratum for: Neuropsychopharmacology. 2014 Dec;39 Suppl 1:S1-647. Neuropsychopharmacology2015;40(6):1560. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW . Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Neuropsychopharmacology2014;39:S340. LeggioL , ZywiakWH , EdwardsSM , TideyJW , SwiftRM , KennaGA . A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology2015;232(1):233-43. [DOI: 10.1007/s00213-014-3652-9]">Leggio 2015</a>). </p> <div class="figure" id="CD012557-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="original image" data-id="CD012557-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-FIG-08.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <section id="CD012557-sec-0087"> <h6 class="title">1.7.1 Subgroup analyses: daily doses of baclofen</h6> <p>We found no differences between baclofen and placebo among studies using low, medium and high doses (low: RR 1.81, 95% CI 0.61 to 5.32; IÂ² = 0%; 8 studies, 564 participants; medium: RR 6.11, 95% CI 0.82 to 42.25; IÂ² = 0%; 4 studies, 150 participants; high: RR 1.21, 95% CI 0.68 to 2.13; IÂ² = 13%; 4 studies, 785 participants; <a href="./references#CD012557-fig-0049" title="">Analysis 2.7</a>). </p> </section> <section id="CD012557-sec-0088"> <h6 class="title">1.7.2 Subgroup analyses: duration of treatment</h6> <p>We found no differences between baclofen and placebo among 12âweek and longer than 12âweek studies (12 weeks: RR 3.00, 95% CI 0.93 to 9.66; IÂ² = 0%; 10 studies, 588 participants; longer than 12âweeks: RR 1.22, 95% CI 0.76 to 1.98; IÂ² = 0%; 6 studies, 911 participants; <a href="./references#CD012557-fig-0056" title="">Analysis 3.7</a>). </p> </section> <section id="CD012557-sec-0089"> <h6 class="title">1.7.3 Subgroup analyses: consumption of alcohol at beginning of treatment</h6> <p>We found no differences between baclofen and placebo among studies with detoxified and nonâdetoxified participants (toxified: RR 1.08, 95% CI 0.59 to 1.98; IÂ² = 0%; 12 studies, 879 participants; nonâdetoxified: RR 1.87, 95% CI 0.97 to 3.61; IÂ² = 0%; 4 studies, 620 participants; <a href="./references#CD012557-fig-0063" title="">Analysis 4.7</a>). </p> </section> </section> <section id="CD012557-sec-0090"> <h5 class="title">1.8 Craving</h5> <p>We identified 17 studies with 1275 people reporting cravings. There was no difference between baclofen and placebo (SMD â0.16, 95% CI â0.37 to 0.04). Heterogeneity was substantial (ChiÂ² = 39.36, df = 15 (P &lt; 0.001); IÂ² = 62%; <a href="./references#CD012557-fig-0016" title="">Analysis 1.8</a>). </p> </section> <section id="CD012557-sec-0091"> <h5 class="title">1.9 Anxiety</h5> <p>We identified 15 studies with 1123 participants reporting anxiety. There was no difference between baclofen and placebo (SMD â0.01, 95% CI â0.14 to 0.11; <a href="./references#CD012557-fig-0017" title="">Analysis 1.9</a>). </p> </section> <section id="CD012557-sec-0092"> <h5 class="title">1.10 Depression</h5> <p>We identified 11 studies with 1029 participants reporting depression. There was no difference between baclofen and placebo (SMD 0.07, 95% CI â0.12 to 0.27; <a href="./references#CD012557-fig-0018" title="">Analysis 1.10</a>). </p> </section> <section id="CD012557-sec-0093"> <h5 class="title">1.11 Adverse events: fatigue, tiredness</h5> <p>We identified 13 studies involving 1311 participants. Baclofen increased the frequency of fatigue or tiredness (or both) compared with placebo (RR 1.31, 95% CI 1.09 to 1.59; <a href="./references#CD012557-fig-0019" title="">Analysis 1.11</a>). </p> </section> <section id="CD012557-sec-0094"> <h5 class="title">1.12 Adverse events: insomnia</h5> <p>We identified 11 studies with 1100 participants reporting insomnia. There was no difference between baclofen and placebo (RR 0.92, 95% CI 0.62 to 1.35; <a href="./references#CD012557-fig-0020" title="">Analysis 1.12</a>). </p> </section> <section id="CD012557-sec-0095"> <h5 class="title">1.13 Adverse events: pain (diverse)</h5> <p>We identified three studies with 98 participants reporting pain. There was no difference between baclofen and placebo (RR 0.51, 95% CI 0.19 to 1.33; <a href="./references#CD012557-fig-0021" title="">Analysis 1.13</a>). </p> </section> <section id="CD012557-sec-0096"> <h5 class="title">1.14 Adverse events: vertigo, dizziness</h5> <p>We identified 15 studies with 1415 participants. Baclofen increased the frequency of vertigo compared with placebo (RR 1.70, 95% CI 1.35 to 2.13; <a href="./references#CD012557-fig-0022" title="">Analysis 1.14</a>). </p> </section> <section id="CD012557-sec-0097"> <h5 class="title">1.15 Adverse events: constipation</h5> <p>We identified 11 studies with 1124 participants reporting constipation. There was no difference between baclofen and placebo (RR 0.95, 95% CI 0.61 to 1.47; <a href="./references#CD012557-fig-0023" title="">Analysis 1.15</a>). </p> </section> <section id="CD012557-sec-0098"> <h5 class="title">1.16 Adverse events: somnolence, sleepiness, drowsiness or sedation</h5> <p>We identified 17 studies with 1543 participants. Baclofen increased the frequency of somnolence compared with placebo (RR 1.36, 95% CI 1.19 to 1.56; <a href="./references#CD012557-fig-0024" title="">Analysis 1.16</a>). </p> </section> <section id="CD012557-sec-0099"> <h5 class="title">1.17 Adverse events: muscle pain</h5> <p>We identified five studies with 594 participants reporting muscle pain. There was no difference between baclofen and placebo (RR 0.93, 95% CI 0.38 to 2.25; <a href="./references#CD012557-fig-0025" title="">Analysis 1.17</a>). </p> </section> <section id="CD012557-sec-0100"> <h5 class="title">1.18 Adverse events: dry mouth</h5> <p>We identified eight studies with 933 participants. Baclofen increased the frequency of dry mouth compared with placebo (RR 1.79, 95% CI 1.01 to 3.18; <a href="./references#CD012557-fig-0026" title="">Analysis 1.18</a>). </p> </section> <section id="CD012557-sec-0101"> <h5 class="title">1.19 Adverse events: nausea</h5> <p>We identified 10 studies with 1060 participants reporting nausea. There was no difference between baclofen and placebo (RR 1.17, 95% CI 0.88 to 1.54; <a href="./references#CD012557-fig-0027" title="">Analysis 1.19</a>). </p> </section> <section id="CD012557-sec-0102"> <h5 class="title">1.20 Adverse events: skin rash</h5> <p>We identified seven studies with 446 participants reporting skin rash. There was no difference between baclofen and placebo (RR 0.80, 95% CI 0.33 to 1.93; <a href="./references#CD012557-fig-0028" title="">Analysis 1.20</a>). </p> </section> <section id="CD012557-sec-0103"> <h5 class="title">1.21 Adverse events: headaches</h5> <p>We identified 13 studies with 1304 participants. Baclofen increased the frequency of headaches compared with placebo (RR 1.31, 95% CI 1.04 to 1.64; <a href="./references#CD012557-fig-0029" title="">Analysis 1.21</a>). </p> </section> <section id="CD012557-sec-0104"> <h5 class="title">1.22 Adverse events: paraesthesia/numbness</h5> <p>We identified six studies with 914 participants. Baclofen increased the frequency of paraesthesia (RR 2.87, 95% CI 1.17 to 7.06; <a href="./references#CD012557-fig-0030" title="">Analysis 1.22</a>). </p> </section> <section id="CD012557-sec-0105"> <h5 class="title">1.23 Adverse events: diarrhoea</h5> <p>We identified three studies with 816 participants. There was no difference between baclofen and placebo (RR 0.64, 95% CI 0.40 to 1.02; <a href="./references#CD012557-fig-0031" title="">Analysis 1.23</a>). </p> </section> <section id="CD012557-sec-0106"> <h5 class="title">1.24 Adverse events: tinnitus</h5> <p>We identified two studies with 496 participants reporting tinnitus. There was no difference between baclofen and placebo (RR 1.77, 95% CI 0.16 to 20.16). Heterogeneity was considerable (ChiÂ² = 8.44, df = 1 (P = 0.004); IÂ² = 88%; <a href="./references#CD012557-fig-0032" title="">Analysis 1.24</a>). </p> </section> <section id="CD012557-sec-0107"> <h5 class="title">1.25 Adverse events: muscle spasm/rigidity</h5> <p>We identified three studies with 552 participants. Baclofen increased the frequency of muscle spasm (RR 1.94, 95% CI 1.07 to 3.52; <a href="./references#CD012557-fig-0033" title="">Analysis 1.25</a>). </p> </section> <section id="CD012557-sec-0108"> <h5 class="title">1.26 Adverse events: hyperhidrosis</h5> <p>We identified three studies with 816 participants reporting hyperhidrosis. There was no difference between baclofen and placebo (RR 1.50, 95% CI 0.89 to 2.51; <a href="./references#CD012557-fig-0034" title="">Analysis 1.26</a>). </p> </section> <section id="CD012557-sec-0109"> <h5 class="title">1.27 Adverse events: nasopharyngitis</h5> <p>We identified four studies with 872 participants reporting nasopharyngitis. There was no difference between baclofen and placebo (RR 0.89, 95% CI 0.40 to 1.95). Heterogeneity was considerable (ChiÂ² = 7.53, df = 3 (P = 0.06); IÂ² = 60%; <a href="./references#CD012557-fig-0035" title="">Analysis 1.27</a>). </p> </section> <section id="CD012557-sec-0110"> <h5 class="title">1.28 Adverse events: decreased appetite/anorexia</h5> <p>We identified three studies with 816 participants reporting decreased appetite/anorexia. There was no difference baclofen and placebo (RR 0.74, 95% CI 0.31 to 1.75). Heterogeneity was substantial (ChiÂ² = 5.16, df = 2 (P = 0.08); IÂ² = 61%; <a href="./references#CD012557-fig-0036" title="">Analysis 1.28</a>). </p> </section> <section id="CD012557-sec-0111"> <h5 class="title">1.29 Adverse events: dysgeusia/ageusia</h5> <p>We identified three studies with 816 participants reporting dysgeusia/ageusia. There was no difference between baclofen and placebo (RR 1.73, 95% CI 0.57 to 5.24). Heterogeneity was moderate (ChiÂ² = 3.65, df = 2 (P = 0.16); IÂ² = 45%; <a href="./references#CD012557-fig-0037" title="">Analysis 1.29</a>). </p> </section> <section id="CD012557-sec-0112"> <h5 class="title">1.30 Adverse events: tremor</h5> <p>We identified three studies with 816 participants reporting tremor. There was no difference between baclofen and placebo (RR 0.69, 95% CI 0.42 to 1.15; <a href="./references#CD012557-fig-0038" title="">Analysis 1.30</a>). </p> </section> <section id="CD012557-sec-0113"> <h5 class="title">1.31 Adverse events: weakness</h5> <p>We identified three studies with 552 participants reporting weakness. There was no difference between baclofen and placebo (RR 1.19, 95% CI 0.70 to 2.01; <a href="./references#CD012557-fig-0039" title="">Analysis 1.31</a>). </p> </section> <section id="CD012557-sec-0114"> <h5 class="title">1.32 Adverse events: vomiting</h5> <p>We identified three studies with 816 participants reporting vomiting. There was no difference between baclofen and placebo (RR 1.07, 95% CI 0.66 to 1.71; <a href="./references#CD012557-fig-0040" title="">Analysis 1.32</a>). </p> </section> <section id="CD012557-sec-0115"> <h5 class="title">1.33 Adverse events: urinary frequency</h5> <p>We identified four studies with 340 participants reporting urinary frequency. There was no difference between baclofen and placebo (RR 1.10, 95% CI 0.45 to 2.68; <a href="./references#CD012557-fig-0041" title="">Analysis 1.33</a>). </p> </section> <section id="CD012557-sec-0116"> <h5 class="title">1.34 Adverse events: shortness of breath</h5> <p>We identified two studies with 104 participants reporting shortness of breath. There was no difference between baclofen and placebo (RR 0.89, 95% CI 0.04 to 22.31; <a href="./references#CD012557-fig-0042" title="">Analysis 1.34</a>). </p> </section> </section> <section id="CD012557-sec-0117"> <h4 class="title">Comparison 2: baclofen versus acamprosate</h4> <p>Two RCTs compared baclofen to acamprosate (<a href="./references#CD012557-bbs2-0013" title="KumarA , SharmaA , BansalPD , BahetraM , GillHK , KumarR . A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. Indian Journal of Psychiatry2020;62(6):650-8. ">Kumar 2020a</a>; <a href="./references#CD012557-bbs2-0015" title="MishraSN , SwainSP , ShuklaRK , SarkarP . A study of comparative efficacy of baclofen vs acamprosate in reducing alcohol craving and abuse. Orissa Journal of Psychiatry2010;-:48-53. ">Mishra 2010</a>). </p> <section id="CD012557-sec-0118"> <h5 class="title">2.1 Relapse: return to any drinking at end of treatment</h5> <p>We identified one study with 60 participants reporting return to any drinking at the end of treatment. There was no difference between baclofen and acamprosate (RR 1.25, 95% CI 0.71 to 2.20; very lowâcertainty evidence; <a href="./references#CD012557-fig-0064" title="">Analysis 5.1</a>; <a href="./full#CD012557-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD012557-sec-0119"> <h5 class="title">2.2 Adverse events: number of participants with at least one adverse event at end of treatment </h5> <p>We identified one study with 60 participants reporting number of participants with at least one adverse event at the end of treatment. There was no difference between baclofen and acamprosate (RR 0.63, 95% CI 0.23 to 1.69; very lowâcertainty evidence; <a href="./references#CD012557-fig-0065" title="">Analysis 5.2</a>; <a href="./full#CD012557-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD012557-sec-0120"> <h5 class="title">2.3 Dropouts at end of treatment</h5> <p>We identified one study with 60 participants reporting dropouts at the end of treatment. There was no difference between baclofen and acamprosate (RR 0.56, 95% CI 0.21 to 1.46; very lowâcertainty evidence; <a href="./references#CD012557-fig-0066" title="">Analysis 5.3</a>; <a href="./full#CD012557-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD012557-sec-0121"> <h5 class="title">2.4 Dropouts due to adverse events</h5> <p>We identified one study with 60 participants reporting dropouts due to adverse events. There was no difference between baclofen and acamprosate (RR 0.33, 95% CI 0.01 to 7.87; very lowâcertainty evidence; <a href="./references#CD012557-fig-0067" title="">Analysis 5.4</a>; <a href="./full#CD012557-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD012557-sec-0122"> <h5 class="title">2.5 Craving</h5> <p>We identified two studies with 109 participants. There was no difference between baclofen and acamprosate (MD 5.80, 95% CI â11.84 to 23.44). Heterogeneity was considerable (ChiÂ² = 38.87, df = 1 (P &lt; 0.001); IÂ² = 97%; <a href="./references#CD012557-fig-0068" title="">Analysis 5.5</a>). </p> </section> <section id="CD012557-sec-0123"> <h5 class="title">2.6 Adverse events: fatigue, tiredness</h5> <p>We identified one study with 60 participants reporting fatigue or tiredness (or both). There was no difference between baclofen and acamprosate (RR 3.00, 95% CI 0.13 to 70.83; <a href="./references#CD012557-fig-0069" title="">Analysis 5.6</a>). </p> </section> <section id="CD012557-sec-0124"> <h5 class="title">2.7 Adverse events: vertigo, dizziness</h5> <p>We identified one study with 60 participants reporting vertigo or dizziness (or both). There was no difference between baclofen and acamprosate (RR 2.00, 95% CI 0.19 to 20.90; <a href="./references#CD012557-fig-0070" title="">Analysis 5.7</a>). </p> </section> <section id="CD012557-sec-0125"> <h5 class="title">2.8 Adverse events: nausea</h5> <p>We identified one study with 60 participants reporting nausea. There was no difference between baclofen and acamprosate (RR 0.33, 95% CI 0.01 to 7.87; <a href="./references#CD012557-fig-0071" title="">Analysis 5.8</a>). </p> </section> <section id="CD012557-sec-0126"> <h5 class="title">2.9 Adverse events: skin rash</h5> <p>We identified one study with 60 participants reporting skin rash. There was no difference between baclofen and acamprosate (RR 0.20, 95% CI 0.01 to 4.00; <a href="./references#CD012557-fig-0072" title="">Analysis 5.9</a>). </p> </section> <section id="CD012557-sec-0127"> <h5 class="title">2.10 Adverse events: decreased appetite/anorexia</h5> <p>We identified one study with 60 participants reporting decreased appetite/anorexia. There was no difference between baclofen and acamprosate (RR 1.00, 95% CI 0.15 to 6.64; <a href="./references#CD012557-fig-0073" title="">Analysis 5.10</a>). </p> </section> <section id="CD012557-sec-0128"> <h5 class="title">2.11 Adverse events: acidity</h5> <p>We identified one study with 60 participants reporting acidity. There was no difference between baclofen and acamprosate (RR 0.33, 95% CI 0.01 to 7.87; <a href="./references#CD012557-fig-0074" title="">Analysis 5.11</a>). </p> </section> <section id="CD012557-sec-0129"> <h5 class="title">2.12 Adverse events: palpitations</h5> <p>We identified one study with 60 participants reporting palpitations. There was no difference between baclofen and acamprosate (RR 0.33, 95% CI 0.01 to 7.87; <a href="./references#CD012557-fig-0075" title="">Analysis 5.12</a>). </p> </section> <section id="CD012557-sec-0130"> <h5 class="title">2.13 Adverse events: tremor</h5> <p>We identified one study with 60 participants reporting tremor (<a href="./references#CD012557-bbs2-0013" title="KumarA , SharmaA , BansalPD , BahetraM , GillHK , KumarR . A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. Indian Journal of Psychiatry2020;62(6):650-8. ">Kumar 2020a</a>). There were no events in either group. </p> </section> <section id="CD012557-sec-0131"> <h5 class="title">2.14 Adverse events: erectile dysfunction</h5> <p>We identified one study with 60 participants reporting erectile dysfunction (<a href="./references#CD012557-bbs2-0013" title="KumarA , SharmaA , BansalPD , BahetraM , GillHK , KumarR . A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. Indian Journal of Psychiatry2020;62(6):650-8. ">Kumar 2020a</a>). There were no events in either group. </p> </section> </section> <section id="CD012557-sec-0132"> <h4 class="title">Comparison 3: baclofen versus naltrexone</h4> <p>Two RCTs compared baclofen to naltrexone (<a href="./references#CD012557-bbs2-0008" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b2</a>; <a href="./references#CD012557-bbs2-0013" title="KumarA , SharmaA , BansalPD , BahetraM , GillHK , KumarR . A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. Indian Journal of Psychiatry2020;62(6):650-8. ">Kumar 2020a</a>). </p> <section id="CD012557-sec-0133"> <h5 class="title">3.1 Relapse: return to any drinking at end of treatment</h5> <p>We identified one study with 60 participants reporting return to any drinking at the end of treatment. Naltrexone reduced the risk of relapse compared to baclofen (RR 2.50, 95% CI 1.12 to 5.56; very lowâcertainty evidence; <a href="./references#CD012557-fig-0076" title="">Analysis 6.1</a>; <a href="./full#CD012557-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD012557-sec-0134"> <h5 class="title">3.2 Frequency of use: percentage of days abstinent at end of treatment</h5> <p>We identified one study with 20 participants (<a href="./references#CD012557-bbs2-0007" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b1</a>). The percentage of days abstinent at the of treatment was 55.4% with baclofen and 33.4% with placebo. Standard deviations were not reported. </p> </section> <section id="CD012557-sec-0135"> <h5 class="title">3.3 Frequency of use: percentage of heavy drinking days at end of treatment</h5> <p>We identified one study with 20 participants (<a href="./references#CD012557-bbs2-0007" title="GarbuttJC , Kalka-JuhlL , Kampov-PolevoyAB , WellsS , NicholasL , GallopR , et al. Feasibility and tolerability of a combination of naltrexone and baclofen for alcohol dependence: a pilot study. Alcoholism: Clinical and Experimental Research2010;34(6):178A. ">Garbutt 2010b1</a>). The percentage of HDDs at the end of treatment was 17.9% with baclofen and 10.7% with placebo. Standard deviations were not reported. </p> </section> <section id="CD012557-sec-0136"> <h5 class="title">3.4 Adverse events: number of participants with at least one adverse event at end of treatment </h5> <p>We identified two studies with 80 participants. Naltrexone may increase the risk of adverse events slightly compared to baclofen (RR 0.35, 95% CI 0.15 to 0.80; very lowâcertainty evidence; <a href="./full#CD012557-tbl-0003">summary of findings Table 3</a>). There was no heterogeneity (ChiÂ² = 0.73, df = 1 (P = 0.39); IÂ² = 0%; <a href="./references#CD012557-fig-0077" title="">Analysis 6.2</a>). </p> </section> <section id="CD012557-sec-0137"> <h5 class="title">3.5 Dropouts at end of treatment</h5> <p>We identified one study with 60 participants. There was no difference between baclofen and naltrexone (RR 1.00, 95% CI 0.32 to 3.10; very lowâcertainty evidence; see <a href="./full#CD012557-tbl-0003">summary of findings Table 3</a>). There was no heterogeneity (ChiÂ² = 0.73, df = 1 (P = 0.39); IÂ² = 0%; <a href="./references#CD012557-fig-0078" title="">Analysis 6.3</a>). </p> </section> <section id="CD012557-sec-0138"> <h5 class="title">3.6 Dropouts due to adverse events</h5> <p>We identified one study with 60 participants (<a href="./references#CD012557-bbs2-0013" title="KumarA , SharmaA , BansalPD , BahetraM , GillHK , KumarR . A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. Indian Journal of Psychiatry2020;62(6):650-8. ">Kumar 2020a</a>). There were no dropouts in either group. </p> </section> <section id="CD012557-sec-0139"> <h5 class="title">3.7 Craving</h5> <p>We identified one study with 60 participants reporting cravings. There was no difference between baclofen and naltrexone (MD 2.08, 95% CI â3.71 to 7.87; <a href="./references#CD012557-fig-0079" title="">Analysis 6.4</a>). </p> </section> <section id="CD012557-sec-0140"> <h5 class="title">3.8 Adverse events: fatigue, tiredness</h5> <p>We identified one study with 60 participants reporting fatigue or tiredness (or both). There was no difference between baclofen and naltrexone (RR 3.00, 95% CI 0.13 to 70.83; <a href="./references#CD012557-fig-0080" title="">Analysis 6.5</a>). </p> </section> <section id="CD012557-sec-0141"> <h5 class="title">3.9 Adverse events: insomnia</h5> <p>We identified one study with 20 participants reporting insomnia. There was no difference between baclofen and naltrexone (RR 0.14, 95% CI 0.01 to 2.45; <a href="./references#CD012557-fig-0081" title="">Analysis 6.6</a>). </p> </section> <section id="CD012557-sec-0142"> <h5 class="title">3.10 Adverse events: vertigo, dizziness</h5> <p>We identified one study with 60 participants reporting vertigo or dizziness or both. There was no difference between baclofen and naltrexone (RR 0.40, 95% CI 0.08 to 1.90; <a href="./references#CD012557-fig-0082" title="">Analysis 6.7</a>). </p> </section> <section id="CD012557-sec-0143"> <h5 class="title">3.11 Adverse events: somnolence, sleepiness, drowsiness or sedation</h5> <p>We identified one study with 20 participants reporting somnolence, sleepiness, drowsiness or sedation. There was no difference between baclofen and naltrexone (RR 0.33, 95% CI 0.04 to 2.69; <a href="./references#CD012557-fig-0083" title="">Analysis 6.8</a>). </p> </section> <section id="CD012557-sec-0144"> <h5 class="title">3.12 Adverse events: nausea</h5> <p>We identified two studies with 80 participants reporting nausea. There was no difference between baclofen and naltrexone (RR 0.26, 95% CI 0.03 to 2.20; <a href="./references#CD012557-fig-0084" title="">Analysis 6.9</a>). </p> </section> <section id="CD012557-sec-0145"> <h5 class="title">3.13 Adverse events: skin rash</h5> <p>We identified one study with 60 participants reporting skin rash (<a href="./references#CD012557-bbs2-0013" title="KumarA , SharmaA , BansalPD , BahetraM , GillHK , KumarR . A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. Indian Journal of Psychiatry2020;62(6):650-8. ">Kumar 2020a</a>). There were no events in either group. </p> </section> <section id="CD012557-sec-0146"> <h5 class="title">3.14 Adverse events: decreased appetite/anorexia</h5> <p>We identified one study with 60 participants. There was no difference between baclofen and naltrexone (RR 2.00, 95% CI 0.19 to 20.90; <a href="./references#CD012557-fig-0085" title="">Analysis 6.10</a>). </p> </section> <section id="CD012557-sec-0147"> <h5 class="title">3.15 Adverse events: tremor</h5> <p>We identified one study with 60 participants reporting tremor. There was no difference between baclofen and naltrexone (RR 0.33, 95% CI 0.01 to 7.87; <a href="./references#CD012557-fig-0086" title="">Analysis 6.11</a>). </p> </section> <section id="CD012557-sec-0148"> <h5 class="title">3.16 Adverse events: acidity</h5> <p>We identified one study with 60 participants reporting acidity. There was no difference between baclofen and naltrexone (RR 0.20, 95% CI 0.01 to 4.00; <a href="./references#CD012557-fig-0087" title="">Analysis 6.12</a>). </p> </section> <section id="CD012557-sec-0149"> <h5 class="title">3.17 Adverse events: palpitations</h5> <p>We identified one study with 60 participants reporting palpitations (<a href="./references#CD012557-bbs2-0013" title="KumarA , SharmaA , BansalPD , BahetraM , GillHK , KumarR . A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. Indian Journal of Psychiatry2020;62(6):650-8. ">Kumar 2020a</a>). There were no events in either group. </p> </section> <section id="CD012557-sec-0150"> <h5 class="title">3.18 Adverse events: erectile dysfunction</h5> <p>We identified one study with 60 participants reporting erectile dysfunction. There was no difference between baclofen and naltrexone (RR 0.33, 95% CI 0.01 to 7.87; <a href="./references#CD012557-fig-0088" title="">Analysis 6.13</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012557-sec-0151" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012557-sec-0151"></div> <section id="CD012557-sec-0152"> <h3 class="title" id="CD012557-sec-0152">Summary of main results</h3> <p>We included 17 RCTs with 1818 participants. Ten RCTs had a single arm and the other 7 RCTs had two arms each. Fifteen RCTs compared baclofen with placebo, two RCTs compared baclofen with acamprosate, and two RCTs compared baclofen with naltrexone. </p> <section id="CD012557-sec-0153"> <h4 class="title">Comparison 1: baclofen versus placebo</h4> <p>In comparison to placebo, metaâanalyses found moderateâcertainty evidence suggesting that baclofen probably reduces the risk to return to any drinking and highâcertainty evidence that it increases the rate of abstinent days at the end of treatment. Subgroup analyses found evidence that baclofen may reduce the risk to return to any drinking among detoxified participants but not among other subgroups of participants. We found evidence that baclofen may increase the rate of abstinent days in all the subgroups of participants except among those who received moderate doses of baclofen. </p> <p>In addition, metaâanalyses found moderateâcertainty evidence suggesting that baclofen probably has no effect in the rate of HDDs and in the number of drinks per drinking days, and highâcertainty evidence that it does not increase the number of participants with at least one adverse event, the number of participants who dropped out for any reason, and those who dropped out due to adverse events at the end of treatment. These results were confirmed in all the subgroup analyses except for dropout that was lower among participants who received high doses of baclofen compared to placebo and among participants recruited to studies longer than 12 weeks. </p> <p>Metaâanalyses of all the studies found no differences between baclofen and placebo in craving, anxiety, and depression. </p> <p>Finally, compared to placebo, baclofen increased the frequency of fatigue, dizziness, somnolence, dry mouth, paraesthesia and muscle spasms while, for all the other adverse events, there were no differences between baclofen and placebo. </p> </section> <section id="CD012557-sec-0154"> <h4 class="title">Comparison 2: baclofen versus acamprosate</h4> <p>Compared to acamprosate, metaâanalyses found no differences in any primary outcome evaluated: relapse, number of participants with at least one adverse event, dropouts, dropouts due to adverse events (very lowâcertainty evidence). We found no differences between baclofen and acamprosate in craving and nine different adverse events. However, most of these metaâanalyses were based on a single study with 60 participants, so should be interpreted with caution. </p> </section> <section id="CD012557-sec-0155"> <h4 class="title">Comparison 3: baclofen versus naltrexone</h4> <p>Compared to naltrexone, metaâanalyses found very lowâcertainty evidence that baclofen may increase the risk of relapse and decrease slightly the number of participants with at least one adverse event. We found no differences between the treatments in dropouts at the end of treatment (very lowâcertainty evidence), craving, and 11 different adverse events. However, for most of these metaâanalyses, results were based on a single study of 60 participants, so should be interpreted with caution. </p> </section> </section> <section id="CD012557-sec-0156"> <h3 class="title" id="CD012557-sec-0156">Overall completeness and applicability of evidence</h3> <section id="CD012557-sec-0157"> <h4 class="title">Overall completeness</h4> <p>In this review, the completeness rates of the analyses of primary outcomes range from 36% to 86%. In detail, considering that our database comprised 14 RCTs (after the exclusion of one study because of heterogeneity), the completeness rates of primary outcome analyses were the following: relapse (return to any drinking): 8 RCTs (57.1%); percentage of days abstinent: 11 RCTs (78.6%); HDDs: 9 RCTs (64.3%); number of drinks per drinking day: 5 RCTs (35.7%); number of people with at least one adverse event: 6 RCTs (42.9%); dropouts from treatment: 12 RCTs (85.7%); and dropouts due to adverse events: 11 RCTs (78.6%). The completeness rates of the analyses of secondary outcomes ranged from 7.1% (shortness of breath; 1 RCT) to 85.7% (sedation; 12 RCTs). The completeness rates of primary outcomes overlap those of other Cochrane Reviews on other medications for the treatment of AUD reflecting the large variety of outcomes used to evaluate the effectiveness of treatments in the field of AUD research (<a href="./references#CD012557-bbs2-0133" title="RÃ¶snerS , Hackl-HerrwerthA , LeuchtS , LehertP , VecchiS , SoykaM . Acamprosate for alcohol dependence. Cochrane Database of Systematic Reviews2010, Issue 9. Art. No: CD004332. [DOI: 10.1002/14651858.CD004332.pub2]">RÃ¶sner 2010a</a>; <a href="./references#CD012557-bbs2-0134" title="RÃ¶snerS , Hackl-HerrwerthA , LeuchtS , VecchiS , SrisurapanontM , SoykaM . Opioid antagonists for alcohol dependence. Cochrane Database of Systematic Reviews2010, Issue 12. Art. No: CD001867. [DOI: 10.1002/14651858.CD001867.pub3]">RÃ¶sner 2010b</a>). Despite this large variety, the present review achieves a good overall completeness. The larger range of completeness of secondary outcomes was mainly due to the inclusion of rare specific adverse event (e.g. shortness of breath) into the list of secondary outcomes. </p> </section> <section id="CD012557-sec-0158"> <h4 class="title">Applicability of evidence</h4> <p>The RCTs included in this review largely vary in the daily dose of baclofen, titration schedules, duration of treatment, comorbidity, and baseline alcohol use. Despite these differences among RCTs and their participants, metaâanalyses including all the selected RCTs found moderateâcertainty evidence that baclofen reduces the risk of relapse and subgroup analyses confirmed this evidence among certain participants (i.e. detoxified participants) but not others (nonâdetoxified participants). Similarly, including all the RCTs, this review found highâcertainty evidence that baclofen increases the rate of abstinent days and subgroup analyses confirmed this evidence among almost all the subgroup analyses. Finally, this review found moderateâ to highâcertainty evidence that baclofen probably has no effect in the other primary outcomes (HDDs, drinks per drinking days, participants with at least one adverse event, participants who dropout for any reason, participants who dropped out due to adverse events) and this evidence was confirmed by almost all the subgroup analyses. Globally, subgroup analyses sustained the generalisability of the evidence of the demonstrated results. </p> <p>In addition, RCTs selected by this review took place in different countries including the USA (29.4%); Australia, France, Italy and India (11.8% each); and Germany, Israel, the Netherlands and Russia (5.9% each). This is an important issue in terms of generalisability of the evidence, because different social contexts can influence AUD severity and the availability to receive medical treatment for this disorder. </p> <p>However, generalisability might be restricted from the exclusion of participants with severe psychiatric disorders by most of the selected RCTs. Furthermore, this review found that baclofen increased the risk of adverse events such as fatigue, dizziness and somnolence but did not increase the number of participants with at least one adverse event. Subgroup analyses indicated that no daily dose of baclofen increased the number of participants with at least one adverse event. However, the subgroup of high doses included only one large RCT (<a href="./references#CD012557-bbs2-0022" title="PouchainD . A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients. The Alpadir study. Exercer-La Revue Francophone De Medecine Generale2018;142:163-5. ReynaudM , AubinHJ , TrinquetF , ZakineB , DanoC , DematteisM , et al. A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients â the ALPADIR Study. Alcohol and Alcoholism2017;52(4):439-46. ">Reynaud 2017</a>). These findings underline the paucity of literature for some important outcomes. Nevertheless, our findings do not allow conclusions on the safety of baclofen in combination with other sedative drugs (e.g. alcohol and benzodiazepines) or in specific patient subgroups, such as people with suicidal ideation (e.g. <a href="./references#CD012557-bbs2-0038" title="AgabioR , SinclairJM , AddoloratoG , AubinHJ , BerahaEM , CaputoF , et al. Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry2018;5(12):957-60. [PMID: 30413394]">Agabio 2018a</a>; <a href="./references#CD012557-bbs2-0062" title="deBeaurepaireR , SinclairJM , HeydtmannM , AddoloratoG , AubinHJ , BerahaEM , et al. The use of baclofen as a treatment for alcohol use disorder: a clinical practice perspective. Frontiers in Psychiatry2019;9:708. [PMID: 30662411]">de Beaurepaire 2019</a>; <a href="./references#CD012557-bbs2-0084" title="HollaB , GowdaGS , PrabhuL , BabyS , ViswanathB , ChandP , et al. High doses of baclofen as suicide attempt in patients with alcohol use disorders â a serious concern. Asian Journal of Psychiatry2015;17:99-100.">Holla 2015</a>; <a href="./references#CD012557-bbs2-0123" title="PelissierF , deHaroL , CardonaF , PicotC , PuskarczykE , SaporiJM , et al. Self-poisoning with baclofen in alcohol-dependent patients: national reports to French Poison Control Centers, 2008â2013. Clinical Toxicology2017;55(4):275-84.">Pelissier 2017</a>). </p> <p>Finally, the results of two recent studies suggest that women may respond better to baclofen for the treatment of AUD than men (<a href="./references#CD012557-bbs2-0009" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âLD</a>; <a href="./references#CD012557-bbs2-0010" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. [PMID: 34155332]NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âMD</a>; <a href="./references#CD012557-bbs2-0116" title="MorleyKC , LouieE , HurzelerT , BaillieA , DoreG , PhungN , et al. Sex as a potential moderator for baclofen response in the treatment of alcohol dependence. Frontiers in Global Women's Health2022;3:807269. [PMID: 35425938]">Morley 2022</a>). In detail, one study observed that, compared to men, women required lower doses of baclofen to increase the rate of abstinent days (<a href="./references#CD012557-bbs2-0009" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âLD</a>; <a href="./references#CD012557-bbs2-0010" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. [PMID: 34155332]NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âMD</a>). Another study found that baclofen delayed the time to the first drink for women with AUD but not men (<a href="./references#CD012557-bbs2-0116" title="MorleyKC , LouieE , HurzelerT , BaillieA , DoreG , PhungN , et al. Sex as a potential moderator for baclofen response in the treatment of alcohol dependence. Frontiers in Global Women's Health2022;3:807269. [PMID: 35425938]">Morley 2022</a>). These results provide some support for the hypothesis that gender may be a potential moderator of baclofen response in the treatment of AUD. Although medications for the treatment of AUD have been studied almost exclusively in men (<a href="./references#CD012557-bbs2-0037" title="AgabioR , PaniPP , PretiA , GessaGL , FranconiF . Efficacy of medications approved for the treatment of alcohol dependence and alcohol withdrawal syndrome in female patients: a descriptive review. European Addiction Research2016;22(1):1-16. [PMID: 26314552]">Agabio 2016</a>), these findings are in line with other studies showing numerous gender differences in response to the other pharmacological treatments (<a href="./references#CD012557-bbs2-0110" title="Mauvais-JarvisF , BertholdHK , CampesiI , CarreroJJ , DakalS , FranconiF , et al. Sex- and gender-based pharmacological response to drugs. Pharmacological Reviews2021;73(2):730-62. [DOI: 10.1124/pharmrev.120.000206]">MauvaisâJarvis 2021</a>). Unfortunately, the generalisability might be restricted as most RCTs did not provide separate data for men and women. </p> </section> </section> <section id="CD012557-sec-0159"> <h3 class="title" id="CD012557-sec-0159">Quality of the evidence</h3> <p>Applying the criteria recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012557-bbs2-0082" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>), we judged most of the RCTs to have a low or unclear risk of selection, performance, detection (subjective outcome), attrition and reporting bias. </p> <p>One potential threat of bias that concerns all RCTs applying inert placebo is the unmasking of blinding, which is a methodological limitation that is associated with an overestimation of effects for antidepressant substances (<a href="./references#CD012557-bbs2-0112" title="MoncrieffJ , WesselyS , HardyR . Active placebos versus antidepressants for depression. Cochrane Database of Systematic Reviews2004, Issue 1. Art. No: CD003012. [DOI: 10.1002/14651858.CD003012.pub2]">Moncrieff 2004</a>). Even though baclofen and placebo were of identical appearance in most RCTs, perceptible differences between treatment groups such as adverse events can reveal participants' affiliation to treatment conditions. Thus, from a theoretical perspective, we could not definitely exclude the possibility that proof of efficacy in some studies is attributable to an overestimation of effects caused by an unmasking of treatment allocation. </p> <p>Overall, we rated the certainty of evidence as high for the outcomes of percentage of days abstinent, participants with at least one adverse event, dropouts due to any reason and dropouts due to adverse events; moderate for relapse to any drinking, HDDs, number of drinks per drinking days and percent days abstinent. Reasons for downgrading were heterogeneity among study for the outcomes relapse and HDDs and inconsistency for the outcome drinks per drinking days. </p> </section> <section id="CD012557-sec-0160"> <h3 class="title" id="CD012557-sec-0160">Potential biases in the review process</h3> <p>To lower the risk of bias in the review process, two review authors independently screened abstracts, assessed full texts, rated risk of bias for included studies and extracted data from primary studies. None of the review authors had any personal, scientific or financial conflicts of interest or expected advantages from significant results in terms of reviewer decisions or raising funds, lowering the risk for confirmation bias (<a href="./references#CD012557-bbs2-0119" title="NickersonRS . Confirmation bias: a ubiquitous phenomenon in many guises. Review of General Psychology1998;2(2):175-220.">Nickerson 1998</a>), and significance bias (<a href="./references#CD012557-bbs2-0089" title="KagerekiE , GakonyoJ , SimilaH . Significance bias: an empirical evaluation of the oral health literature. BMC Oral Health2016;16(1):53.">Kagereki 2016</a>). Visual inspection of funnel plots for the analyses with more than 10 studies showed no asymmetry suggesting the risk of publication bias. Furthermore, we wrote to the authors of published studies and searched on <a href="http://apps.who.int/trialsearch/" target="_blank">ClincialTrials.gov</a> and <a href="http://www.who.int/ictrp/en/" target="_blank">ICTRP</a> to search for unpublished studies to minimise the risk of publication bias. </p> </section> <section id="CD012557-sec-0161"> <h3 class="title" id="CD012557-sec-0161">Agreements and disagreements with other studies or reviews</h3> <p>Compared to the previous Cochrane (<a href="./references#CD012557-bbs2-0160" title="MinozziS , SaulleR , RÃ¶snerS . Baclofen for alcohol use disorder. Cochrane Database of Systematic Reviews2018, Issue 11. Art. No: CD012557. [DOI: 10.1002/14651858.CD012557.pub2]">Minozzi 2018</a>) and nonâCochrane metaâanalyses (<a href="./references#CD012557-bbs2-0041" title="AgabioR , BaldwinDS , AmaroH , LeggioL , SinclairJM . The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: a systematic review and meta-analysis. Neuroscience &amp; Biobehavioral Reviews2021;125:296-313. [PMID: 33454289]">Agabio 2021b</a>; <a href="./references#CD012557-bbs2-0051" title="BschorT , HensslerJ , MÃ¼llerM , BaethgeC . Baclofen for alcohol use disorder â a systematic meta-analysis. Acta Psychiatrica Scandinavica2018;138(3):232-42. [PMID: 29888478]">Bschor 2018</a>; <a href="./references#CD012557-bbs2-0097" title="LesouefN , BelletF , MounierG , BeyensMN . Efficacy of baclofen on abstinence and craving in alcohol-dependent patients: a meta-analysis of randomized controlled trials. Therapie2014;69(5):427-35.">Lesouef 2014</a>; <a href="./references#CD012557-bbs2-0124" title="PierceM , SutterlandA , BerahaEM , MorleyK , vanden BrinkW . Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: a systematic review and meta-analysis. European Neuropsychopharmacology2018;28(7):795-806. [DOI: 10.1016/j.euroneuro.2018.03.017]">Pierce 2018</a>; <a href="./references#CD012557-bbs2-0132" title="RoseAK , JonesA . Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. Addiction2018;113(8):1396-406.">Rose 2018</a>), the present review included four recent RCTs (<a href="./references#CD012557-bbs2-0009" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âLD</a>; <a href="./references#CD012557-bbs2-0010" title="GarbuttJC , Kampov-PolevoyAB , PedersenC , StansburyM , JordanR , WillingL , et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a doseâresponse, randomized, controlled trial. Neuropsychopharmacology2021;46(13):2250-6. [PMID: 34155332]NCT01980706. Efficacy and safety of high-dose baclofen for alcohol dependence. www.clinicaltrials.gov/ct2/show/NCT01980706 (first received 11 November 2013). PedersenCA , Kampov-PolevoiWA , JordanR , CaseyR , TatrauJ , GallopR , et al. Efficacy and tolerability of high-dose baclofen in a U.S. community population: a randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. ">Garbutt 2021âMD</a>; <a href="./references#CD012557-bbs2-0013" title="KumarA , SharmaA , BansalPD , BahetraM , GillHK , KumarR . A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. Indian Journal of Psychiatry2020;62(6):650-8. ">Kumar 2020a</a>; <a href="./references#CD012557-bbs2-0018" title="HengS , JamshidiN , BaillieA , LouieE , DoreG , PhungN , et al. Baclofen response in alcohol dependent patients concurrently receiving antidepressants: secondary analysis from the BacALD study. Frontiers in Psychiatry2018;9:576. LoggeW , BaillieAJ , MorrisRW , HaberPS , MorleyKC . Baclofen reduces alcohol cue-induced fMRI brain activation in treatment seeking alcohol dependent individuals. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. LoggeWB , BaillieAJ , HaberPS , MorleyKC . Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Human Psychopharmacology2020;35(2):e2722. LoggeWB , HaberPS , BaillieAJ , KosinskiP , MorrisRW , FraserI , et al. Dose-specific baclofen effects on brain structure, function and treatment responses: neuroimaging findings from the BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):20A-21A. LoggeWB , MorleyKC , HaberPS , BaillieAJ . Executive functioning moderates responses to appetitive cues: a study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism2019;54(1):38-46. LoggeWB , MorrisRW , BaillieAJ , HaberPS , MorleyKC . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berlin)2021;238(5):1291-302. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Baclofen for treatment of alcohol use disorder: secondary analyses and implications of the Australian BacALD trial. Drug and Alcohol Review2019;38:S75. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Exploration of the modulating role of the GABAb receptor polymorphism rs29220 on response to baclofen in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):41A. MorleyKC , BaillieA , FraserI , Furneaux-BateA , DoreG , RobertsM , et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry2018;212(6):362-9. MorleyKC , LagopoulosJ , LoggeW , BaillieA , AdamsC , HaberPS . Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addiction Biology2020;25(1):e12702. MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55. MorleyKC , LoggeWB , FraserI , MorrisRW , BaillieAJ , HaberPS . High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology2021;46:28-36. MorleyKC , LuquinN , BaillieA , FraserI , TrentRJ , DoreG , et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction2018;113(12):2205-13. MorleyKC , MorrisR , LoggeW , BaillieA , FraserI , HaberPS . Baclofen administration attenuates insula response during anticipatory anxiety in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. MorleyKC , RiordanB , LoggeW , BaillieA , HaberPS . Moderation of baclofen on the daily relationship between craving and alcohol use: results from the Australian BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):53A. MorleyLC , LuquinN , BaillieA , FraserI , TrentR , DoreG , et al. Moderation of baclofen response by a GABAb receptor polymorphism. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. RomboutsSA , BaillieA , HaberPS , MorleyKC . Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD trial. Alcohol and Alcoholism2019;54(3):272-8. ">Morley 2018âLD</a>; <a href="./references#CD012557-bbs2-0019" title="HengS , JamshidiN , BaillieA , LouieE , DoreG , PhungN , et al. Baclofen response in alcohol dependent patients concurrently receiving antidepressants: secondary analysis from the BacALD study. Frontiers in Psychiatry2018;9:576. LoggeW , BaillieAJ , MorrisRW , HaberPS , MorleyKC . Baclofen reduces alcohol cue-induced fMRI brain activation in treatment seeking alcohol dependent individuals. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. LoggeWB , BaillieAJ , HaberPS , MorleyKC . Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Human Psychopharmacology2020;35(2):e2722. LoggeWB , HaberPS , BaillieAJ , KosinskiP , MorrisRW , FraserI , et al. Dose-specific baclofen effects on brain structure, function and treatment responses: neuroimaging findings from the BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):20A-21A. LoggeWB , MorleyKC , HaberPS , BaillieAJ . Executive functioning moderates responses to appetitive cues: a study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism2019;54(1):38-46. LoggeWB , MorrisRW , BaillieAJ , HaberPS , MorleyKC . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berlin)2021;238(5):1291-302. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Baclofen for treatment of alcohol use disorder: secondary analyses and implications of the Australian BacALD trial. Drug and Alcohol Review2019;38:S75. MorleyK , LuquinN , LagopoulosJ , LoggeW , BaillieA , HaberPS . Exploration of the modulating role of the GABAb receptor polymorphism rs29220 on response to baclofen in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):41A. MorleyKC , BaillieA , FraserI , Furneaux-BateA , DoreG , RobertsM , et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry2018;212(6):362-9. MorleyKC , LagopoulosJ , LoggeW , BaillieA , AdamsC , HaberPS . Brain GABA levels are reduced in alcoholic liver disease: a proton magnetic resonance spectroscopy study. Addiction Biology2020;25(1):e12702. MorleyKC , LeungS , BaillieA , HaberPS . The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials2013;36(2):348-55. MorleyKC , LoggeWB , FraserI , MorrisRW , BaillieAJ , HaberPS . High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology2021;46:28-36. MorleyKC , LuquinN , BaillieA , FraserI , TrentRJ , DoreG , et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction2018;113(12):2205-13. MorleyKC , MorrisR , LoggeW , BaillieA , FraserI , HaberPS . Baclofen administration attenuates insula response during anticipatory anxiety in alcohol dependent patients. Alcoholism: Clinical and Experimental Research2018;42(Suppl 1):65A. MorleyKC , RiordanB , LoggeW , BaillieA , HaberPS . Moderation of baclofen on the daily relationship between craving and alcohol use: results from the Australian BacALD trial. Alcoholism: Clinical and Experimental Research2021;45(Suppl 1):53A. RomboutsSA , BaillieA , HaberPS , MorleyKC . Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD Trial. Alcohol and Alcoholism2019;54(3):272-8. ">Morley 2018âMD</a>; <a href="./references#CD012557-bbs2-0023" title="JauryPH . Baclofen for the treatment of alcohol drinkers (Bacloville). Alcoholism: Clinical and Experimental Research2014;38:215a. RigalL , SidorkiewiczS , TrÃ©luyerJM , PerrodeauE , Le JeunneC , PorcherR , et al. Titrated baclofen for high-risk alcohol consumption: a randomized placebo-controlled trial in out-patients with 1-year follow-up. Addiction2020;115(7):1265-76. ">Rigal 2020</a>), and one previously unavailable RCT (<a href="./references#CD012557-bbs2-0002" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , BedogniG , CaputoF , et al. Doseâresponse effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism2011;46(3):312-7. [PMID: 21414953]">Addolorato 2011âLD</a>; <a href="./references#CD012557-bbs2-0003" title="AddoloratoG , LeggioL , FerrulliA , CardoneS , BedogniG , CaputoF , et al. Doseâresponse effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism2011;46(3):312-7. [PMID: 21414953]">Addolorato 2011âMD</a>). </p> <p>The results of the present review suggest that baclofen may reduce the risk to return to any drinking. Other nonâCochrane systematic reviews found that baclofen significantly increases the number of abstinent participants (<a href="./references#CD012557-bbs2-0097" title="LesouefN , BelletF , MounierG , BeyensMN . Efficacy of baclofen on abstinence and craving in alcohol-dependent patients: a meta-analysis of randomized controlled trials. Therapie2014;69(5):427-35.">Lesouef 2014</a>; <a href="./references#CD012557-bbs2-0124" title="PierceM , SutterlandA , BerahaEM , MorleyK , vanden BrinkW . Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: a systematic review and meta-analysis. European Neuropsychopharmacology2018;28(7):795-806. [DOI: 10.1016/j.euroneuro.2018.03.017]">Pierce 2018</a>; <a href="./references#CD012557-bbs2-0132" title="RoseAK , JonesA . Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. Addiction2018;113(8):1396-406.">Rose 2018</a>). As return to any drinking and abstinent participants are complementary outcomes, these results of the present review are in line with those of other systematic reviews. In addition, the present review provides the results of subgroup analyses conducted dividing participants according to the daily dose of baclofen, the duration of the studies and the consumption of alcohol at the beginning of the treatment. These subgroup analyses showed that baclofen probably reduces the risk to return to any drinking (or increases the number of abstinent participants) only among participants already detoxified at the beginning of treatment but not among other subgroups of participants (e.g. participants who were still drinking at the beginning of treatment). </p> <p>The present review found that baclofen increases the rate of abstinent days at the end of treatment while the previous version of this Cochrane Review (<a href="./references#CD012557-bbs2-0160" title="MinozziS , SaulleR , RÃ¶snerS . Baclofen for alcohol use disorder. Cochrane Database of Systematic Reviews2018, Issue 11. Art. No: CD012557. [DOI: 10.1002/14651858.CD012557.pub2]">Minozzi 2018</a>), and many of the nonâCochrane Reviews (<a href="./references#CD012557-bbs2-0051" title="BschorT , HensslerJ , MÃ¼llerM , BaethgeC . Baclofen for alcohol use disorder â a systematic meta-analysis. Acta Psychiatrica Scandinavica2018;138(3):232-42. [PMID: 29888478]">Bschor 2018</a>; <a href="./references#CD012557-bbs2-0097" title="LesouefN , BelletF , MounierG , BeyensMN . Efficacy of baclofen on abstinence and craving in alcohol-dependent patients: a meta-analysis of randomized controlled trials. Therapie2014;69(5):427-35.">Lesouef 2014</a>; <a href="./references#CD012557-bbs2-0124" title="PierceM , SutterlandA , BerahaEM , MorleyK , vanden BrinkW . Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: a systematic review and meta-analysis. European Neuropsychopharmacology2018;28(7):795-806. [DOI: 10.1016/j.euroneuro.2018.03.017]">Pierce 2018</a>; <a href="./references#CD012557-bbs2-0132" title="RoseAK , JonesA . Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. Addiction2018;113(8):1396-406.">Rose 2018</a>), found no differences between baclofen and placebo in this outcome. However, another systematic review found that baclofen may increase the rate of abstinent days (<a href="./references#CD012557-bbs2-0041" title="AgabioR , BaldwinDS , AmaroH , LeggioL , SinclairJM . The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: a systematic review and meta-analysis. Neuroscience &amp; Biobehavioral Reviews2021;125:296-313. [PMID: 33454289]">Agabio 2021b</a>). As this review was aimed at investigating the potential role of anxiety in influencing the effects of baclofen, it included only RCTs that provided anxiety levels of participants both at baseline and at the end of treatment. This review found that baclofen increases the rate of abstinent days only among participants with high anxiety levels and not among participants with low anxiety levels at baseline (<a href="./references#CD012557-bbs2-0041" title="AgabioR , BaldwinDS , AmaroH , LeggioL , SinclairJM . The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: a systematic review and meta-analysis. Neuroscience &amp; Biobehavioral Reviews2021;125:296-313. [PMID: 33454289]">Agabio 2021b</a>). These findings suggest that baclofen may be useful only for certain people with AUD and that treatment should be personalised. </p> <p>The present review found moderateâcertainty evidence of no difference between baclofen and placebo in the number of drinks per drinking days. In the previous version of this review, we found that baclofen increased the number of drinks per drinking days compared to placebo (<a href="./references#CD012557-bbs2-0160" title="MinozziS , SaulleR , RÃ¶snerS . Baclofen for alcohol use disorder. Cochrane Database of Systematic Reviews2018, Issue 11. Art. No: CD012557. [DOI: 10.1002/14651858.CD012557.pub2]">Minozzi 2018</a>). However, this finding was mainly based on one study that we excluded in the present update from the metaâanalyses because of the elevated heterogeneity due to its inclusion and the substantial difference of the participants and setting of this study when compared to the other included studies (<a href="./references#CD012557-bbs2-0014" title="BollingerJ , EdwardsSM , ZywiakWK , TideyJW , SwiftRW , KennaGA , et al. A double-blind, placebo-controlled randomized pilot study of the effects of baclofen on alcohol-tobacco co-use and alcohol cue-reactivity in alcoholic smokers. Clinical and Translational Science2014;7(3):265. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW , et al. Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Erratum for: Neuropsychopharmacology. 2014 Dec;39 Suppl 1:S1-647. Neuropsychopharmacology2015;40(6):1560. FarokhniaM , EdwardsSM , BollingerJ , AmodioJ , ZywiakWH , TideyJW . Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Neuropsychopharmacology2014;39:S340. LeggioL , ZywiakWH , EdwardsSM , TideyJW , SwiftRM , KennaGA . A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology2015;232(1):233-43. [DOI: 10.1007/s00213-014-3652-9]">Leggio 2015</a>). </p> <p>Finally, the present review found no difference between baclofen and placebo in anxiety, depression and anxiety. These findings are in line with those of previous metaâanalyses (<a href="./references#CD012557-bbs2-0041" title="AgabioR , BaldwinDS , AmaroH , LeggioL , SinclairJM . The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: a systematic review and meta-analysis. Neuroscience &amp; Biobehavioral Reviews2021;125:296-313. [PMID: 33454289]">Agabio 2021b</a>; <a href="./references#CD012557-bbs2-0097" title="LesouefN , BelletF , MounierG , BeyensMN . Efficacy of baclofen on abstinence and craving in alcohol-dependent patients: a meta-analysis of randomized controlled trials. Therapie2014;69(5):427-35.">Lesouef 2014</a>; <a href="./references#CD012557-bbs2-0160" title="MinozziS , SaulleR , RÃ¶snerS . Baclofen for alcohol use disorder. Cochrane Database of Systematic Reviews2018, Issue 11. Art. No: CD012557. [DOI: 10.1002/14651858.CD012557.pub2]">Minozzi 2018</a>; <a href="./references#CD012557-bbs2-0132" title="RoseAK , JonesA . Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. Addiction2018;113(8):1396-406.">Rose 2018</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012557-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA study flow diagram." data-id="CD012557-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/full#CD012557-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD012557-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/full#CD012557-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD012557-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/full#CD012557-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-FIG-04" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD012557-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/full#CD012557-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-FIG-05" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD012557-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/full#CD012557-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-FIG-06" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD012557-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/full#CD012557-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-FIG-07" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD012557-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/full#CD012557-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-FIG-08" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD012557-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-FIG-08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/full#CD012557-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-FIG-08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 1: Relapse: return to any drinking at end of treatment" data-id="CD012557-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 1: Relapse: return to any drinking at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 2: Frequency of use: % days abstinence at end of treatment" data-id="CD012557-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 2: Frequency of use: % days abstinence at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 3: Frequency of use: heavy drinking days at end of treatment" data-id="CD012557-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 3: Frequency of use: heavy drinking days at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 4: Amount of use: drinks per drinking days at end of treatment" data-id="CD012557-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 4: Amount of use: drinks per drinking days at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 5: Adverse events: number of participants with at least one adverse event at end of treatment" data-id="CD012557-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 5: Adverse events: number of participants with at least one adverse event at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 6: Dropouts at end of treatment" data-id="CD012557-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 6: Dropouts at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 7: Dropouts due to adverse events" data-id="CD012557-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 7: Dropouts due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 8: Craving" data-id="CD012557-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 8: Craving</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 9: Anxiety" data-id="CD012557-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 9: Anxiety</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 10: Depression" data-id="CD012557-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 10: Depression</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 11: Adverse events: fatigue, tiredness" data-id="CD012557-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 11: Adverse events: fatigue, tiredness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 12: Adverse events: insomnia" data-id="CD012557-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 12: Adverse events: insomnia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 13: Adverse events: pain (diverse)" data-id="CD012557-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 13: Adverse events: pain (diverse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 14: Adverse events: vertigo, dizziness" data-id="CD012557-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 14: Adverse events: vertigo, dizziness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 15: Adverse events: constipation" data-id="CD012557-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 15: Adverse events: constipation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 16: Adverse events: somnolence, sleepiness, drowsiness or sedation" data-id="CD012557-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 16: Adverse events: somnolence, sleepiness, drowsiness or sedation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 17: Adverse events: muscle pain" data-id="CD012557-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 17: Adverse events: muscle pain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 18: Adverse events: dry mouth" data-id="CD012557-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 18: Adverse events: dry mouth </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 19: Adverse events: nausea" data-id="CD012557-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 19: Adverse events: nausea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 20: Adverse events: skin rash" data-id="CD012557-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 20: Adverse events: skin rash </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 21: Adverse events: headaches" data-id="CD012557-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 21: Adverse events: headaches</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 22: Adverse events: paraesthesia/numbness" data-id="CD012557-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 22: Adverse events: paraesthesia/numbness</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 23: Adverse events: diarrhoea" data-id="CD012557-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 23: Adverse events: diarrhoea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 24: Adverse events: tinnitus" data-id="CD012557-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 24: Adverse events: tinnitus</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 25: Adverse events: muscle spasm/rigidity" data-id="CD012557-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 25: Adverse events: muscle spasm/rigidity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 26: Adverse events: hyperhidrosis" data-id="CD012557-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 26: Adverse events: hyperhidrosis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.27" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 27: Adverse events: nasopharyngitis" data-id="CD012557-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.27.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 27: Adverse events: nasopharyngitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.27.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.28" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 28: Adverse events: decrease appetite/anorexia" data-id="CD012557-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.28.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.28.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 28: Adverse events: decrease appetite/anorexia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.28.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.29" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 29: Adverse events: dysgeusia/ageusia" data-id="CD012557-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.29.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.29.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 29: Adverse events: dysgeusia/ageusia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.29.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.30" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 30: Adverse events: tremor" data-id="CD012557-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.30.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.30.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 30: Adverse events: tremor</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.30.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.31" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 31: Adverse events: weakness" data-id="CD012557-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.31.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.31.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 31: Adverse events: weakness</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.31.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.32" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 32: Adverse events: vomiting" data-id="CD012557-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.32.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.32.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 32: Adverse events: vomiting</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.32.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.33" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 33: Adverse events: urinary frequency" data-id="CD012557-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.33.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.33.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 33: Adverse events: urinary frequency </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.33.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-001.34" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Baclofen versus placebo (all studies), Outcome 34: Adverse events: shortness of breath" data-id="CD012557-fig-0042" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.34.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-001.34.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.34</div> <div class="figure-caption"> <p>Comparison 1: Baclofen versus placebo (all studies), Outcome 34: Adverse events: shortness of breath </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-001.34.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Baclofen versus placebo (divided into low, medium and high doses of baclofen), Outcome 1: Relapse: return to any drinking at end of treatment" data-id="CD012557-fig-0043" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Baclofen versus placebo (divided into low, medium and high doses of baclofen), Outcome 1: Relapse: return to any drinking at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Baclofen versus placebo (divided into low, medium and high doses of baclofen), Outcome 2: Frequency of use: % days abstinence at end of treatment" data-id="CD012557-fig-0044" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Baclofen versus placebo (divided into low, medium and high doses of baclofen), Outcome 2: Frequency of use: % days abstinence at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Baclofen versus placebo (divided into low, medium and high doses of baclofen), Outcome 3: Frequency of use: % of heavy drinking days at end of treatment" data-id="CD012557-fig-0045" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Baclofen versus placebo (divided into low, medium and high doses of baclofen), Outcome 3: Frequency of use: % of heavy drinking days at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Baclofen versus placebo (divided into low, medium and high doses of baclofen), Outcome 4: Amount of use: drinks per drinking days at end of treatment" data-id="CD012557-fig-0046" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Baclofen versus placebo (divided into low, medium and high doses of baclofen), Outcome 4: Amount of use: drinks per drinking days at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Baclofen versus placebo (divided into low, medium and high doses of baclofen), Outcome 5: Adverse events: number of participants with at least one adverse event at end of treatment" data-id="CD012557-fig-0047" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Baclofen versus placebo (divided into low, medium and high doses of baclofen), Outcome 5: Adverse events: number of participants with at least one adverse event at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Baclofen versus placebo (divided into low, medium and high doses of baclofen), Outcome 6: Dropouts at end of treatment" data-id="CD012557-fig-0048" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Baclofen versus placebo (divided into low, medium and high doses of baclofen), Outcome 6: Dropouts at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Baclofen versus placebo (divided into low, medium and high doses of baclofen), Outcome 7: Dropouts due to adverse events" data-id="CD012557-fig-0049" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Baclofen versus placebo (divided into low, medium and high doses of baclofen), Outcome 7: Dropouts due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Baclofen versus placebo (divided into 12âweek and longer than 12âweek studies), Outcome 1: Relapse: return to any drinking at end of treatment" data-id="CD012557-fig-0050" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Baclofen versus placebo (divided into 12âweek and longer than 12âweek studies), Outcome 1: Relapse: return to any drinking at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Baclofen versus placebo (divided into 12âweek and longer than 12âweek studies), Outcome 2: Frequency of use: % days abstinence at end of treatment" data-id="CD012557-fig-0051" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Baclofen versus placebo (divided into 12âweek and longer than 12âweek studies), Outcome 2: Frequency of use: % days abstinence at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Baclofen versus placebo (divided into 12âweek and longer than 12âweek studies), Outcome 3: Frequency of use: % of heavy drinking days at end of treatment" data-id="CD012557-fig-0052" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Baclofen versus placebo (divided into 12âweek and longer than 12âweek studies), Outcome 3: Frequency of use: % of heavy drinking days at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Baclofen versus placebo (divided into 12âweek and longer than 12âweek studies), Outcome 4: Amount of use: drink per drinking days at end of treatment" data-id="CD012557-fig-0053" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Baclofen versus placebo (divided into 12âweek and longer than 12âweek studies), Outcome 4: Amount of use: drink per drinking days at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Baclofen versus placebo (divided into 12âweek and longer than 12âweek studies), Outcome 5: Adverse events: number of participants with at least one adverse event at end of treatment" data-id="CD012557-fig-0054" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Baclofen versus placebo (divided into 12âweek and longer than 12âweek studies), Outcome 5: Adverse events: number of participants with at least one adverse event at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Baclofen versus placebo (divided into 12âweek and longer than 12âweek studies), Outcome 6: Dropouts at end of treatment" data-id="CD012557-fig-0055" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Baclofen versus placebo (divided into 12âweek and longer than 12âweek studies), Outcome 6: Dropouts at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Baclofen versus placebo (divided into 12âweek and longer than 12âweek studies), Outcome 7: Dropout due to adverse events" data-id="CD012557-fig-0056" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Baclofen versus placebo (divided into 12âweek and longer than 12âweek studies), Outcome 7: Dropout due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Baclofen versus placebo (divided into detoxified and nonâdetoxified participants), Outcome 1: Relapse: return to any drinking at end of treatment" data-id="CD012557-fig-0057" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Baclofen versus placebo (divided into detoxified and nonâdetoxified participants), Outcome 1: Relapse: return to any drinking at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Baclofen versus placebo (divided into detoxified and nonâdetoxified participants), Outcome 2: Frequency of use: % days abstinence at end of treatment" data-id="CD012557-fig-0058" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Baclofen versus placebo (divided into detoxified and nonâdetoxified participants), Outcome 2: Frequency of use: % days abstinence at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Baclofen versus placebo (divided into detoxified and nonâdetoxified participants), Outcome 3: Frequency of use: % of heavy drinking days at end of treatment" data-id="CD012557-fig-0059" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Baclofen versus placebo (divided into detoxified and nonâdetoxified participants), Outcome 3: Frequency of use: % of heavy drinking days at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Baclofen versus placebo (divided into detoxified and nonâdetoxified participants), Outcome 4: Amount of use: drink per drinking days at end of treatment" data-id="CD012557-fig-0060" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Baclofen versus placebo (divided into detoxified and nonâdetoxified participants), Outcome 4: Amount of use: drink per drinking days at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Baclofen versus placebo (divided into detoxified and nonâdetoxified participants), Outcome 5: Adverse events: number of participants with at least one adverse event at end of treatment" data-id="CD012557-fig-0061" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Baclofen versus placebo (divided into detoxified and nonâdetoxified participants), Outcome 5: Adverse events: number of participants with at least one adverse event at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Baclofen versus placebo (divided into detoxified and nonâdetoxified participants), Outcome 6: Dropouts at end of treatment" data-id="CD012557-fig-0062" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Baclofen versus placebo (divided into detoxified and nonâdetoxified participants), Outcome 6: Dropouts at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Baclofen versus placebo (divided into detoxified and nonâdetoxified participants), Outcome 7: Dropouts due to adverse events" data-id="CD012557-fig-0063" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Baclofen versus placebo (divided into detoxified and nonâdetoxified participants), Outcome 7: Dropouts due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Baclofen versus acamprosate, Outcome 1: Relapse: return to any drinking at end of treatment" data-id="CD012557-fig-0064" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Baclofen versus acamprosate, Outcome 1: Relapse: return to any drinking at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Baclofen versus acamprosate, Outcome 2: Adverse events: number of participants with at least one adverse event at end of treatment" data-id="CD012557-fig-0065" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Baclofen versus acamprosate, Outcome 2: Adverse events: number of participants with at least one adverse event at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Baclofen versus acamprosate, Outcome 3: Dropouts at end of treatment" data-id="CD012557-fig-0066" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Baclofen versus acamprosate, Outcome 3: Dropouts at end of treatment</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Baclofen versus acamprosate, Outcome 4: Dropouts due to adverse events" data-id="CD012557-fig-0067" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Baclofen versus acamprosate, Outcome 4: Dropouts due to adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Baclofen versus acamprosate, Outcome 5: Craving" data-id="CD012557-fig-0068" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Baclofen versus acamprosate, Outcome 5: Craving</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Baclofen versus acamprosate, Outcome 6: Adverse events: fatigue, tiredness" data-id="CD012557-fig-0069" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Baclofen versus acamprosate, Outcome 6: Adverse events: fatigue, tiredness</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Baclofen versus acamprosate, Outcome 7: Adverse events: vertigo, dizziness" data-id="CD012557-fig-0070" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Baclofen versus acamprosate, Outcome 7: Adverse events: vertigo, dizziness</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-005.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Baclofen versus acamprosate, Outcome 8: Adverse events: nausea" data-id="CD012557-fig-0071" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-005.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-005.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5: Baclofen versus acamprosate, Outcome 8: Adverse events: nausea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-005.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-005.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Baclofen versus acamprosate, Outcome 9: Adverse events: skin rash" data-id="CD012557-fig-0072" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-005.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-005.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5: Baclofen versus acamprosate, Outcome 9: Adverse events: skin rash</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-005.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-005.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Baclofen versus acamprosate, Outcome 10: Adverse events: decrease appetite/anorexia" data-id="CD012557-fig-0073" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-005.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-005.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5: Baclofen versus acamprosate, Outcome 10: Adverse events: decrease appetite/anorexia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-005.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-005.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Baclofen versus acamprosate, Outcome 11: Adverse events: acidity" data-id="CD012557-fig-0074" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-005.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-005.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5: Baclofen versus acamprosate, Outcome 11: Adverse events: acidity</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-005.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-005.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Baclofen versus acamprosate, Outcome 12: Adverse events: palpitations" data-id="CD012557-fig-0075" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-005.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-005.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5: Baclofen versus acamprosate, Outcome 12: Adverse events: palpitations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-005.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Baclofen versus naltrexone, Outcome 1: Relapse: return to any drinking at end of treatment" data-id="CD012557-fig-0076" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Baclofen versus naltrexone, Outcome 1: Relapse: return to any drinking at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Baclofen versus naltrexone, Outcome 2: Adverse events: number of participants with at least one adverse event at end of treatment" data-id="CD012557-fig-0077" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Baclofen versus naltrexone, Outcome 2: Adverse events: number of participants with at least one adverse event at end of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Baclofen versus naltrexone, Outcome 3: Dropouts at end of treatment" data-id="CD012557-fig-0078" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Baclofen versus naltrexone, Outcome 3: Dropouts at end of treatment</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Baclofen versus naltrexone, Outcome 4: Craving" data-id="CD012557-fig-0079" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Baclofen versus naltrexone, Outcome 4: Craving</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Baclofen versus naltrexone, Outcome 5: Adverse events: fatigue, tiredness" data-id="CD012557-fig-0080" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Baclofen versus naltrexone, Outcome 5: Adverse events: fatigue, tiredness</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-006.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Baclofen versus naltrexone, Outcome 6: Adverse events: insomnia" data-id="CD012557-fig-0081" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-006.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6: Baclofen versus naltrexone, Outcome 6: Adverse events: insomnia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-006.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Baclofen versus naltrexone, Outcome 7: Adverse events: vertigo, dizziness" data-id="CD012557-fig-0082" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-006.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6: Baclofen versus naltrexone, Outcome 7: Adverse events: vertigo, dizziness</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-006.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Baclofen versus naltrexone, Outcome 8: Adverse events: somnolence, sleepiness, drowsiness or sedation" data-id="CD012557-fig-0083" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-006.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6: Baclofen versus naltrexone, Outcome 8: Adverse events: somnolence, sleepiness, drowsiness or sedation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-006.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Baclofen versus naltrexone, Outcome 9: Adverse events: nausea" data-id="CD012557-fig-0084" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-006.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6: Baclofen versus naltrexone, Outcome 9: Adverse events: nausea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-006.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Baclofen versus naltrexone, Outcome 10: Adverse events: decrease appetite/anorexia" data-id="CD012557-fig-0085" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-006.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6: Baclofen versus naltrexone, Outcome 10: Adverse events: decrease appetite/anorexia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-006.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Baclofen versus naltrexone, Outcome 11: Adverse events: tremor" data-id="CD012557-fig-0086" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-006.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.11</div> <div class="figure-caption"> <p>Comparison 6: Baclofen versus naltrexone, Outcome 11: Adverse events: tremor</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-006.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Baclofen versus naltrexone, Outcome 12: Adverse events: acidity" data-id="CD012557-fig-0087" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-006.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.12</div> <div class="figure-caption"> <p>Comparison 6: Baclofen versus naltrexone, Outcome 12: Adverse events: acidity</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012557-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/urn:x-wiley:14651858:media:CD012557:CD012557-CMP-006.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Baclofen versus naltrexone, Outcome 13: Adverse events: erectile dysfunction" data-id="CD012557-fig-0088" src="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_t/tCD012557-CMP-006.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.13</div> <div class="figure-caption"> <p>Comparison 6: Baclofen versus naltrexone, Outcome 13: Adverse events: erectile dysfunction</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/media/CDSR/CD012557/image_n/nCD012557-CMP-006.13.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012557-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span>Â <span class="table-title">Summary of findings table â Baclofen compared to placebo for alcohol use disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Baclofen compared to placebo for alcohol use disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> alcohol use disorder<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> baclofen<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>â of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with baclofen</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse: return to any drinking at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>816 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>710 per 1000</b><br/>(628 to 808) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.87</b><br/>(0.77 to 0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1057<br/>(12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compared to placebo, baclofen probably decreases the risk to relapse to any drinking.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Frequency of use: % days abstinence at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean frequency of use: % days abstinence at end of treatment was <b>53.58</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>9.07 higher</b><br/>(3.3 higher to 14.85 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1273<br/>(16 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compared to placebo, baclofen increases the % of days abstinent.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Frequency of use: heavy drinking days at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD <b>0.18 lower</b><br/>(0.48 lower to 0.11 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>840<br/>(13 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compared to placebo, baclofen may not reduce heavy drinking days.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amount of use: drink per drinking days at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean amount of use: drink per drinking days at end of treatment was <b>4.28</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.45 lower</b><br/>(1.2 lower to 0.3 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>392<br/>(9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Moderate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compared to placebo, baclofen probably does not reduce the number of drinks per drinking days. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: number of participants with â¥ 1 adverse event at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>636 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>668 per 1000</b><br/>(629 to 706) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b><br/>(0.99 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>738<br/>(10 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compared to placebo, baclofen does not increase the number of participants with â¥ 1 adverse event at the end of treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dropouts at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>420 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>369 per 1000</b><br/>(311 to 432) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b><br/>(0.74 to 1.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1563<br/>(17 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compared to placebo, baclofen does not increase the number of participants who dropout at the end of treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dropouts due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61 per 1000</b><br/>(39 to 95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.39</b><br/>(0.89 to 2.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1499<br/>(16 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compared to placebo, baclofen does not increase the number of dropouts due to adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_432179672169955326" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_432179672169955326</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for inconsistency IÂ² = 73%.<br/><sup>b</sup> Downgraded one level for inconsistency IÂ² = 71%.<br/><sup>c</sup> Downgraded one level for risk of bias: one study at high risk for attrition and reporting bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span>Â <span class="table-title">Summary of findings table â Baclofen compared to placebo for alcohol use disorder</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/full#CD012557-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012557-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span>Â <span class="table-title">Summary of findings table â Baclofen compared to acamprosate for alcohol use disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Baclofen compared to acamprosate for alcohol use disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> alcohol use disorder<br/><b>Setting:</b> <br/><b>Intervention:</b> baclofen<br/><b>Comparison:</b> acamprosate </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>â of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with acamprosate</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with baclofen</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse: return to any drinking at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b><br/>(284 to 880) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.25</b><br/>(0.71 to 2.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is uncertain whether baclofen and acamprosate differ in the return to any drinking.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: number of participants with at least one adverse event at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>267 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>168 per 1000</b><br/>(61 to 451) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.63</b><br/>(0.23 to 1.69) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is uncertain whether baclofen and acamprosate differ in the number of participants with â¥ 1 adverse event at the end of treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dropouts at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>168 per 1000</b><br/>(63 to 438) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.56</b><br/>(0.21 to 1.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is uncertain whether baclofen and acamprosate differ in dropouts at the end of treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dropouts due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b><br/>(0 to 262) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b><br/>(0.01 to 7.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is uncertain whether baclofen and acamprosate differ in dropouts due to adverse events at the end of treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_432318545502233572" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_432318545502233572</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level: one study at high risk of performance, detection, and attrition bias and at unclear risk of selection bias.<br/><sup>b</sup> Downgraded two levels for imprecision: fewer than 100 events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span>Â <span class="table-title">Summary of findings table â Baclofen compared to acamprosate for alcohol use disorder</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/full#CD012557-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012557-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span>Â <span class="table-title">Summary of findings table â Baclofen compared to naltrexone for alcohol use disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Baclofen compared to naltrexone for alcohol use disorder</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> alcohol use disorder<br/><b>Setting:</b> <br/><b>Intervention:</b> baclofen<br/><b>Comparison:</b> naltrexone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>â of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with naltrexone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with baclofen</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse: return to any drinking at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b><br/>(224 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.50</b><br/>(1.12 to 5.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is uncertain whether baclofen and naltrexone differ in the risk to return to any drinking. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: number of participants with â¥ 1 adverse event at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>450 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>158 per 1000</b><br/>(68 to 360) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.35</b><br/>(0.15 to 0.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is uncertain whether baclofen and naltrexone differ in the number of participants with â¥ 1 adverse event at the end of treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dropouts at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b><br/>(53 to 517) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/>(0.32 to 3.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is uncertain whether baclofen and naltrexone differ in dropouts at the end of treatment.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_432318841614592889" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_432318841614592889</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level: one study at high risk of performance, detection and attrition bias.<br/><sup>b</sup> Downgraded two levels due to imprecision: fewer than 100 events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span>Â <span class="table-title">Summary of findings table â Baclofen compared to naltrexone for alcohol use disorder</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/full#CD012557-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012557-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span>Â <span class="table-title">Baclofen versus placebo (all studies)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Relapse: return to any drinking at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1057</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.77, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Frequency of use: % days abstinence at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.07 [3.30, 14.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Frequency of use: heavy drinking days at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>840</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>â0.18 [â0.48, 0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Amount of use: drinks per drinking days at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>â0.45 [â1.20, 0.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Adverse events: number of participants with at least one adverse event at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>738</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.99, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Dropouts at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1563</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.74, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Dropouts due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.89, 2.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Craving <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>â0.16 [â0.37, 0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Anxiety <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>â0.01 [â0.14, 0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1029</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [â0.12, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Adverse events: fatigue, tiredness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [1.09, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Adverse events: insomnia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.62, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Adverse events: pain (diverse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.19, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Adverse events: vertigo, dizziness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.35, 2.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Adverse events: constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.61, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Adverse events: somnolence, sleepiness, drowsiness or sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [1.19, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Adverse events: muscle pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>594</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.38, 2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Adverse events: dry mouth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>933</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [1.01, 3.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Adverse events: nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1060</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.88, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Adverse events: skin rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.33, 1.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 Adverse events: headaches <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [1.04, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.22 Adverse events: paraesthesia/numbness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>914</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.87 [1.17, 7.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.23 Adverse events: diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>816</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.40, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.24 Adverse events: tinnitus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>496</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [0.16, 20.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.25 Adverse events: muscle spasm/rigidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [1.07, 3.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.26 Adverse events: hyperhidrosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>816</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.89, 2.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.27 Adverse events: nasopharyngitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>872</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.40, 1.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.28 Adverse events: decrease appetite/anorexia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>816</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.31, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.29 Adverse events: dysgeusia/ageusia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>816</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.57, 5.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.30 Adverse events: tremor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>816</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.42, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.31 Adverse events: weakness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.70, 2.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.32 Adverse events: vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>816</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.66, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.33 Adverse events: urinary frequency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.45, 2.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.34 Adverse events: shortness of breath <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.04, 22.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span>Â <span class="table-title">Baclofen versus placebo (all studies)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012557-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span>Â <span class="table-title">Baclofen versus placebo (divided into low, medium and high doses of baclofen)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Relapse: return to any drinking at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1057</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.77, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Low doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.64, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Medium doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.37, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 High doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.71, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Frequency of use: % days abstinence at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.07 [3.30, 14.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Low doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.59 [0.77, 20.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Medium doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.14 [â3.10, 17.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 High doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.09 [4.39, 17.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Frequency of use: % of heavy drinking days at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>840</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>â0.18 [â0.48, 0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Low doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [â0.15, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Medium doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>â0.47 [â1.15, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 High doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>â0.21 [â0.43, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Amount of use: drinks per drinking days at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>â0.45 [â1.20, 0.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Low doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>â0.06 [â1.33, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Medium doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>â0.64 [â1.95, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Adverse events: number of participants with at least one adverse event at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>738</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.99, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Low doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.92, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Medium doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.63, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.3 High doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.99, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Dropouts at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1563</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.74, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Low doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.70, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 Medium doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.65, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.3 High doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.67, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Dropouts due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.89, 2.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Low doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [0.61, 5.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 Medium doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.11 [0.82, 45.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.3 High doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.68, 2.13]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span>Â <span class="table-title">Baclofen versus placebo (divided into low, medium and high doses of baclofen)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012557-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span>Â <span class="table-title">Baclofen versus placebo (divided into 12âweek and longer than 12âweek studies)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Relapse: return to any drinking at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1057</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.77, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 12âweek studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.40, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Longer than 12âweek studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.93, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Frequency of use: % days abstinence at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.07 [3.30, 14.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 12âweek studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>682</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.90 [3.17, 18.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Longer than 12âweek studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.05 [1.09, 15.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Frequency of use: % of heavy drinking days at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>840</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>â0.18 [â0.48, 0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 12âweek studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>â0.07 [â0.27, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Longer than 12âweek studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>440</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>â0.54 [â1.68, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Amount of use: drink per drinking days at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>â0.45 [â1.20, 0.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 12âweek studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>â0.36 [â1.29, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 Longer than 12âweek studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>â0.49 [â2.31, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Adverse events: number of participants with at least one adverse event at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>738</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.99, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 12âweek studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.70, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 Longer than 12âweek studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [1.00, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Dropouts at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1563</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.74, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 12âweek studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.73, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.2 Longer than 12âweek studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>911</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.69, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Dropout due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.89, 2.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 12âweek studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.93, 9.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.2 Longer than 12âweek studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>911</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.76, 1.98]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span>Â <span class="table-title">Baclofen versus placebo (divided into 12âweek and longer than 12âweek studies)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012557-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span>Â <span class="table-title">Baclofen versus placebo (divided into detoxified and nonâdetoxified participants)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Relapse: return to any drinking at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1057</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.77, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Detoxified participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.55, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 Nonâdetoxified participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.94, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Frequency of use: % days abstinence at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.07 [3.30, 14.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Detoxified participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.76 [3.22, 20.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Nonâdetoxified participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.03 [â1.59, 13.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Frequency of use: % of heavy drinking days at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>840</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>â0.18 [â0.48, 0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Detoxified participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>â0.08 [â0.32, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 Nonâdetoxified participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>â0.34 [â0.98, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Amount of use: drink per drinking days at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>â0.45 [â1.20, 0.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Detoxified participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>â0.36 [â1.29, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 Nonâdetoxified participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>â0.49 [â2.31, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Adverse events: number of participants with at least one adverse event at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>738</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.99, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 Detoxified participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.99, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.2 Nonâdetoxified participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.84, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Dropouts at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1563</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.74, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 Detoxified participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>879</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.71, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.2 Noâdetoxified participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>684</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.69, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Dropouts due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.89, 2.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 Detoxified participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>879</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.59, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.2 Noâdetoxified participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [0.97, 3.61]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span>Â <span class="table-title">Baclofen versus placebo (divided into detoxified and nonâdetoxified participants)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012557-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 5.</span>Â <span class="table-title">Baclofen versus acamprosate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Relapse: return to any drinking at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.71, 2.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Adverse events: number of participants with at least one adverse event at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.23, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Dropouts at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.21, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Dropouts due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Craving <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.80 [â11.84, 23.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Adverse events: fatigue, tiredness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 70.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Adverse events: vertigo, dizziness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.19, 20.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.8 Adverse events: nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.9 Adverse events: skin rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.10 Adverse events: decrease appetite/anorexia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.15, 6.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.11 Adverse events: acidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.12 Adverse events: palpitations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span>Â <span class="table-title">Baclofen versus acamprosate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012557-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 6.</span>Â <span class="table-title">Baclofen versus naltrexone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Relapse: return to any drinking at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [1.12, 5.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Adverse events: number of participants with at least one adverse event at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.15, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Dropouts at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.32, 3.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Craving <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.08 [â3.71, 7.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Adverse events: fatigue, tiredness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 70.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.6 Adverse events: insomnia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.7 Adverse events: vertigo, dizziness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.08, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.8 Adverse events: somnolence, sleepiness, drowsiness or sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 2.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.9 Adverse events: nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.03, 2.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.10 Adverse events: decrease appetite/anorexia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.19, 20.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.11 Adverse events: tremor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.12 Adverse events: acidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.13 Adverse events: erectile dysfunction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span>Â <span class="table-title">Baclofen versus naltrexone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012557.pub3/references#CD012557-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012557.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012557-note-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012557-note-0015">EspaÃ±ol</a> </li> <li class="section-language"> <a class="" href="fa#CD012557-note-0012">ÙØ§Ø±Ø³Û</a> </li> <li class="section-language"> <a class="" href="fr#CD012557-note-0013">FranÃ§ais</a> </li> <li class="section-language"> <a class="" href="hr#CD012557-note-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD012557-note-0010">æ¥æ¬èª</a> </li> <li class="section-language"> <a class="" href="ms#CD012557-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012557-note-0014">Polski</a> </li> <li class="section-language"> <a class="" href="th#CD012557-note-0008">à¸ à¸²à¸©à¸²à¹à¸à¸¢</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012557-note-0007">ç¹é«ä¸­æ</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright Â© 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">Â Â Facebook</a> <a class="a2a_button_x share-button">Â Â X(Twitter)</a> <a class="a2a_button_whatsapp share-button">Â Â WhatsApp</a> <a class="a2a_dd share-button">Â Â View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012557\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012557\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012557\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012557\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012557\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012557\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012557\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012557\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012557\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012557\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012557\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012557\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012557\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012557\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012557\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012557\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012557\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012557\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mvgXlmVk&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012557.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012557.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">EspaÃ±ol</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">ÙØ§Ø±Ø³Û</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">FranÃ§ais</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">à¤¹à¤¿à¤¨à¥à¤¦à¥</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">æ¥æ¬èª</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">íêµ­ì´</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">PortuguÃªs</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Ð ÑÑÑÐºÐ¸Ð¹</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">RomÃ¢nÄ</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">à®¤à®®à®¿à®´à¯</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">à¸ à¸²à¸©à¸²à¹à¸à¸¢</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">ç¹é«ä¸­æ</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">ç®ä½ä¸­æ</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012557.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012557.pub3/full/es">EspaÃ±ol</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012557.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719651564"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012557.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719651570"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012557.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dedf41f099371',t:'MTc0MDcxOTY1Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 